Marine and terrestrial natural products discovery by Timmers, M
 i 
Marine and Terrestrial 
Natural Products 
Discovery 
 
 
 
 
Michael Timmers 
 
Bsc. (Applied Science), Hons. (Chemistry) 
 
 
 
A thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy 
 
 
 
School of Applied Sciences (Discipline of Applied Chemistry) 
RMIT University 
February 2013 
 ii 
Declaration 
I certify that except where due acknowledgement has been made, the work is that of the 
author alone; the work has not been submitted previously, in whole or in part, to qualify for 
any other academic award; the content of the thesis is the result of work which has been 
carried out since the official commencement date of the approved research program; and, 
any editorial work, paid or unpaid, carried out by a third party is acknowledged. 
 
 
Michael Anthony Timmers 
20th February 2013 
 iii 
 
 
 
Dedication 
 
 
 
 
To my family, 
For your support and faith in me, 
I dedicate my research to you. 
 
 
 
 
 iv 
 
 
 
 
 
 
 
“Bad times have a scientific value. These are 
occasions a good learner would not miss.” 
 
Ralph Waldo Emerson 
(1803-1882) 
 
 
 
 v 
Acknowledgements 
I would like to thank my supervisor, Dr. Sylvia Urban for offering me this project, showing 
faith and for the effort she has put into editing my chapters. Dr Urban is an extremely 
hardworking and conscientious supervisor and I apologise for trying her patience on so 
many occasions. I do appreciate that she has gone beyond the call of duty and I would 
like to thank her for the great favours she has done me throughout the period of my 
candidature. 
 
To my second supervisor, Dr Julie Niere, I am forever grateful for all that you have done 
for me over the years. From allowing me to reside in the NMR lab, to reading my chapters, 
your support during difficult times, listening to my rants and crazy times, taking on 
supervision of me for a year and always being there for me when I needed. 
 
I would also like to acknowledge the Australian Postgraduate Award (APA), for granting 
me the scholarship to allow me to do this PhD. 
 
To all past and present members of the MATNAP research group at RMIT University. I am 
especially grateful for the help provided by Dr Daniel Dias and Mrs Priyanka Reddy, 
particularly early in my PhD teaching me all I needed to know lab and instrument wise, 
and for giving up their time to assist me when needed. 
 
I would like to thank, Dr Daniel Dias, Dr Gerald Kraft, Mrs Priyanka Reddy, Mr Allan 
Tinker, Dr Rick Tinker, and Dr Sylvia Urban for collections of organisms studied in this 
thesis. Also I would like to thank Dr Gerald Kraft for taxonomy of marine algae and to Mr 
Allan Tinker for the identification of two of the Australian plants. 
 
 vi 
I would like to acknowledge any previous studies and fractionation conducted within the 
MATNAP research group. I would like to thank Ngoc Han Nguyen for the preliminary 
studies and fractionation of the alga Cystophora torulosa, Dr Daniel Dias for help with the 
HPLC-NMR of the Plocamium angustum sample, as well as for his pre-fractionation and 
isolation of some compounds from the Drosera sample. I would also like to thank Dr 
Daniel Dias, Mr Claudio Silva and David Goble for their pre-fractionation of the initial 
collection of the Haemodorum sample, as well as providing spectra for comparison. 
 
I would like to acknowledge Ms Gill Ellis from the University of Canterbury (Christchurch, 
New Zealand) for all of the biological activity work; Associate Professor Jonathan White 
from the University of Melbourne (Australia) for the X-ray crystallography work, including 
solving my crystal structure and attempts with other crystals, Miss Sally Duck from 
Monash University (Australia) for HR-ESI-MS analyses and Associate Professor Peter 
Cullis (RMIT University, Australia) for help with mass spectrometry. Thank you also to 
Professor Mark Rizzacassa from the University of Melbourne (Australia) for allowing me to 
the use the polarimeter at the Bio21 Institute; to Mr Paul Morrison for his help with running 
HR-GC-MS for me. I also have to acknowledge and thank Dr Rachel Williamson from the 
Australia Synchrotron (Macromolecular crystallography beamline), for her attempts at 
obtaining a crystal structure on one of the new Haemodorum compounds isolated. 
 
To the technical staff within the chemistry department at RMIT University, Mrs Shirley 
Cocks, Mr Sunly Prum for all of your support and help with everything that I needed, no 
matter how small or big the problem, you were both always willing to go out of your way to 
help me. To Mr Frank Antolasic for assistance with the GC-MS and ESI-MS and for 
maintaining the instruments. To Mr Karl Lang, without you the chemistry department at 
RMIT would never run. To Mr Peter Laming, Mrs Zahra Homan, Mrs Nadia Zakhartchouk, 
Mrs Ruth Cepriano-Hall and Mrs Dianne Mileo, thank you all for your assistance and 
technical support over the years. 
 vii 
To Dr Gemma Kirwan and Dr Krist Frost, your help with all manner of things along the 
way was invaluable and your friendship means a lot to me. To Dr Lisa Dias and Dr 
Konstantin Kouremenos and Mr Chris Ruehle, your support and lending an ear when 
needed was a wonderful when I needed it most. To Dr Zheng Liu, over the last few years 
you have become a very good friend and it was always a laugh having you around 
keeping my spirits up.  
 
To my friends, firstly the Sefton family, you are always there for me through the rough 
times and were always willing to catch up for a coffee or a beer to chat about things that 
were going on. To the Martin family, your hospitality and also being there for when I 
needed you was wonderful. Thank you also, in no particular order, to Daniel Smith, 
Eleanor Dryley, Mel and Pyxee, among others, thank you all for your support and 
friendship over the past year, all the chats etc. over this time has kept me company and 
taking my mind off my thesis when needed.  
 
A special thank you to Jacqulyn Evans for all of your support over the last year, I may 
have only met you about a year ago, but your friendship means so much to me. You are 
always there for a chat and a hug when they are needed, and your cooking always puts a 
smile on my face. From “I miss my cupcake”, “But I need tacos! I need them or I will 
explode” and my personal favourite, “WHY? WHY MY PIGGY? I LOVEDED YOU PIGGY! 
I LOVEDED YOUUUUU!”. I can’t thank you enough for all that you have done for me over 
the last year. 
 
To Rowie’s family, your help, be it from realising how sane I am compared to all of you, 
your hospitality and help along the way have been great to me over the years. Being there 
for me when I needed, especially when things were not going well for me and allowing me 
to stay at your houses. 
 
 viii 
To my family, I would not be where I am today without all of your help and guidance. To 
my grandparents thank you for all you have done to assist me through the years. To my 
mum, you have always been there for me, supporting me always and allowing me to 
follow my dreams, you have sacrificed so much for me and for that I am eternally grateful. 
I know there have been some tough times, and I thank you for helping me get through 
them, and I am thankful that you were strong when the chips were down for you, it made 
things so much easier to cope with knowing you were positive through the whole thing. 
 
Last but not least, to my fiancée Rowie, you mean the world to me. This period has been 
the most stressful and difficult part of my life so far, but you have always been there, 
through thick and thin and always there to support me through everything that has 
happened along the way. I cannot thank you enough for putting up with me, listening to 
my rants and whinging, putting up with the crazy, and everything especially during the 
writing of my thesis. My mood swings, tiredness and dealing with everything and being 
there for me through it all, I love you so much and I cannot wait to start the next part of our 
lives together. 
 
 
 ix 
Journal Publications 
The following is a list of the journal publications that have arisen as a result of the studies 
conducted in this thesis: 
 
1. Timmers, M.; Urban, S., On-line (HPLC-NMR) and Off-line Phytochemical Profiling 
of the Australian plant, Lasiopetalum macrophyllum. Natural Product 
Communications, 2011, 6, 1605-1616. 
 
This paper was awarded the “Gerald Blunden Award” for the best paper in Natural 
Products Communications for 2011 and was republished as detailed below. 
 
2. Timmers, M.; Urban, S., On-line (HPLC-NMR) and Off-line Phytochemical Profiling 
of the Australian plant, Lasiopetalum macrophyllum. Natural Product 
Communications, 2012, 7, 551-560. 
 
3. Timmers, M. A.; Dias, D. A.; Urban, S., Application of HPLC-NMR in the 
Identification of Plocamenone and Isoplocamenone from the Marine Red Alga 
Plocamium angustum. Marine Drugs 2012, 10, 2089-2102. 
 
4. Timmers, M. A.; Dias, D. A.; Urban, S., HPLC-NMR Chemical Profiling of the 
Australian Carnivorous plant, Drosera erythrorhiza subspecies magna. The Natural 
Products Journal, 2013, 3, (1), 35-41. 
 
5. Urban, S.; Timmers, M. A., HPLC-NMR Chemical Profiling and Dereplication 
Studies of the Marine Brown Alga, Cystophora torulosa. Natural Product 
Communications, 2013, 8 (6) 715-719. 
 
6. Timmers, M. A.; Brkljača, R.; White, J. M.; Urban, S., Phenylphenalenones and 
Oxabenzochrysenones from the Australian Plant Haemodorum simulans. 
Phytochemistry, (submitted). 
 x 
Conference Presentations (Posters) 
The following is a list of the conference presentations (posters) that have been presented 
as a result of the studies conducted in this thesis: 
 
1. Dias, D.; Timmers, M.; Urban, S. “Application of On-flow LC-NMR Analysis to 
Profile Natural Products from Marine Extracts” 12th International Conference on 
Marine Natural Products (Manapro XII), Queenstown, New Zealand, 4th – 9th 
February, 2007. 
 
2. Dias, D.; Reddy, P.; Timmers, M.; and Urban, S. “Bioprospecting for Drugs from 
the Marine Environment”, 12th International Symposium on Marine Natural 
Products (MANAPRO XII), Queenstown, New Zealand, 4th-9th February, 2007. 
 
3. Dias, D.; Timmers, M.; and Urban, S. “Application of On-flow LC-NMR to Profile 
Natural Products from Marine Extracts”, RACI Natural Products Chemistry Group 
One-Day Symposium, University of New South Wales, Sydney, Australia, 28th 
September, 2007. 
 
4. Dias, D, Reddy, P, Timmers, M, and Urban, S, “Bioprospecting for Drugs from the 
Marine Environment”, RACI Natural Products Chemistry Group One-Day 
Symposium, University of New South Wales, Sydney, Australia, 28th September, 
2007. 
 
5. Timmers, M.; Niere, J.; Urban, S. “Application of HPLC-NMR to Identify Secondary 
Metabolites from the Plant Drosera sp.” RMIT College of Science, Engineering and 
Health Higher Degree by Research Student Conference, 23rd October, 2009. 
 
6. Timmers, M.; Urban, S. “Chemical Profiling of Flavonoid Glycosides from 
Lasiopetalum macrophyllum” 27th International Symposium on the Chemistry of 
Natural Products (ISCNP27), Brisbane, Australia, 10th – 15th July, 2011. 
 
7. Brkljača, B, Timmers, M, and Urban, S., “Recent Advancements in HPLC-NMR 
and its Application to Rapidly Profile Marine Natural Products”, 27th International 
Symposium on the Chemistry of Natural Products (ISCNP27), Brisbane, 
Australia,10th-15th July, 2011. 
 xi 
Abstract 
This thesis describes the study of three Australian plants and two marine algae. The 
application of the hyphenated spectroscopic technique, HPLC-NMR, was successfully 
implemented in the partial identification or as a dereplication of the secondary metabolites 
present in each of the studied organisms. HPLC-NMR was particularly suited to the 
identification of an unstable new secondary metabolite identified from one of the marine 
organisms. In total this thesis has resulted in the isolation and structural elucidation of five 
new secondary metabolites, one new X-ray crystal structure of a previously reported 
compound and twenty-two known secondary metabolites, of which five structural and/or 
chemical shift re-assignments were deduced. The five new natural products were isolated 
from two of the Australian plants and one marine alga, and were elucidated using detailed 
spectroscopic and chemical techniques. Also presented are the biological activities of all 
crude extracts studied and a selection of the isolated secondary metabolites. 
 
Chapter 1: A general introduction of marine and terrestrial natural products, covering both 
the history of natural products isolation and advancements in technology is detailed. 
Following this a review of the biological activity (anti-cancer and anti-parasitic activity) of 
the flavonoid and naphthoquinone structure classes covering the period 2008-2012 is 
presented. The selection of the flavonoids and naphthoquinones was made on the basis 
that these represented two of the structure classes that were isolated during the course of 
these studies that either displayed bioactivity or are known to possess biological activity. 
 
Chapter 2: Describes the on-line (HPLC-NMR) and off-line (HPLC, NMR and MS) 
methodologies utilised to profile the constituents present in the crude methanolic extract of 
the Australian plant, Lasiopetalum macrophyllum. On-flow and stop-flow HPLC-NMR 
supported the presence of trans-tiliroside (2.12) and permitted partial identification of cis-
 xii 
tiliroside (2.13) and 4′-methoxy-trans-tiliroside (2.14), while a fourth related secondary 
metabolite, observed in the analytical HPLC chromatogram, was not observed in the on-
flow or stop-flow analyses due to its low concentration in the crude extract. Subsequent 
off-line isolation led to the unequivocal identification of four flavonoid glycosides including 
a new structural derivative, 4′-methoxy-cis-tiliroside (2.15). This is the first report of 
flavonoid glycosides occurring in this plant genus. In addition, a number of structure 
revisions have been proposed for previously reported flavonoid glycosides that were 
incorrectly assigned. The stability of flavonoid glycosides was also determined, with a 
conversion of pure trans or cis isomers into a mixture of the two isomers over time. It was 
observed that the cis isomers converted into a mixture at a much quicker rate than that of 
the trans isomers. With this conversion, it was found that trans-tiliroside (2.12) converted 
to an equilibrium mixture of trans- (2.12) and cis-tiliroside (2.13) in a ratio of ~4:1, which 
corresponded to the approximate ratio observed in the initial extract. The methoxy 
derivatives of trans-tiliroside (2.12) and cis-tiliroside (2.13) were established to be natural 
products and not artefacts of the isolation procedure. 
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Chapter 3: The investigation of the Australian plant Haemodorum simulans 
(Haemodoraceae) was carried out using a combination of on-line HPLC-NMR chemical 
profiling of enriched fractions as well as off-line isolation and purification methodologies. 
This resulted in the isolation and identification of two new phenylphenalenones, 
haemoxiphidone (3.42) and haemodordioxolane (3.45), from the bulbs together with the 
first report of an oxabenzochrysenone glycoside, haemodoroxychrysenose (3.46), from 
the aerial parts of the plant. Also isolated were two previously described 
phenylphenalenones 5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione 
(3.44) and haemodorone (3.41) and two oxabenzochrysenones 5-hydroxy-2-methoxy-1H-
naphtho[2,1,8-mna]xanthen-1-one (3.4) and 5-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-
one (3.2). The X-ray structure of the phenylphenalenone 5,6-dimethoxy-7-phenyl-1H,3H-
naphtho[1,8-cd]pyran-1,3-dione (3.44) was secured for the first time. HPLC-NMR 
chemical profiling of an enriched fraction containing a mixture of haemodordioxolane 
(3.45) and 5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione (3.44) as well 
as a separate HPLC-NMR analysis of an enriched fraction containing haemodorone (3.41) 
and haemoxiphidone (3.42), facilitated the partial identification of these secondary 
metabolites. All structural elucidations were unequivocally established via detailed 
spectroscopic analyses.  
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Chapter 4: Describes the on-line HPLC-NMR chemical profiling of crude extracts derived 
from the bulbs of the Australian carnivorous plant Drosera erythrohiza subspecies magna. 
A combination of on-flow and stop-flow HPLC-NMR methodologies enabled partial 
identification of two structurally related naphthoquinones, droserone (4.7) and 
hydroxydroserone (4.8), as well as a mixture of their corresponding glycosides (4.9 and 
4.10). Subsequent semi-preparative HPLC off-line isolation followed by NMR 
spectroscopic and mass spectrometric analysis of the crude extracts of the bulbs of the 
plant permitted the unequivocal identification of droserone (4.7), hydroxydroserone (4.8), 
droserone-5-O--glycoside (4.9) and hydroxydroserone-5-O--glycoside (4.10). In addition 
off-line separation methodologies of the aerial parts of the plant led to the identification of 
plumbagin (1.267). Of the isolated compounds, plumbagin (1.267), was found to be the 
most active, with potent P388 anti-tumour activity, potent anti-microbial activity against 
Candida albicans, Bacillus subtilis and Trichophyton mentagrophytes, while possessing 
selective mild anti-fungal activity against Cladosporium resinae.  
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Chapter 5: Describes the use of a combination of on-line HPLC-NMR and off-line 
chemical investigations of the crude extract of the southern Australian red alga Plocamium 
angustum that resulted in the identification of the previously reported polyhalogenated 
monoterpene plocamenone (5.21), together with the new structural analogue 
isoplocamenone (5.24). On-flow and stop-flow HPLC-NMR analyses (including the 
acquisition of WET 2D NMR spectra) rapidly assisted in the identification of the major 
component plocamenone (5.21) and in the partial identification of its unstable double bond 
isomer isoplocamenone (5.24). Conventional off-line isolation and structural 
characterisation techniques were employed to unequivocally confirm both structures, 
leading to a structural revision for plocamenone (5.21), as well as obtaining sufficient 
quantities for biological testing. The unstable isoplocamenone (5.24) was isolated as a 
mixture with plocamenone (5.21) in order to allow for the unequivocal assignment of 
isoplocamenone (5.24). 
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Chapter 6: Describes the on-line HPLC-NMR chemical profiling/dereplication study of the 
southern Australian brown alga, Cystophora torulosa. On-flow HPLC-NMR analyses of the 
crude extract in combination with the use of the MarinLit database ultimately allowed for 
the identification of two classes of secondary metabolites, resorcinol derivatives and 
polyenes. In total seven secondary metabolites were identified by on-flow HPLC-NMR 
analysis, including five resorcinol derivatives (6.14 and 6.16-6.18) and two polyenes (6.1 
and 6.2). Off-line small-scale analytical HPLC collection and subsequent ESI-MS analysis 
of the crude extract allowed for the identification of seven resorcinol derivatives, with two 
additional resorcinol derivatives (6.12 and 6.19) identified from the analytical HPLC 
 xvi 
collection, subsequent ESI-MS analysis and the use of the MarinLit database. The two 
polyenes (6.1 and 6.2) were also isolated by analytical HPLC collection and subjected to 
GC-MS analysis, thereby allowing these secondary metabolites to be identified. Validation 
of this on-line dereplication strategy was supported by the isolation and complete 2D NMR 
assignment of the major secondary metabolite (6.14). The data was in full accordance 
with that reported for the major secondary metabolite (6.14) in the literature, while the off-
line 1H NMR spectrum was very similar in appearance to that of the WET-1D 1H NMR 
spectrum obtained from the HPLC-NMR chemical profiling exercise. This indicated that 
this methodology is suitable for the rapid on-line identification of the resorcinol and 
polyene structure classes which are often observed in the genus Cystophora. 
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Chapter 1  
Introduction 
1.1 General Introduction 
1.1.1 History of Natural Products 
The term “natural product” or “secondary metabolite” refers to a compound that is produced 
by an organism that is not directly associated with the growth and survival of the organism 
[1]. The use of natural extracts for the treatment of illnesses and disease dates back 
thousands of years to ancient China with the Traditional Chinese Medicines (TCM) (~3,000 
BC), India with Ayurvedic medicine (~1,000-3,000 BC) and Egypt with the ancient Ebers 
papyrus and Kahun papyrus describing early Egyptian medicinal knowledge (~3,000 BC) [2, 
3]. The use of specific compounds as medicines began in the 18th and 19th centuries, with 
compounds such as digoxin (1.1) (from the plant genus Digitalis), aspirin (1.2) (a derivative of 
salicylic acid obtained from the bark of the willow tree) and morphine (1.3) (from the plant 
Papaver somniferum) [2]. In the 20th century, the focus continued to transfer from 
natural/herbal medicines to pharmaceuticals for the treatment of illnesses and diseases, with 
the discovery of penicillin (1.4) a major influence on the pharmaceutical industry. Following 
this, in the 1930’s and later, drug discovery moved to the screening of natural products and 
the isolation of active compounds from well-established biologically active plant extracts [3]. 
Despite the increasing prominence of the pharmaceutical industry during the 20th century to 
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the present day, it is estimated by the World Health Organisation (WHO) that 75% of the 
world’s population still relies on traditional medicines for primary health care [1].  
After 1980, the focus moved away from looking at natural products as a means of providing 
new pharmacophores or new drugs, instead progressing to other methods as a means to 
discover new drugs and drug leads [3]. This was mainly due to advancements in high-
throughput screening (HTS) and combinatorial chemistry methodologies, where micro-scale 
syntheses produced a vast array of compounds which could be tested for biological activity 
and therapeutic potential. However these HTS techniques were not as successful as 
anticipated, with only one compound derived from combinatorial chemistry resulting in an 
approved drug, namely the anti-tumour drug sorafenib (1.5). This lack of success prompted 
the re-instatement of natural products as a means for providing potential drug leads [3, 4]. In 
the period from 1981-2010, a total of 1,355 drugs were approved, with fifty-nine (4%) being 
natural products and two hundred and ninety-nine (22%) derived from natural products as 
shown in Figure 1.1 [5].  
 
 
Figure 1.1. All approved drugs from 1981-2010 (sourced from Newman and Cragg [5]). 
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Also in this period the total number of approved anti-cancer drugs was one hundred and 
twenty-eight, with eleven (9%) being of natural product origin. The most well-known of these 
is paclitaxel (also known as Taxol) (1.6) from the Pacific yew tree, Taxus brevifolia. Another 
thirty-two (25%) approved anti-cancer drugs were derived from natural products (Figure 1.2) 
[5].  
 
 
Figure 1.2. All approved cancer drugs from 1981-2010 (sourced from Newman and Cragg 
[5]). 
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1.1.2 Approaches to Natural Products Isolation 
Classical approaches used in the isolation, characterisation and biological evaluation of 
secondary metabolites from natural product extracts can still result in the discovery of 
biologically active new compounds. Often these studies are motivated by the ethnobotanical 
and/or ethnopharmacological properties that the extract is known to possess. The limitation 
of this approach is that there is no way of predicting if the isolated compounds will possess 
biological activity [1]. There is also the problem that isolated compounds are generally only 
tested for biological activity in a limited number of bioassays, which decreases the chances 
of observing significant biological activity.  
Modern strategies for the isolation of natural product drug leads involve the use of bioassay-
guided fractionation, whereby the biological activity of the crude extract and subsequent 
fractions are assessed throughout the isolation procedure. This approach guides the 
fractionation/isolation process so as to assist in the isolation of bioactive compounds and can 
therefore remove the uncertainty as to whether compounds may or may not possess the 
activity displayed by the crude extract. Limitations arise when activity of the crude extract 
diminishes as fractionation/isolation steps are conducted or when active fractions are 
obtained in such low quantities that identification of individual compounds is impossible with 
current techniques. Further technological advancements in the area of natural products 
isolation/identification include chemical fingerprinting/profiling, metabolomics and 
dereplication [1].  
Dereplication is the methodology by which bioactive natural product extracts can be excluded 
from in-depth chemical investigation studies so as to avoid re-discovery of either previously 
well-established biologically active natural products or isolation of nuisance compounds (eg. 
chlorophylls, fatty acids etc.). The process involves the analysis of natural product extracts or 
enriched fractions in order to quickly ascertain information regarding the possibility of novel 
compounds being present [1]. Together with the spectroscopic information obtained from a 
dereplication exercise (eg. NMR, MS and UV-Vis), the use of specific databases can be an 
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invaluable tool in this process. The ability to search the chemical literature based on 
taxonomy, structural information, as well as other spectroscopic information such as 
molecular mass, is particularly important to circumvent lengthy isolation procedures that 
would otherwise lead to the re-isolation of previously reported compounds. These databases 
can be very broad in their scope, for example Chemical Abstracts [6] and the Dictionary of 
Natural Products [7], or they can be more specific such as databases like MarinLit [8] which 
contains only information pertaining to the marine natural product literature. 
1.1.3 Hyphenated Spectroscopic Techniques 
The use of hyphenated spectroscopic techniques is also a key advancement in the 
dereplication process as structural information can be obtained much more quickly than from 
conventional isolation methods. The combination of a separation technique followed by 
spectroscopic analysis without intervening handling, allows for the collection of information 
that can be entered into databases to determine whether the extract should be subjected to 
off-line isolation procedures. The major hyphenated techniques used in the dereplication 
process include HPLC-NMR, HPLC-MS, GC-MS, as well as HPLC-NMR-MS. Each 
hyphenated technique has advantages and limitations, for example GC-MS analysis is very 
sensitive and only requires small quantities of material in order to obtain the mass spectra of 
compounds that are present in the sample as well as often providing fragmentation to give 
further structural insights. GC-MS however is a destructive technique and is only suited to 
the analysis of volatile compounds. This often means that there is a requirement to derivatise 
compounds to increase their volatility and this is not suited to an isolation in which the 
compound’s integrity needs to be maintained for bioassay. HPLC-MS has the advantage of 
being a less destructive technique than GC-MS, with only the small portion of the sample that 
is diverted through to the mass spectrometer being destroyed. Overall this is a non-
destructive technique which offers separation and mass spectral information. One limitation 
with HPLC-MS, specifically HPLC-ESI-MS, is that not all compounds in an extract will ionise 
readily in both or either ionisation modes, meaning multiple injections are required in an 
Marine and Terrestrial Natural Products Discovery 
6 
attempt to get all of the compounds present to ionise. In addition, solubility issues can often 
arise for non-polar constituents.  
HPLC-NMR is a hyphenated spectroscopic technique that is not as popular as HPLC-MS 
(owing to the marked difference in sensitivity) in the dereplication process. However, it can 
offer great insights into the structures of the compounds that are present. HPLC-NMR is a 
non-destructive technique that allows for the fraction/extract injected to be analysed in situ 
and then collected intact. This provides the ability for the fraction/extract to be evaporated 
and then re-used for the isolation of the secondary metabolites present. The three modes of 
operation in HPLC-NMR are the on-flow, stop-flow and time-sliced modes. On-flow HPLC-
NMR analysis allows for direct on-line analysis of the compounds present in an extract or 
fraction, whereby a series of continuous WET-1D 1H NMR spectra as separated out by HPLC 
can be obtained for the sample. Stop-flow analysis allows for the trapping of single 
compounds in the NMR flow cell for an indefinite period, allowing for longer acquisition times 
and for 2D NMR analysis of individual components. Once one component is analysed, the 
HPLC pumps can be re-started so as to continue the elution, allowing for the next peak to be 
trapped for similar analysis. Time-slicing is a method where the pump is stopped 
automatically at intervals during the HPLC run and longer WET-1D spectra are acquired. 
Once these are complete, the pump then restarts and is then stopped after the next interval 
[9]. Time-slicing is a good method for the detection of peaks with poor separation and for 
automated stop-flow analysis of compounds that do not possess a UV chromophore. As 
noted earlier, the limitations with HPLC-NMR are those associated with sensitivity. With the 
NMR as the detector, higher concentrations of compounds than is suitable for analytical 
HPLC are required. This translates to the need to overload the analytical HPLC separation 
method to accommodate the need for greater quantities of compounds that are necessary for 
the NMR analysis, often at a cost to the quality of the chromatography. This need for 
overloading of the sample is diminishing with the advancements in technology, with high-field 
magnets, cryogenic probes and software improvements allowing for smaller quantities of 
material to be analysed. Another major problem associated with HPLC-NMR usage is the 
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need for at least one deuterated solvent for the analysis (generally D2O is used) which is 
costly given the constant flow during analysis. An extension of HPLC-NMR is the addition of 
a further spectroscopic technique, as in the case of HPLC-NMR-MS, whereby the sample, 
once separated by HPLC, is diverted for analysis by NMR and MS simultaneously. 
Alternatively, after analysis by NMR, the sample is split between the MS and waste to allow 
for the MS analysis. The greater amount of information that can be acquired by a single 
analysis, complemented by the use of databases, can dramatically reduce the need for an 
off-line isolation and therefore also reduce the total number of previously reported 
compounds being re-isolated. These hyphenated spectroscopic approaches allow for a 
greater insight into the probable secondary metabolites present in any given organism. 
1.1.4 Marine Natural Products 
While the terrestrial environment has been studied extensively for biologically active natural 
products, especially those derived from traditional medicines, the marine environment has 
not been studied as thoroughly. The focus for the study of marine organisms as a means of 
providing potentially biologically active compounds was prompted by the fact that 70% of the 
world’s surface is oceans [10] and should therefore provide rich biodiversity. Marine natural 
products research was initially limited to the study of organisms from shallow waters until the 
advancements in the areas of SCUBA diving and trawling [10]. The world’s oceans provide 
tremendous biodiversity with many areas (e.g. hydrothermal vents and sea mounts) not 
having been extensively studied owing to the difficulty in collection. Because there is very 
little traditional medicinal knowledge associated with marine organisms (as opposed to the 
rich lore regarding terrestrial organisms such as plants), the search for biologically active 
compounds from marine sources has occurred via a more random selection of organisms. 
The first drug candidates that were isolated from marine sources were Ara-C (1.7), an anti-
leukemic drug, and the similar Ara-A (1.8) an anti-viral drug, both derived from the marine 
sponge Tethya crypta [11, 12]. The field of marine natural products has grown extensively 
over the last fifty years, as shown by an increase in the total number of isolated compounds 
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per year. In 2003, six hundred and fifty-six compounds were reported [13] while in 2009, 
1,011 compounds were documented [14]. While there has been a steady increase in the 
number of marine natural products isolated or reported, the number of potential 
pharmaceuticals that have been discovered from marine sources is limited. The most notable 
marine natural product pharmaceuticals include the anti-tumour drug ET-743 (1.9), from the 
tunicate Ecteinascidia turbinate [12], the analgesic conotoxin peptide Ziconotide, from the 
cone snail Conus magus [11] and cephalosporins such as cephalosporin C (1.10) from 
marine fungi [15].  
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The discovery of marine natural products as potential drug candidates comes with some 
problems. Firstly, these biologically active constituents are generally present in very small 
quantities within the sample. This poses difficulties in terms of re-isolation or scale-up for 
further biological testing and has implications in terms of harvesting (the actual mass of 
organism required for large-scale isolation as well as issues associated with ecological 
considerations). Consequently, synthesis of the active compound(s) is often required to 
provide sufficient material for further biological activity studies [12]. These problems are 
compounded by the inherent complex nature of many of the marine natural product scaffolds. 
One of the strategies to overcome the problems associated with obtaining sufficient 
quantities of these compounds is to adopt a semi-synthetic approach in the synthesis of 
biologically active marine natural products (which also results in the synthesis of structural 
analogues). Technological advances such as HTS, computational biology and bioinformatics 
are also being increasingly employed [12]. 
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1.1.5 Plant Natural Products 
Plants have been studied for centuries for their biologically active components, primarily on 
the basis of the traditional uses of the plants. For example, in 1630 it was discovered that the 
bark of the Cinchona tree in Peru could overcome fevers. When it was introduced to Europe, 
it was found to have specific anti-malarial activity [16]. This activity was later shown to be due 
to the primary component, quinine (1.11) [16]. For nearly three hundred years, the only 
recorded treatments of malaria were quinine (1.11) or its natural source, the powdered bark 
of the Cinchona tree [16]. Other examples of plant natural product derived drugs are listed in 
the general introduction in Section 1.1.1. 
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1.1.6 Natural Product Studies Conducted 
During the course of this research, a total of two marine and three terrestrial plants were 
investigated. A combination of on-line profiling and traditional natural product isolation 
methodologies resulted in a total of seven structure classes being identified. Two of the 
structure classes that were identified during this research were of the flavonoid and 
naphthoquinone structure classes. These classes of compounds are well-known to possess 
a broad range of biological activity, as well as being found throughout the plant kingdom. A 
range of natural and synthetic derivatives of these two structure classes are provided as a 
review in the sections that follow (Section 1.2 and Section 1.3) 
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1.2 Flavonoids 
1.2.1 General Introduction  
Flavonoids is the general name given to the group of polyphenolics such as the flavanones, 
flavones, flavonols, flavanol, isoflavones and anthocyanidins, the structures of which are 
given in Figure 1.3 [17]. Flavonoids can be present in nature as the free aglycones or as 
glycosides [18], with the main variations in structure being the degree of oxygenation as well 
as type, degree and pattern of alkyl substitution throughout the core flavonoid structure [19]. 
Flavonoids are one of the most widely spread classes of natural products found within the 
plant kingdom [18, 20], with more than 6,500 different flavonoids known to exist [19]. The 
biological activities of flavonoids, especially those found in food, have been studied 
extensively, with the use of flavonoid-containing extracts (e.g. from Ginko biloba, Tilia spp., 
Equisetum spp., Moringa oleifera and Sophora japonica), being used for the treatment of 
many types of illnesses [20]. Flavonoids have been found to possess anti-oxidant, anti-
osteoporotic, anti-diabetic, anti-inflammatory, anti-microbial, anti-cancer, cardio-protective, 
neuro-protective, estrogenic/anti-estrogenic, anxiolytic, analgesic and anti-allergic activities 
[20].  
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Figure 1.3. Structure classes described as flavonoids 
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4CL - 4-coumarate:CoA ligase; ANR - anthocyanidin reductase; ANS - anthocyanidin synthase; C4H - cinnamate 
4-hydroxylase; CHI - chalcone isomerase; CHR - chalcone reductase; CHS - chalcone synthase; DFR - 
dihydroflavonol 4-reductase; F3H - flavonone 3-hydroxylase; F3’H - flavonoid 3’-hydroxylase; F3’5’H - flavonoid 
3’5’-hydroxylase; FLS - flavonol synthase; FNSI/II - flavone synthase; Glc – glucose; IFS - isoflavone synthase; 
LAR - leucoanthocyanidin reductase; PAL - phenylalanine ammonia lyase; UFGT - UDP-glucose: flavonoid 3-O-
glucosyltransferase 
Scheme 1.1. The biosynthetic pathway for the major subclasses of flavonoids (sourced from 
Tsao and McCallum [21]) 
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1.2.2 Biological Activity  
1.2.2.1 Anti-cancer flavonoids 
The anti-cancer activity of flavonoids has been well documented since 2008, with over six 
hundred references citing the cytotoxicity and anti-cancer activity of flavonoids [22]. Selected 
references from the period 2008-2012 are reviewed below. 
 
Many studies into the anti-cancer activity of flavonoids and flavonoid glycosides have shown 
that flavonoids such as kaempferol (1.12) have a preventative effect against many forms of 
cancer [20, 23]. It has been shown that dietary flavonoids inhibit cytochrome P450 CYP1 
enzymes, which is important for their cancer preventative characteristics [24, 25]. The direct 
mode of action of flavonoids and flavonoid glycosides against different forms of cancer is 
starting to become understood, together with the mechanism of the synergistic effect of 
flavonoids such as kaempferol (1.12) that are administered with other anti-cancer drugs. 
These reports are accompanied by suggestions that flavonoids may have adjuvant therapy 
applications [20, 25]. The actual mechanism for the anti-cancer activity of some flavonoids 
has been suggested to be associated with their antimitotic activity [25]. The flavonoids 
kaempferol (1.12), quercetin (1.13), apigenin (1.14), chrysin (1.15), fisetin (1.16), wogonin 
(1.17) and lutelin (1.18), are all known to exhibit anti-cancer activity [26]. It was thought that 
the anti-cancer activity of these flavonoids (1.12-1.18) may be due to the anti-angiogenic 
activity shown [26].  
The flavonoid wogonin (1.17), isolated from Scutellaria baicalensis Georgi has been shown 
to possess cytotoxic and cytostatic activity towards several anti-cancer cell lines, while also 
having low toxicity towards normal cells, as well as possessing synergistic effects when 
administered with other drugs [27].  
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Silibinin (1.19), isolated from Silybum marianum, is known to possess anti-cancer activity 
towards prostate, colon, bladder and lung cancers, with the compound found to be active 
against the migration, invasion and metastasis of cancer cells [27]. Silibinin (1.19) has also 
been found to protect against angiogenesis and late-stage metastasis, suggesting it has the 
potential to improve the survival and reduce the morbidity in prostate cancer patients [27].  
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Luteolin (1.18), a dietary flavonoid that can be found in many green vegetables, has been 
found to possess anti-tumour activity for various types of cancer in vitro, with IC50 values 
ranging from 3 M to 50 M [27]. Apigenin (1.14), another dietary flavonoid, has been shown 
to provide cancer preventative benefits, displaying anti-cancer activity against many forms of 
cancer, while also possessing low toxicity levels to normal cells [23, 28]. Apigenin (1.14) has 
also been shown to inhibit regulation of the p14ARF-Mdm2-p53 pathway in breast cancer cell 
growth as well as increasing the expression of UDP-glucuronosyltransferase in colon cancer 
and increasing the down-regulation of NF-jB activity with the suppression of Akt in pancreatic 
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cancer [23]. Quercetin (1.13) increases the efficacy of cisplatin both in vivo and in vitro, while 
also providing protection from cisplatin toxicity in normal cells [29]. In vitro studies have also 
revealed that quercetin (1.13) possesses synergistic effects when combined with anti-cancer 
compounds such as busulfan and cyclophosphamide, while also decreasing resistance of 
multidrug-resistant cell lines to chemotherapy [29]. Quercetin (1.13) is known to inhibit the 
MCF-7 breast adenocarcinoma, HT-29 human colon adenocarcinoma and K562 human 
chronic myelogenous leukaemia cell lines [30]. The flavonoid breviflavone B (1.20), isolated 
from Epimedium brevicornum, was found to possess activity against breast cancer cell 
proliferation [31]. Compound 1.21, from Triplaris cumingiana, showed cytotoxicity to the H-
460 lung cancer cell line [31], while a study of Muntingia calabura afforded compounds 1.22 
and 1.23 which showed cytotoxicity towards the P388 cell line [31].  
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In a study of the prenylated flavonoid, arochamin C (1.24), this compound showed activity 
against a number of human tumour cell lines, while artoindonesianin U (1.25) was found to 
possess P388 anti-tumour activity [31]. In a study on the aerial parts of Eucalyptus 
occidentalis, compound 1.26 was found to induce apoptosis in human myeloid leukemia cells 
[31]. The flavonoids 1.27 and 1.28, isolated from Zingiber aromaticum, have been shown to 
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have activity against the CYP3A4 and CYP2D6 cytochromes, with the tri-acetyl derivative 
1.28 being the more active (IC50 values of 14.4 M and 43.3 M against the two isoforms 
respectively) [31]. The flavonoids 1.29 and 1.30, isolated from Dendrolobium lanceolatum, 
were found to possess moderate activity in cytotoxicity assays [31]. The flavonoid styracifolin 
B (1.31) was shown to be active against the KB mouth epidermoid carcinoma cell line and 
MRC-5 human diploid embryonic lung cells, with IC50 values of 5.6 M and 4.7 M 
respectively [32]. The use of fisetin (1.16) in combination with the anti-cancer compound 
cisplatin established that these two compounds activate the cell death receptor pathway and 
could be a useful combined therapy for the elimination of embryonic carcinoma cells [33].  
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From a study of Leucenia leucocephala myricetin 3-O-(2’,3’,4’-tri-O-galloyl)--L-
rhamnopyranoside (1.32) was found to possess Hep-G2 hepatocellular carcinoma cell line 
activity, with an IC50 value of 2.14 g/mL [34]. In a study, the flavonoid 1.33 isolated from 
Macrothelypteris torresiana, a structural derivative of protoapigenone (1.34), was found to 
have activity towards the human Hep-G2 cell line, while being inactive towards normal cells 
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[35]. A further study of protoapigenone (1.34) from the same source showed that this 
compound was active against Hep-G2 (2.3 g/mL), Tca-8113 oral squamous cell carcinoma 
(0.6 g/mL), MCF-7 (0.8 g/mL) and K562 human erythroleukemic (0.9 g/mL) cell lines [36]. 
Chrysin (1.15) has been found to possess activity against many varieties of cancer, such as 
the cervical cancer cell line HeLa (IC50 values of between 14.2 M and 30 M), U937 
leukaemia cell line (16 M), possessing activity against other cell lines of leukaemia, 
cytotoxicity towards KYSE-510 oesophageal squamous carcinoma (63 M), as well as 
showing activity against malignant glioma, breast carcinoma and prostate cancer [37]. From 
a study into the MDA-MB-468 human breast cancer cell line, activities of the flavonoids 
chrysin (1.15) (IC50 20.5 M), genkwanin (1.35) (IC50 1.6 M), baicalein (1.36) (IC50 6.3 M), 
scutellarein (1.37) (IC50 12.8 M) and sinensetin (1.38) (IC50 0.2 M) were established [38]. 
The flavonoids luteolin (1.18) and diosmetin (1.39) from the flowers of the plant species 
Chrysanthemum morifolium were found to possess anti-cancer activity against the Colon205 
cell line, with IC50 values of 96.9 M and 82.9 M respectively for the two compounds [39].  
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In a report of the cytotoxicity of the flavonoid and flavonoid glycosides isolated from 
Horwoodia dicksoniae against the Hep-G2 hepatocellular carcinoma cell line, MCF-7 breast 
adenocarcinoma and HCT-116 colon cell line, the activity for the flavonoids luteolin (1.18) 
(pg 12) (IC50 values for HEP-G2 12.3 M, HCT-166 9.5 M and MCF-7 12.7 M), luteolin 7-
O--ᴅ-glucopyranside (1.40) (10.7 M, 9.3 M and 9.9 M) and luteolin 6-C--ᴅ-
galactopyranoside (1.41) (15.8 M, 11.2 M and 19.5 M) showed that each compound 
displayed activity in the same order of magnitude to that of doxorubicin (~4.5 M against 
each cell line) [40]. From a study of the constituents present in Andrographis paniculata four 
flavonoids (1.42-1.45) were evaluated for biological activity against the Jurkat human 
lymphocytic cancer cell line, the PC-3 human prostate cancer cell line and the Colon205 
human colonic cancer cell line, with 1.42-1.45 displaying activity towards the Jurkat cell line 
with IC50 values between 50-150 M, while displaying no cytotoxicity towards any of the other 
cell lines up to the highest concentration tested of 20 M [41].  
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Of the twenty-two flavonoids isolated from a Brazilian propolis, a natural resinous product 
collected by honey bees from various plants, (2S)-7-hydroxy-6-methoxyflavanone (1.46) was 
found to be the most active compound against all strains of cancer, with activity against 
Colon 26-L5 colon carcinoma (IC50 5.9 M), B16-BL6 melanoma (IC50 6.7 M), LLC lewis 
lung carcinoma (IC50 9.3 M), A549 lung adenocarcinoma (IC50 8.6 M), HeLa cervical 
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adenocarcinoma (IC50 5.6 M) and HT-1080 fibrosarcoma (IC50 7.9 M) having been 
observed [42].  
Isolated from the plant species Artocarpus communis, the flavonoids arcommunol A (1.47), 
arcommunol B (1.48) and 8-geranyl-3’,4’,7’-trihydroxyflavone (1.49) were shown to possess 
activity against the Hep-G2 hepatocellular carcinoma cell line, Hep-3B hepatoma, PLC-5 
hepatocellular carcinoma and SK-Hep-1 hepatocellular carcinoma cell lines [43]. The activity 
of each compound was assessed and the following IC50 values were reported: arcommunol A 
(1.47) (IC50 values Hep-G2 9.19 M, Hep-3B 20.4 M, PLC-5 30.3 M and SK-Hep-1 2.05 
M); arcommunol B (1.48) (IC50 values of 5.55 M, 23.9 M, 13.1 M and 7.82M) and 8-
geranyl-3’,4’,7’-trihydroxyflavone (1.49) (IC50 values of 4.42 M, 9.95 M, 9.24 M and 6.65 
M) [43].  
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The study by Lee et al [44] of four hundred and fifty flavonoids for anti-cancer activity against 
human cervical and prostate cancer cells, revealed that 3,6-dihydroxyflavone (1.50) is a 
potent agonist of hPPAR with cytotoxicity towards both cervical and prostate cancer cells 
[44]. Flavonoids isolated from Diplotaxis harra (Forssk.) Boiss. were assessed for cytotoxicity 
against the HCT-116 human colonic carcinoma cell line, with quercetin (1.13) (page 12) (IC50 
20.1 g/mL), quercetin-3-O--glycoside (1.51) (IC50 24.3 g/mL), isorhamnetin-7-O--
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glycoside (1.52) (IC50 22.8 g/mL) and kaempferol-3-O--glycoside (1.53) (IC50 41.9 g/mL) 
displaying moderate cytotoxicity [45].  
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The three flavonoids isolated from the shrub Smilax china L. were found to possess anti-
cancer activity towards the MCF-7 breast adenocarcinoma and MDA-MB-231 human breast 
carcinoma cell lines, namely dihydrokaempferol (1.54) (IC50 values of MCF-7 15.1 g/mL, 
MDA-MB-231 33.1 g/mL), kaepferol-7-O--glycoside (1.55) (IC50 values of 8.4 g/mL, 23.1 
g/mL) and dihydrokaempferol-3-O-ᴅ-L-rhamnoside (1.56) (IC50 values of 18.0 g/mL, 20.8 
g/mL) [46].  
From a study into the flavonoids found in citrus fruits, it was determined that apigenin (1.14) 
(pg 12) and quercetagetin (1.57) exhibit potent anti-cancer activity against SW480 human 
colon cancer cells by inducing apoptosis [47]. A separate study of hesperetin (1.58), found in 
citrus fruits such as oranges and grapefruit, showed that 1.58 possessed activity towards the 
Notch1 signalling pathway, which was shown to be essential in the suppression of carcinoid 
tumours proliferation, suggesting that 1.58 could be a potential treatment for carcinoid 
cancers such as colon, renal and small cell lung cancers [48]. 
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The flavonoids (1.13, 1.18 and 1.59-1.64) isolated from the Chinese herb, Rabdosia 
rubenscens, were assessed against the HL-60 human promyelocytic leukemia cell line and 
while 5,8,4’-trihydroxy-6,7,3’-trimethoxyflavone (1.59) showed no activity at the highest 
concentration tested (100 M), quercetin (1.13) (pg 12) (IC50 69.68 M), luteolin (1.18) (IC50 
46.64 M), nodifloretin (1.61) (IC50 69.34 M), pedalitin (1.62) (IC50 61.98 M) and penduletin 
(1.63) (IC50 52.00 M) showed moderate activity, with 5,4’-dihydroxy-6,7,8,3’-
tetramethoxyflavone (1.60) being the most active with an IC50 of 7.55 M, comparable to the 
known anti-cancer drug doxorubicin (IC50 4.64 M) [49].  
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Rosa canina L. was also found to contain the flavonoid quercetin (1.13) (pg 12) and it was 
once again found to be a potent inhibitor of the HeLa cervical adenocarcinoma (IC50 10.3 
g/mL), HT-29 colon adenocarcinoma (IC50 12.7 g/mL) and MCF-7 breast adenocarcinoma 
(IC50 25.3 g/mL) cell lines [50]. 
Of the ten flavonoids isolated from Rosmarinus officinalis it was found that kaempferol (1.12) 
possessed weak activity against the HL-60 human promyelocytic leukemia cell line (IC50 82 
M) and that luteolin (1.18) possessed moderate activity against the same cell line (IC50 39.6 
M) [51].  
In a report of the flavonoids from the two species of the perennial herb Scutellaria (S. 
immaculata and S. ramosissima), a total of thirty-one flavonoids were identified and 
evaluated for biological activity towards the HeLa cervical adenocarcinoma, Hep-G2 
hepatocellular carcinoma and MCF-7 breast adenocarcinoma cell lines [52]. It was found that 
of the six flavonoids subjected to biological evaluation against these cancer cell lines, only 
apigenin (1.14) (IC50 33.3 g/mL) and chrysin (1.15) (IC50 22.8 g/mL) showed moderate 
activity towards the HeLa cell line, while apigenin (1.14) (IC50 64.6 g/mL), chrysin (1.15) 
(IC50 14.0 g/mL) and scutellarin (1.65) (IC50 94.6 g/mL) displayed moderate activity towards 
the Hep-G2 cell line. The same three compounds displayed moderate activity towards the 
Hep-G2 cell line (apigenin (1.14) (IC50 17.3 g/mL), chrysin (1.15) (IC50 22.7 g/mL) and 
scutellarin (1.65) (IC50 31.8 g/mL)) [52].  
A study into the activity of the dietary flavonoid luteolin (1.18) on oral squamous cell 
carcinoma concluded that continuous administration of luteolin (1.18) was effective in the 
suppression of xenograft tumours in mice, while used in conjunction with taxol, it enhanced 
the cytotoxic effect of taxol [53]. 
Four of the flavonoids (1.66-1.69) that were isolated from the tropical tree, Macaranga triloba, 
were evaluated against the HL-60, MCF-7 and HeLa cell lines, with 6-prenyl-3’-
methoxyeriodictyol (1.66) (HL-60 IC50 15.1 g/mL, MCF-7 IC50 22.8 g/mL and HeLa IC50 
12.2 g/mL), nymphaeol B (1.67) (IC50 21.3 g/mL, IC50 23.5 g/mL, IC50 17.0 g/mL) and 
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nymphaeol C (1.68) (IC50 11.6 g/mL, IC50 23.0 g/mL, IC50 18.2 g/mL) showing moderate to 
weak activity against the cell lines, while 6-farnesyl-3’,4’,5,7-tetrahydroxyflavanone (1.69) 
(IC50 3.3 g/mL, IC50 5.6 g/mL, IC50 1.3 g/mL) was found to have potent activity against 
each of these cell lines [54].  
Research into the effect of commercial myricectin (1.70) on pancreatic cancer showed that, 
in vitro, myricetin (1.70) induced pancreatic cancer cell death via apoptosis, while in vivo 
treatment resulted in the regression of tumours and decreased the level of metastatic spread. 
These observations together with the fact that, in vitro and in vivo, myricetin (1.70) was non-
toxic to normal cells, suggest that 1.70 is a potential therapeutic agent against pancreatic 
cancer [55].  
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The synthetic flavonoid flavopiridol (1.71), a derivative of the natural product, rohutikine 
(1.72), isolated from Dysoxylum binectariferum Hook., is currently undergoing Phase I/II 
clinical trials against various forms of cancer, with fifty-one active or completed trials [9, 56]. 
From a series of forty-nine synthetically prepared flavonoid derivatives that were screened 
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for breast cancer activity, compound (1.73) was found to be the most active with an IC50 of 1 
M, while compounds 1.74 (IC50 2 M), 1.75 (IC50 5 M), 1.76 (IC50 5 M), 1.77 (IC50 7 M), 
1.78 (IC50 5 M), 1.79 (IC50 5 M), 1.80 (IC50 5 M) and 1.81 (IC50 7 M) also displayed potent 
activity [57].  
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Two synthetic analogues (1.83 and 1.84) based on the natural flavonoid gericudranin A 
(1.82) were tested for anti-cancer activity towards sixteen human cancer cell lines and were 
found to possess potent activity. Compound 1.83 was active against CAKi-1 kidney clear cell 
carcinoma (IC50 1.9 M), SNB-75 glioblastoma (IC50 2.7 M) and NCI-H522 lung Cancer (IC50 
2.3 M), while 1.84 was most active against LOX-IMVI melanoma (IC50 2.1 M), HCT-15 
colon carcinoma (IC50 2.8 M) NCI-H522 (IC50 3.0 M) and SNB-19 glioblastoma (IC50 0.7 
M), the last of which was comparable to doxorubicin (IC50 0.6 M) [58].  
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The flavonoid dimer remangiflavone C (1.85) from Physena madagascariensis was shown to 
exhibit activity in the A2780 ovarian cancer cell line cytotoxicity assay, with an IC50 of 2.5 
g/mL [31]. The flavonoid dimers 7,7’’-dimethyl lanaraflavone (1.86), agathisflavone (1.87) 
and 7’’-methyl agathisflavone (1.88), isolated from Lonicera japonica (Japenese 
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Honeysuckle) and Benincasa hispida (Chinese Winter Melon) were evaluated for their 
activities against HT-29 human colon adenocarcinoma, NCI-H460 human non-small cell lung 
carcinoma, RXF-393 human renal cell carcinoma, MCF-7 breast adenocarcinoma and 
OVCAR-3 human ovarian adenocarcinoma cell lines [59]. The study established that 7,7’’-
dimethyl lanaraflavone (1.86) possessed activity against the NCI-H460 (IC50 value of 1.77 
M), RXF-393 (IC50 41.6 g/mL), MCF-7 (IC50 3.42 g/mL) and OVCAR-3 (IC50 3.59 g/mL) 
cell lines but no activity against HT-29. Compound 1.88 was found to be active against HT-
29 (IC50 4.38 g/mL), NCI-H460 (IC50 5.36 g/mL), RXF-393 (IC50 4.86 g/mL), MCF-7 (IC50 
5.58 g/mL) and OVCAR-3 (IC50 5.18 g/mL) but agathisflavone (1.87) was only slightly 
active against RXF-393 (IC50 45.9 g/mL), and showed no activity against the other cell lines 
used in this study [59]. Investigations into the biological activity of the flavonoid dimer 
ochnaflavone (1.89), also found in Lonicera japonica, showed anti-cancer activity towards the 
HCT-15 colon cancer cell line, with an IC50 value of 4.1 M. The authors suggested that cell 
cycle arrest and induction of apoptosis could be the mechanism by which these compounds 
target cancer cells [60]. 
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1.2.2.2 Anti-parasitic flavonoids 
Parasitic diseases are a major cause of death in tropical and sub-tropical regions and many 
of the most deadly parasitic infections affect some of the poorest regions of the world [61, 
62]. Prevention and treatment of parasitic infections is very important, with the need for 
cheap treatment methods being imperative, due to the poor economic regions mainly 
affected by these parasites. The use of traditional remedies for the treatment of these 
diseases has led to the isolation of novel compounds with anti-parasitic properties, and 
synthetic chemists have developed new compounds based on known pharmacophores in 
order to find more effective treatments for these diseases. The three major parasitic diseases 
that affect some of the poorest regions of the world are malaria, leishmaniasis and 
trypanosomiasis. 
 
1.2.2.2.1 Anti-malarial flavonoids 
Malaria is a parasitic disease caused by five species of Plasmodium parasites and spread by 
the Anopheles mosquito [61]. Malaria is largely prominent in equatorial countries, with sub-
Saharan Africa being the major area for cases of malaria, although Asia, Latin America and, 
to a lesser extent, the Middle East and parts of Europe are also areas of risk [62]. WHO 
reports that ninety-nine countries or territories have ongoing transmission of malaria and 
estimates that 216 million cases of malaria occurred in 2010 and that 655,000 people died of 
which 86% were children under five years of age [62]. The WHO has noted that growth in 
global funding for malaria prevention slowed between 2010 and 2012 and has suggested 
that this could threaten the recent gains in the fight against malaria [62]. The WHO has a 
target for a 75% reduction in cases of malaria by 2015, with fifty of the ninety-nine countries 
expected to reduce new cases of malaria by this amount. However, these fifty countries only 
represent ~3% of worldwide malaria cases [62]. With the large number of cases and deaths 
caused by malaria each year, and the ongoing issues with the treatment of people with 
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malaria, development of compounds for prevention and treatment of malaria are two major 
areas of interest for both natural product and synthetic chemists. 
 
The extract of the Madagascan legume, Dalbergia louvelii, which is a traditional anti-malarial 
treatment, was found to contain the flavonoid 7,4’-dihydroxy-3’-methoxyflavone (1.90). This 
compound possesses moderate anti-parasitic activity towards the chloroquine-resistant strain 
FcB1 of P. falciparum, with an IC50 of.8.7 M [9].  
In Kenya, the use of the bark of Erythrina abyssinica is the most prominent malaria 
treatment. Flavonoids isolated from the bark displayed activity against the D6 and W2 strains 
of P. falciparum, with the prenylated flavonoid abyssinin III (1.91) displaying the greatest 
activity towards P. falciparum, with an IC50 of 4.9 M against the W2 strain [9]. The flavonoid 
glycosides luteolin-7-O--ᴅ-glucopyranoside (1.92) and chrysoeriol-7-O--ᴅ-glucopyranoside 
(1.93), isolated from the perennial herb, Phlomis brunneogaleata, were shown to possess 
IC50 values of 5.4 M and 12.8 M respectively against the chloroquine-resistant strain K1 of 
P. falciparum [9]. Compound 1.92 also showed further activity with enzyme-inhibitory 
potential towards enoyl-ACP reductase (FAB I) of P. falciparum with an IC50 of 22.3 M [10]. 
This is the first natural product to target the FAB I enzyme, the key regulator of type II fatty 
synthase (FAS-II) in P. falciparum [9].  
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The flavonoid obovatin (1.94), isolated from seedpods of the bushy perennial,Tephrosia 
elata, was found to possess an IC50 of less than 27.6 M against both D6 and W2 strains of 
P. falciparum [63].  
The anti-malarial activity of the natural flavonoids lupinifolin (1.95), citflavone (1.96), 
erythrisenegalone (1.97), lonchocarpol A (1.98), liquiritigenin (1.99) and 8-prenyldaidzein 
(1.100), isolated from Erythrina fusca Lour., towards the K1 strain of P. falciparum was 
assessed. Compounds 1.96, 1.98 and 1.100 all displayed an IC50 of less than 12.5 M, with 
1.98 being the most active with an IC50 of 3.9 M [63].  
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Tests on (+)-catechin (1.101) and its 5-gallate (1.102) and 3-gallate (1.103) derivatives, 
isolated from Piptadenia pervillei Vatke revealed that, while (+)-catechin (1.101) showed no 
activity towards the chloroquine-resistant FcB1 strain P. falciparum, the 5-gallate (1.102) and 
3-gallate (1.103) derivatives possessed anti-malarial activity with IC50 values of 1.2 M and 
1.0 M respectively [63].  
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Anti-malarial activity was also found for the flavonoids artemetin (1.104) (IC50 26 M), casticin 
(1.105) (IC50 24 M), chrysoplenetin (1.106) (IC50 23 M), chrysosplenol-D (1.107) (IC50 32 
M), cirsilineol (1.108) (IC50 36 M) and eupatorin (1.09) (IC50 65 M), isolated from Artemisia 
annua [64].  
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The dietary flavonoid luteolin (1.18) (pg 12), as well as displaying anti-cancer activity, was 
found to possess anti-malarial activity towards the 3D7 and 7G8 strains of P. falciparum with 
an IC50 of 11 M and 12 M respectively [63]. Luteolin (1.18) prevents the progression of 
parasite growth, but does not affect susceptibility to the anti-malarial drugs chloroquine or 
artemisinin [63].  
As well as the anti-cancer activity mentioned earlier in this review (pg 21), anti-malarial 
activity towards the 3D7 strain of P. falciparum was also found for nymphaeol B (1.66) (IC50 
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4.02 M), nymphaeol C (1.67) (IC50 2.04 M) and 6-farnesyl-3’,4’,5,7-tetrahydroxyflavanone 
(1.68) (IC50 0.06 M), isolated from Macaranga triloba. [54].  
The Coral or Lucky Bean Tree, Erythrina burttii, contains many compounds that possess 
anti-malarial activity towards the D6 and W2 strains of P. falciparum, namely the flavonoids 
4’-O-methylsigmoidin B (1.110) (IC50 values of 12.4 M, 12.7 M respectively), abyssinone V 
(1.111) (IC50 values of 5.7 M, 6.6 M) and abyssinone V methyl ether (1.112) (IC50 values of 
10.7 M, 11.9 M) [65].  
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The anti-malarial activity towards the K1 strain of P. falciparum of compounds 1.113 to 1.117, 
isolated from Goat Weed (Ageratum conyzoides L.), has been measured [66]. Compounds 
1.113 (IC50 11 M), 1.114 (IC50 11 M), 1.116 (IC50 7 M) and 1.117 (IC50 9 M) displayed 
moderate activity, while compound 1.115 was found to be inactive [66]. 
The flavonoid styracifolin B (1.31) (pg 14) isolated from Artocarpus stryacifolium was found 
to possess activity towards the FcB1 strain of P. falciparum, with an IC50 value of 1.12 M 
[32]. 
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Dimeric flavonoids have also been isolated and tested for their anti-malarial properties. The 
flavonoid dimer lanaroflavone (1.118), isolated from Campnosperma panamense, possesses 
an IC50 of 0.37 M against the chloroquine-resistant K1 strain of P. falciparum, and also 
exhibits anti-leishmanial activity [9]. The anti-malarial activity of the dimeric flavonoids 
isolated from the Wikstroemia indica, sikokianin B (1.119) and sikokianin C (1.120), was 
determined for the chloroquine-sensitive strain FcR3 (IC50 values of ~0.9 M and 1 M 
respectively) and a chloroquine-resistant K1 strain (IC50 values of ~0.9 M and 0.61 M 
respectively) [9].  
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The flavonoid dimers morelloflavone (1.121) and volkensiflavone (1.122) were found to 
possess anti-malarial activity with an IC50 of <23.6 M [63].  
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In an investigation of the Indian medicinal herb Selaginella bryopteris, of the eleven flavonoid 
dimers (1.123-1.133) tested for their activity towards the K1 strain of P. falciparum 
compounds 1.131 and 1.133 exhibited potent activity with IC50 values of 0.30 M and 0.26 
M respectively [67].  
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The dimeric flavonoid methylenebissantin (1.134), isolated from Dodonaea viscosa, was 
found to have moderate enzyme inhibitory activity against P. falciparum enoyl-ACP 
reductase with an IC50 value of 91 M [68]. 
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1.2.2.2.2 Anti-leishmanial flavonoids 
Leishmaniasis is one of the most neglected parasitic diseases. It is caused by protozoa of 
the genus Leishmania and is transmitted by phlebotomine sand flies [62, 69]. It has been 
suggested that 350 million people are considered at risk of leishmaniasis in eighty-eight 
countries, with approximately two million new cases of leishmaniasis occurring annually [69]. 
There are four main types of leishmaniasis, with cutaneous forms (heals within a few months 
leaving scars), diffuse cutaneous form (leaves chronic disseminated skin lesions similar to 
lepromatous leprosy and is very difficult to treat), mucocutaneous forms (lesions can partially 
or fully destroy mucous membranes of the nose, mouth, throat and surrounding tissues) and 
visceral forms (cause high fever, weight loss, swelling to spleen and liver, as well as 
anaemia, and when left untreated can cause death) [62]. For cutaneous leishmaniasis, it is 
thought that there are up to 1.5 million new cases per year, while for visceral leishmaniasis, it 
is estimated that there are about 500,000 new cases each year [61]. Visceral leishmaniasis 
affects poor areas of India, Bangladesh and Nepal, which have a great need for cost 
effective, viable treatments [62].  
 
The flavonoids 1.92 and 1.93 (pg 26) possess anti-leishmanial activity against Leishmania 
donovani, with IC50 values of 2.5 M and 8.9 M respectively [9]. Flavonoids isolated from 
Consolida oliveriana were tested for activity towards Leishmania (V) peruviana and 
Leishmania (V) braziliensis [70]. It was found that the activity towards L.(V) peruviana and 
L.(V) braziliensis was observed for kaempferol (1.12) (pg 12) (IC50 71 M and 54 M 
respectively), acetylated kaempferol (1.135) (IC50 53 M and 69 M respectively), quercetin 
(1.13) (IC50 60 M and 30.5 M respectively), acetylated quercetin (1.136) (IC50 11 M and 
47 M respectively), 6’’-O-acetylhyperoside (1.137) (IC50 87 M and 52 M respectively) and 
octa-O-acetylhyperoside (1.138) (IC50 7 M and 6 M respectively) [70].  
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While all nine flavonoid and flavonoid glycosides (1.139-1.147) isolated from Delphinium 
staphisagria were active against the two strains Leishmania infantum and Leishmania 
braziliensis, compound 1.146 was found to be the most active [69].  
The anti-leishmanial activity (Leishmania donovani axenic amastigotes assay) of the bi-
flavonoids (1.123-1.133) (pg 31), isolated from Selaginella bryopteris was determined, with 
hinokiflavone (1.127) (IC50 2.9 M), 2,3-dihydrohinokiflavone (1.128) (IC50 1.6 M), 2,3,2’’,3’’-
tetrahydrohinokiflavone (1.129) (IC50 4.2 M) and 7-O-methylhinokiflavone (1.130) (IC50 1.7 
M) found to be active [67]. The anti-leishmanial activity towards Leishmania donovani was 
determined for the flavonoids 1.115 (pg 30) (IC50 12 M), 1.116 (IC50 21 M), 1.117 (IC50 9 
M), isolated from Ageratum conyzoides L. [66]. 
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A group of seventy-three synthetic flavonoid dimers with polyethylene glycol or 
aminoethyleneglycol linkers were assessed for anti-leishmanial activity towards three strains 
of Leishmania donovani (LdAG83, Ld39 and LdAG83PentR50). Of the seventy-three 
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synthetic flavonoid dimers, fourteen (1.148-1.161) were found to possess potent activity 
towards one or more of the three strains, with values for each of these fourteen compounds 
given in Table 1.1. 
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Table 1.1. Anti-leishmanial activity of synthetic flavonoid dimers 1.48-1.61 given as an IC50 
(M). 
Compound LdAG83  Ld39 LdAG83PentR50 
1.148 0.20 0.21 0.13 
1.149 5.0 4.2 ND 
1.150 1.4 >50 ND 
1.151 0.19 0.44 ND 
1.152 2.3 4.0 ND 
1.153 2.5 3.1 ND 
1.154 0.63 0.69 ND 
1.155 0.98 0.98 ND 
1.156 0.31 0.36 ND 
1.157 0.56 0.98 ND 
1.158 1.8 >50 ND 
1.159 1.1 >50 ND 
1.160 0.65 >50 ND 
1.161 0.44 0.58 ND 
ND indicates no activity was detected 
 
1.2.2.2.3 Anti-trypanosomal flavonoids 
Trypanosomiasis is a parasitic disease caused by protozoa of the genus Trypanosoma [62]. 
Trypanosomiasis has two major forms, Chagas disease and African sleeping sickness [62]. 
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Chagas disease is found mostly in twenty-one Latin American countries, is caused by the 
species Trypanosoma cruzi and is spread by infected insects called triatomine bugs, with 10 
million people suspected of being infected each year [61, 62]. Chagas disease in the acute 
stage lasts from four to eight weeks and can show very little to no symptoms. It can cause 
swelling at the site of infection during the acute stage, while the chronic phase can last for 
decades and can cause death. This occurs in ~20-30% of Chagas disease patients [61]. 
African sleeping sickness is caused by the parasites Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense and is transmitted mostly by the tsetse fly that is endemic 
to sub-Saharan Africa. A suspected seven thousand new cases were reported in 2010 [61, 
62]. African sleeping sickness occurs in thirty-six sub-Saharan African countries and 95% of 
cases are due to T. brucei gambiense. [62]. Only two treatments are available for the first 
stage of African sleeping sickness, while the four treatments available for second stage can 
be quite dangerous as they need to cross the blood-brain barrier [62].  
Styracifolin B (1.31) (pg 14), isolated from Atrocarpus styracifolius was found to exhibit 
activity towards Trypanosoma brucei brucei, with an IC50 value of 6.9 M [32]. The anti-
trypanosomal activity towards Trypanosoma brucei rhodesiense and Trypanosoma cruzi was 
determined for the flavonoids (1.113-1.117) (pg 30) isolated from Ageratum conyzoides L. 
Activity towards T. brucei rhodesiense was observed for 1.113 (IC50 16 M), 1.114 (IC50 19 
M), 1.115 (IC50 11 M), 1.116 (IC50 21 M) and 1.117 (IC50 8 M), while for T. cruzi only 
slight activity was observed for 1.114 (IC50 51 M) and 1.115 (IC50 61 M) [66]. Further 
studies on the series of compounds (1.139-1.147) (pg 35) isolated by Marin and colleagues 
from Delphinium staphisagria for activity against T. cruzi revealed that astragalin (1.139) (IC50 
16 M), 2’’-acetylastragalin (1.140) (IC50 6.5 M), astragalin heptaacetate (1.141) (IC50 0.8 
M), paeonoside (1.142) (IC50 21 M), 2’’-acetylpaeonoside (1.143) (IC50 22 M), paeonoside 
decaacetate (1.144) (IC50 17 M), petiolaroside (1.145) (IC50 30 M), 2’’-acetylpetiolaroside 
(1.146) (IC50 27 M) and petiolaroside decaacetate (1.147) (IC50 27 M) possessed moderate 
activity. The selectivity index (calculated as IC50 of toxicity/T. cruzi IC50) of astragalin 
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heptaacetate (1.141) was found to be 205 [71]. Of the nineteen flavonoids tested for anti-
trypanosomal activity towards T. cruzi trans-sialidase [72], myricetin (1.70) (pg 21) (IC50 17 
M), quercetin (1.13) (pg 12) (IC50 58 M), tricetin (1.162) (IC50 39 M), luteolin (1.18) (IC50 
22 M), apigenin (1.14) (IC50 78 M), and 6-hydroxy-apigenin (1.163) (IC50 50 M) were 
found to possess moderate activity [72].  
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1.2.3 Summary 
Flavonoids represent a class of compounds that is widely distributed throughout the plant 
kingdom [73]. Many fruits and edible plants contain flavonoids, with some being used as 
traditional remedies for illnesses and diseases. The anti-cancer and anti-parasitic properties 
of flavonoids and their glycosides are not yet fully understood. It has been established that 
the synergistic effects of flavonoids with other known drugs can increase the efficacy of the 
drug(s) in vivo. While the use of flavonoids as independent drugs is not well established 
(none have made it to market as a drug to date), the usefulness of flavonoids is well 
established against some diseases and these compounds are still being studied in other 
areas such as in the prevention of cancer. 
During the course of the research described in this thesis, four flavonoid glycosides were 
isolated, as detailed in Chapter 2. Of these four flavonoid glycosides, one represents a new 
structural analogue. 
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1.3 Naphthoquinones 
1.3.1 General Introduction  
Naphthoquinones represent one of the most widespread classes of compounds that occur in 
plants [74, 75]. They can appear in nature as either free aglycones or glycosides, or as 
dimers or trimers [75]. The use of naphthoquinone-containing extracts for medicinal purposes 
and in cosmetics is fairly well known: Henna from the plant Lawsonia alba is used for skin 
and hair colouring [76], while in Brazil, the naphthoquinone-containing inner bark of Tabebuia 
avellanedae is used for its anti-inflammatory, anti-neoplastic, diuretic and analgesic 
properties, as well as being used as a treatment against cancer [74, 77]. Naphthoquinones 
have been found to possess a wide variety of biological activities, with anti-bacterial, anti-
fungal, anti-inflammatory, anti-parasitic, anti-insecticidal and anti-cancer activity having been 
reported [75, 77]. 
1.3.2 Biological Activity  
1.3.2.1 Anti-cancer naphthoquinones 
The anti-cancer activity of the naphthoquinones has been thoroughly documented between 
2008 and 2012, with over one hundred and seventy articles published within this period [22]. 
In this review a selection of these references are discussed. 
 
The natural naphthoquinone, 2-acetylfuro-1,4-naphthoquinone (1.164), previously isolated 
from the Cameroonian medicinal plant Newbouldia laevis, was subjected to screening 
against fourteen cancer cell lines, with activity observed towards the CCRF-CEM leukaemia 
cell line (IC50 35.9 M), CEM/ADR5000 multidrug-resistant leukaemia (IC50 69.2 M), PF-382 
leukaemia T-cells (IC50 2.36 M), HL-60 promyelocytic leukemia cells (IC50 19.9 M), 
MiaPaCa-2 pancreatic carcinoma (IC50 7.48 M), Capan-1 pancreatic adenocarcinoma (IC50 
15.7 M), MCF-7 breast adenocarcinoma (IC50 6.86 M), SW-680 colon carcinoma (IC50 14.7 
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M), 786-O renal carcinoma (IC50 28.1 M), U87MG glioblastoma-astrocytoma (IC50 8.02 
M), A549 lung adenocarcinoma epithelial (IC50 22.7 M), Colo-38 skin melanoma (IC50 2.77 
M), HeLa cervical carcinoma (IC50 1.65 M) and Caski cervical carcinoma (IC50 0.70 M) 
cell lines, with 2-acetylfuro-1,4-naphthoquinone (1.164) being more potent than doxorubicin 
against PF-382 and Caski cells but possessing similar activity to doxorubicin in the Colo-38 
and HeLa cell lines [78]. A study of the naphthoquinones 1.165-1.168 and their in vitro anti-
cancer activity against the TLT murine hepatocarcinoma cell line, indicated that at 10 g/mL 
compounds 1.165 and 1.168 showed an increase in cell death in TLT cells [79]. It was also 
observed that at a higher concentration (25 g/mL), 1.167 was also found to be active, while 
1.166 was inactive against TLT cells [79]. The anti-tumour activity of compounds 1.165 and 
1.167 had previously been established against MCF-7, NCI-H460, and SF-268 glioblastoma 
cell lines with IC50 values of ~10 M [79].  
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As a result of a study into the anti-cancer activity of the synthetic naphthoquinones 1.169-
1.185 synthesised from the natural naphthoquinone juglone (1.186), it was found that many 
of these synthetic naphthoquinones were active in one or more of the anti-cancer assays as 
given in Table 1.2, with 1.170, 1.171 and 1.184 being the most active [80]. 
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Table 1.2. Anti-cancer activity of the synthetic naphthoquinones 1.169-1.185 shown as an 
GI50 (M).  
Compound A2780 HBL-100 HeLa SW1573 T-47D WiDr 
1.169 1.9 7.8 2.3 34 76 36 
1.170 0.57 0.60 0.42 0.70 8.1 6.3 
1.171 1.1 0.69 0.81 0.76 2.3 2.0 
1.172 2.4 5.7 7.1 5.3 34 17 
1.173 3.1 2.9 5.7 2.0 4.0 3.5 
1.174 1.7 1.9 1.7 1.3 1.8 2.0 
1.175 2.1 2.0 2.4 2.3 2.3 1.9 
1.176 1.0 1.6 1.9 4.3 21 11 
1.177 3.9 21 2.6 18 30 19 
1.178 2.0 19 4.5 7.7 23 7.3 
1.179 1.6 0.41 1.3 0.40 2.5 2.0 
1.180 21 16 24 3.8 30 23 
1.181 1.8 20 3.5 4.8 22 20 
1.182 2.6 2.3 2.1 1.9 21 2.7 
1.183 2.1 2.1 1.8 2.5 20 4.8 
1.184 0.82 0.94 0.80 0.83 2.2 2.0 
1.185 2.2 2.8 2.2 2.7 23 18 
GI50 indicates the concentration required to inhibit the proliferation of cells by 50% 
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The naphthoquinone 5-methoxy-3,4-dehydroxanthomegnin (1.187), isolated from 
Paepalanthus latipes displayed activity towards LM2 murine mammary tumour cells (CI50 
[Cytotoxicity index*] 74.6 M) and LPO7 lung adenocarcinoma tumour cells (CI50 6.2 M) and 
was found to be of a similar potency or more potent than cisplatin (CI50 168.4 M and CI50 
4.34 M respectively) [81]. The synthetic polyamine naphthoquinones (1.188-1.193), which 
are derivatives of the natural naphthoquinones 2-methoxy-lawsone (1.194), 2-methoxy-
lapachol (1.195) and 2-methoxy-nor-lapachol (1.196), displayed moderate activity towards 
the Ehrlich murine breast tumour cell line, with IC50 values between 25 and 50 M, while 
against the HL-60 cell line, compounds 1.188-1.193 displayed IC50 values from 10 to 22 M 
[82]. In addition compounds (1.191-1.193) were found to be active against the MV-3 cell line 
(IC50 39 to 45 M). All compounds (1.188-1.193), were active against the GLC-4 small cell 
lung carcinoma cell line (IC50 14-29 M), while activity against Daudi Burkitt lymphoma cells 
was also displayed by all compounds (IC50 17-30 M), with these amine derivatives being 
more active than the natural products in all of the assays [82]. 
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Both 2’,3-dichloro-1,4-naphthoquinone (1.197) and the synthetically derived compound 2-
chloro-3-(4-pyridyl-amino)naphthoquinone (1.198) were analysed for anti-cancer activity 
towards the MCF-7 cell line, with 2’,3-dichloro-1,4-naphthoquinone (1.197) (IC50 30 M) 
showing less activity than the synthetic 2-chloro-3-(4-pyridyl-amino)-naphthoquinone (1.198) 
(10 M) [83]. It was observed that the synthetic naphthoquinones, 1.199-1.201, were active 
against HCT-116 colon cancer cells and it was postulated that the production of reactive 
oxygen species (ROS) by naphthoquinones played a critical role in the induction of apoptosis 
[84].  
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Synthetic 2-piperazinyl naphthoquinones such as compound (1.202) and 2-piperidinyl 
naphthoquinone derivatives such as compound (1.221) were evaluated for biological activity 
towards the DU-145 prostate carcinoma cell line [85]. Compounds (1.202-1.226) displayed 
activity with IC50 values less than 18 M, with 1.220 (IC50 1.3 M) being the most active [85]. 
Again it was suggested that this activity was due to the induction of apoptosis caused by 
these compounds [85] 20 M, with 1.218 (IC50 1.8 M). As part of the same study, selected 
compounds were evaluated against thirteen human cancer cell lines, with the most active 
against most cell lines being 1.220. Compound (1.220) also displayed the most potent 
activity against the A549 lung adenocarcinoma cell line (IC50 1.7 M) and L-78 (IC50 1.9 M) 
cell lines and was found to be more active than the anti-cancer drug doxorubicin (IC50 1.9 M 
and 2.4 M respectively). The most active compounds against each cell line were: 1.217 
against HT-29 cell line (IC50 1.4 M); 1.218 against the HepG2 (IC50 3.9 M) and U251 cell 
lines (IC50 4.4 M); 1.220 against the HeLa (IC50 2.1 M), HT-1080 (IC50 2.8 M), KB (IC50 1.4 
M), MCF-7 (IC50 3.0 M), MOLT-4 acute lymphoblastic leukaemia (IC50 2.7 M) and SGC-
7901 (IC50 2.5 M) cell lines [85]. Within this study, compounds (1.214, 1.217-1.220, 1.222, 
1.224 and 1.226) were found to be more potent than doxorubicin against the OS-RC-2 renal 
carcinoma cell line [85].  
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The synthetically prepared naphthoquinones 1.227, 1.228 and 1.229 displayed similar 
activity against the A2780 cell line, with IC50 values of 0.75 M, 0.08 M and 0.37 M 
respectively [86].  
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Of the natural naphthoquinones isolated from Lithospermum erythrorhizon Sieb. et Zucc. and 
Macrotomia euchroma (Royale) Pauls. it was found that the naphthoquinones 1.230-1.237 
displayed activity against the HCT-116 cell line (IC50 values of 0.23-0.45 M), and against the 
Hep-G2 cell line (IC50 values of 0.22-0.59 M), while vitamin K (2.238) was less active against 
both cell lines with IC50 values of 1.19 M and 2.34 M respectively [87].  
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On this basis of these results, it was suggested that the enhancement of the activity from 
vitamin K to the hydroxyl-naphthoquinones was due to the hydroxyl moieties present in these 
compounds [87]. The eight naphthoquinone derivatives (1.239-1.246) that were synthesised 
from juglone (1.186) (pg 44) were assessed for anti-cancer activity towards four cell lines, 
HL-60, MDA-MB-435, HCT-8 and SF-295, with IC50 values ranging from 1.7 M to 4.7 M 
being observed. For juglone (1.186) the range of IC50 values against these cell lines ranged 
from 7.6 M to 28.7 M [88]. On the basis of this work, it was established that the 
introduction of a methoxy group at the 5 position increased the toxicity of juglone (1.186), 
and it was demonstrated that 5-methoxy-1,4-naphthoquinone induces apoptosis by an 
extrinsic pathway, indicating that the event was independent of mitochondrial depolarisation 
[88].  
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A study of the synthetic naphthoquinone derivative, N-(3-chloro-1,4-dioxo-1,4-dihydro-
naphthalen-2-yl)-benzamide (1.247), revealed anti-cancer properties against CWR-22 
prostate carcinoma (IC50 2.5 M) and the PC-3 (IC50 2.5 M), DU-145 (IC50 6.5 M) and HS-5 
bone marrow stromal (IC50 25 M) cell lines [89]. Compound (1.247) arrested the G1-phase 
cell cycles of the CWR-22, PC-3 and DU-145 cell lines, while no effect was observed for the 
cell cycle progression of the HS-5 cells, indicating that this compound may be investigated as 
a possible treatment for prostate cancer, while protecting the bone marrow [89]. Of the 
fourteen synthetic derivatives of putative proteasome inhibitor PI-083 (1.248), six of these 
derivatives (1.249-1.254) were found to possess anti-proliferation activity towards the A-549, 
DU-145, KB and KBvin cell lines, with IC50 results ranging from 1.3 M to 23 M for these 
compounds [90].  
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From a study of five fluorinated 1,4-naphthoquinones (1.255-1.259) against the RPMI-8226 
human mammary adenocarcinoma and MCF-7 cell lines, compounds (1.255-1.258) exhibited 
activity with IC50’s between 0.7 M and 2.5 M against the two cell lines, while 1.259 was 
less active with IC50 values of 7.5 M and 4.5 M against RPMI-8226 and MCF-7 
respectively [91]. The same study also determined that the fluorinated naphthoquinones 
were less active against normal cells, with 1.257 and 1.258 showing the greatest difference 
in activity against cancer cells compared to normal cells [91].  
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A study of another group of nine synthetic fluorinated naphthoquinones showed that four of 
these naphthoquinones (1.260-1.263) possessed potent anti-cancer activity towards the 
RPMI-8226 and MCF-7 cell lines, with IC50 values in the range of 2.4 to 12.8 M, while also 
being comparatively non-toxic to normal cells [92].  
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Three naphthoquinones (1.264-1.266) from a group of sixteen synthetic naphthoquinones 
were found to possess potent activity, with 1.264 possessing activity towards the NCI-H187 
cell line (IC50 8.83 M), while 1.265 and 1.266 were the most active towards the KB cell line 
with IC50 values of 9.00 M and 8.62 M respectively [93].  
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The naphthoquinone of 2-methoxy-1,4-naphthoquinone (2-methoxy-lawsone) (1.194) (pg 45) 
from Impatiens balsamina, used in traditional Chinese medicine for the treatment of pain and 
infection, was analysed for in vitro anti-tumour activity against the HepG2 cell line and 
showed an IC50 of 6.08 g/mL [94]. The natural naphthoquinone, plumbagin (1.267), was 
subjected to an in vivo study for the inhibition of transgenic adenocarcinoma of mouse 
prostate, where it was discovered that it could be used as a chemopreventative against 
prostate cancer [95]. Another study subjected plumbagin (1.267) to screening against the A-
549 cell line, with moderate activity being observed (IC50 14.6 M).  
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The four synthetic naphthoquinones, 1.268-1.271, were analysed for activity towards HeLa 
cancer cells and, at a concentration of 10 M, compound (1.271) showed ~99% cell death of 
HeLa cells in vitro after 72 h [96]. The natural naphthoquinone, shikonin (1.272), the main 
Marine and Terrestrial Natural Products Discovery 
53 
component of the traditional Chinese medicinal herb Zi Cao (gromwell), when tested against 
the H22 murine hepatoma and PC-3 cell lines, showed inhibition of cell growth associated 
with suppression of proteasomal activity and induction of cell death in vivo [97]. It was also 
observed that mice with P388 leukaemia, when treated with shikonin (1.272) had significantly 
increased survival times [97]. A further study of shikonin (1.272) found that this compound 
induces apoptosis in hepatocellular carcinoma cells both in vitro and in vivo, with activity 
towards the Huh-7 and BEL-7402 cell lines, but is non-toxic to regular cells [98].  
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A series of 2,3-disubstituted naphthoquinones (2.273-2.278), synthetically prepared from 2,3-
dichloro-1,4-naphthoquinone (1.197) (pg 45), were analysed for anti-cancer activity towards 
HL-60, AGS gastric adenocarcinoma, SK-MES-1 lung carcinoma and J-82 malignant human 
urothelial cell lines [99]. It was established that 1.277 displayed moderate activity against the 
SK-MES-1 cell line with an IC50 of 12.2 M, while exhibiting very weak activity against the 
other cell lines [99]. The other compounds from this study (1.273-1.276 and 1.278) were 
more active, with 1.273 displaying potent HL-60 activity with an IC50 of 1.8 M as well as 
displaying activity between 9 M and 12 M against the other cell lines [99]. Compounds 
(1.274, 1.275 and 1.278) displayed activity against HL-60 with an IC50 of 1.7 M, 1.9 M and 
8.9 M respectively. These three compounds displayed activities of between 5 M and 27 
M against the other cell lines [99]. Compound 1.276 was the most consistently active of this 
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group of synthetic naphthoquinones, with activity observed against each cell line of HL-60 
(IC50 1.3 M), AGS (IC50 5.2 M), SK-MES-1 (IC50 7.1 M) and J-82 (IC50 8.6 M) [99].  
 
O
O
Cl
OCH3
O
O
Cl
O OCH3
O
O
Cl
O O O
Cl
O
O
O
O
Cl
O O O O
O
Cl
O
O
O
Cl
O O O O O
O
O
Cl
O
O
OCH3
OCH3
(1.273) (1.274) (1.275) (1.276)
(1.277) (1.278)
 
 
Of fifteen synthetic naphthoquinones, four (1.279-1.282) were found to possess activity, with 
1.279 displaying moderate activity towards the HaCaT human keratinocyte cell line (IC50 21.0 
g/mL) [100]. Compounds 1.280 and 1.282 were both active towards the MCF-7 cell line 
(IC50 22.0 g/mL and 26.0 g/mL respectively) as well as towards the Hep-G2 cell line (IC50 
24.0 g/mL and 25.0 g/mL respectively), while the most active compound was 1.281 with 
an IC50 towards Hep-G2 of 5.8 g/mL [100].  
Three synthetic naphthoquinones (1.283-1.285) of a group of sixteen were found to possess 
potent anti-cancer activity towards the HT-29 cell line, with IC50 values of 4.24 g/mL, 7.45 
g/mL and 2.40 g/mL respectively [101]. 
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The fourteen synthetically prepared naphthoquinones (1.286-1.299), twelve of which 
contained side chains of 2’-cylclopentyl or 2’-cyclohexyl esters, were tested for anti-tumour 
activity towards the KB, HeLa and Hep-G2 cell lines, with results given in Table 1.3 [102]. It 
was concluded that the 2’,2’-dimethyl naphthoquinone esters were the most active, followed 
by the 2’-cyclopentyl derviatives. The least active were the 2’-cyclohexyl derivatives [102]. 
Among the cyclopentyl derivatives 1.288 to 1.293, 1.288 and 1.292 were found to be most 
active against the KB and HeLa cell lines, with IC50 values of <10 M, while 1.289-1.291 
showed selective potent activity towards the KB cell line with IC50 values of <10 M and 
1.293 showed selective potent activity towards the HeLa cell line with an IC50 of 5.84 M 
[102]. 
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Table 1.3. Anti-tumour activity of naphthoquinones (1.286-1.299) given as an IC50 (M). 
Compound KB HeLa Hep-G2 
1.286 1.53 3.02 4.85 
1.287 1.59 1.17 1.30 
1.288 3.53 7.04 16.90 
1.289 5.41 15.99 83.66 
1.290 4.23 57.80 18.31 
1.291 5.63 16.35 83.09 
1.292 3.68 6.40 21.47 
1.293 65.48 5.48 63.76 
1.294 11.45 17.93 23.24 
1.295 9.56 11.42 14.75 
1.296 11.76 14.91 72.27 
1.297 9.42 15.58 50.16 
1.298 13.81 10.63 50.58 
1.299 11.35 10.22 62.73 
 
Twenty-nine synthetic naphthoquinones (1.300-1.328) were evaluated for activity towards the 
MCF-7 and SK-Br-3 human breast adenocarcinoma cell lines and all were found to be active 
[102]. The most active of these compounds was 1.300 with IC50 values against MCF-7 (0.21 
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M) and SK-Br-3 (0.82 M), while 1.318 was the most active towards SK-Br-3 (0.6 M), with 
the remaining compounds being active in one or both assays with IC50 values of <10 M 
[102]. 
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The naphthoquinone dimers, 1.329-1.333, were shown to possess cytotoxicity towards 
prostate cancer cell lines. This activity was suggested to be due to the accumulation of 
reactive oxygen species and mitochondrial dysfunction [103]. 
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1.3.2.2 Anti-parasitic naphthoquinones 
For a general introduction to parasitic diseases see Section 1.2.2.2. The anti-parasitic 
activities of naphthoquinones against malaria, leishmaniasis and trypanosomiasis are 
discussed below. 
1.3.2.2.1 Anti-malarial naphthoquinones 
The synthetic naphthoquinones, 1.334-1.337, were tested for their activity against 
Plasmodium falciparum and compared to the known anti-malarial naphthoquinone 
atovaquone (1.338). Compound (1.335) displayed the most potent activity with an IC50 of 
17.07 nM, being more potent than atovaquone (1.338) with an IC50 of 19.7 nM, while the 
remaining naphthoquinones also displayed potent activity: 1.334 (IC50 96.2 nM), 1.336 (IC50 
246.5 nM) and 1.337 (IC50 4,452 nM) [104].  
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The synthetic cationic naphthoquinones, 1.339-1.355, were found to possess potent anti-
malarial activity towards P. falciparum, with 1.339 and 1.353 exhibiting the greatest activity 
with IC50 values of 18.7 nM and 17.4 nM respectively, while the activity for 1.340-1.355 
ranged from 28.5 nM to 167.0 nM [105].  
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The fluorinated methyl-1,4-naphthoquinones,1.356-1.358, were found to possess activity 
against P. falciparum with IC50 values of 27.5 M, 22.8 M and 7.0 M respectively [106].  
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From a series of synthetic naphthoquinones, it was found that seven of these compounds 
(1.359-1.365) possessed anti-malarial activity towards the multidrug-resistant P. falciparum 
Dd2 strain, with IC50 values of 46 nM, 79 nM, 29 nM, 55 nM, 54 nM, 46 nM and 103 nM 
respectively, where all compounds were more potent than the anti-malarial drug chloroquine 
(IC50 110 nM) [107].  
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Of a group of twenty six naphthoquinone aliphatic esters, nine (1.366-1.374) were found to 
possess potent activity towards P. falciparum, with activity ranging from IC50 0.03 M to 0.22 
M [108]. 
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1.3.2.2.2 Anti-leishmanial naphthoquinones 
The synthetic naphthoquinones, 1.375-1.382, were evaluated for activity against Leishmania 
donovani. It was found that all were potent inhibitors, with IC50 values ranging between 0.51 
M and 2.37 M, with the most potent being 1.377 [109].  
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The anti-leishmanial activity of the two naphthoquinones, 1.383 and 1.384, was evaluated, 
with activity towards both promastigotes and amastigotes of L. donovani being observed 
[110]. It was established that compounds (1.383 and 1.384) displayed promastigote activity 
at IC50 values of 5.4 M and 7.04 M respectively, while 1.383 and 1.384 showed amastigote 
activity at IC50 values of 0.069 M and 0.26 M respectively [110]. It was also found that IC50 
values for these two compounds towards regular cells were quite high (46.5 M and 49.2 M 
respectively), compared to their IC50 values towards L. donovani cells. The differences in 
cytotoxicity suggested that these compounds could be considered for further analysis for the 
possible treatment of visceral leishmaniasis [110].  
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1.3.2.2.3 Anti-trypanosomal naphthoquinones 
The activity of the synthetic naphthoquinones, 1.375-1.382, against Trypanosoma cruzi and 
Trypanosoma brucei rhodesiense was also investigated. With the exception of 1.381, all 
were found to be active towards T. cruzi with IC50 values of <10 M, with 1.380 (IC50 1.26 
M) being the most active, while compounds (1.375-1.382) all exhibited activity of IC50 <0.6 
M towards T. brucei rhodesiense, with 1.380 being the most active (IC50 0.08 M) [109]. 
The eleven synthetic imido-substituted-1,4-naphthoquinones (1.385-1.395) were evaluated 
for anti-trypanosomal activity towards T. cruzi. The most active was 1.387 (IC50 0.70 M), 
while the other compounds exhibited slightly less activity with IC50 values up to 6.5 M [111]. 
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The trypanocidal activity of lapachol (1.195) (pg 45) and the related compound (1.396) were 
evaluated and IC50 values for 1.195 (31.3 M) and for 1.396 (35.2 M) were reported [74].  
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Compounds (1.397-1.399) were found to have ED50/24 h values of between 160 M and 430 
M [74].  
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The 1,4-naphthoquinones (1.194, 1.197 and 1.400) were evaluated for activity towards T. 
cruzi epimastigote forms and it was found that 1.194 was the least active (IC50 3.19 M), 
while 1.197 (IC50 0.09 M) and 1.400 (IC50 0.02 M) were more active [112]. 
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Synthetic azide naphthoquinones (1.401-1.402) were used to prepare the triazole 
naphthoquinones (1.403-1.408), as well as the mesyl naphthoquinone (1.409), a derivative of 
lapachol (1.195) (pg 45). These compounds were all evaluated for biological activity towards 
T. cruzi, with IC50 values of 41.6 M (1.401), 51.8 M (1.402), 10.9 M (1.403), 45.8 M 
(1.404), 17.7 M (1.405), 80.2 M (1.406), 67.6 M (1.407), 42.0 M (1.408) and 25.7 M 
(1.409) [113].  
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The synthetic naphthoquinone (1.410) was found to possess moderate activity towards the 
trypomastigote forms of T. cruzi (IC50 233 M) [114].  
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The naphthoquinone 2,3-diphenyl-1,4-naphthoquinone (1.411) was evaluated for in vitro and 
in vivo activity towards T. cruzi. The in vitro activity against epimastigote cell-derived 
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trypomastigote, as well as intracellular amastigote forms of T. cruzi was found to have LD50 
values of 2.5 M, while displaying low toxicity towards normal mammalian cells (LC50 = 130 
M) [115].  
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1.3.3 Summary 
Naphthoquinones have a wide range of activity towards many diseases and for this reason 
continue to attract interest, particularly in the area of synthetic organic chemistry. The 
understanding of the mechanism for the biological activity of the naphthoquinones towards 
different forms of cancer and parasitic diseases is starting to emerge, along with the modes 
of action. The bioactivity of naphthoquinones requires further research, especially in the 
development and isolation of novel potent biologically active naphthoquinones that could 
potentially lead to new pharmaceuticals or leads for drug discovery. 
During the course of the research within this thesis, three naphthoquinones and two 
naphthoquinone glycosides were isolated, as detailed in Chapter 4. 
 
67 
 
Chapter 2  
On-line (HPLC-NMR) and Off-line 
Phytochemical Profiling of the Australian 
Plant, Lasiopetalum macrophyllum 
2.1 Introduction 
The plant family Malvaceae, commonly referred to as the Mallow family, consists of two 
hundred and forty-three genera and 4,225 species that are found worldwide [116]. In 1997, 
the taxonomy of the family Malvaceae was broadened to include the families Sterculiaceae, 
Tiliaceae and Bombacaceae [117]. Malvaceae is comprised of many well-known genera 
including Gossypium (cotton) and Hibiscus (ornamental), and many of these genera are 
known to contain biologically active constituents [118, 119]. The Malvaceae has afforded 
many classes of secondary metabolites, including terpenoids (2.1-2.3) [120], alkaloids (2.4-
2.5) [121], steroids (2.6-2.7) [122], naphthalenes (2.8-2.9) [118], and flavonoids (1.12, 1.13, 
1.18, 1.51, 2.10-2.12) [118, 122-126]. The genus Lasiopetalum, belonging to this family, has 
not been studied widely in terms of its secondary metabolites, with only fatty acid analyses of 
seed oils being reported to date [127, 128].  
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An extract of the Australian plant L. macrophyllum was selected for chemical investigation on 
the basis that very little chemistry had been reported for this genus, together with the fact 
that the Malvaceae family is known to produce a wide array of structure classes with 
bioactive properties. 
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2.2 Experimental 
2.2.1 General Experimental 
For all general experimental procedures and spectroscopic methods, see the Experimental 
Chapter Section 7.1. All semi-preparative HPLC analyses were performed using a gradient 
solvent system (0 mins 30% CH3CN/H2O; 20 mins 50% CH3CN/H2O), with detection at max 
254 and 315 nm. Both on-flow and stop-flow HPLC-NMR analyses were performed using 
gradient HPLC conditions (0-2 mins 30% CH3CN/D2O, 20-24 mins 50% CH3CN/D2O, 26 mins 
30% CH3CN/D2O), with detection at max 254 and 315 nm.  
 
2.2.2 Plant material 
The plant specimen (stems and leaves) was collected from Troopers Creek in the Grampians 
National Park, Victoria, Australia on the 23rd September 2006 and identified as L. 
macrophyllum from “The Grampians in Flower” monograph [129]. A voucher specimen, 
designated the code 2006-34, is deposited at the School of Applied Sciences (Discipline of 
Applied Chemistry), RMIT University. A 2 g portion of the L. macrophyllum specimen was 
extracted with 3:1 MeOH:DCM (40 mL) and evaluated for biological activity as described in 
the Experimental chapter Section 7.1.4. The crude extract was found to display modest 
P388 activity with an IC50 of 296 g/mL, along with minimal anti-bacterial activity towards 
Bacillus subtilis. No activity was detected against Eschericha coli, Pseudomonas aeruginosa, 
Candida albicans, Trichophyton mentagrophytes and Cladosporium resinae. 
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L. macrophyllum (2006-34) 
 
 Kingdom: Plantae 
 Phylum: Magnoliophyta 
 Class:  Magnoliopsida 
 Order: Malvales 
 Family: Malvaceae 
 Genus:  Lasiopetalum 
 Species: macrophyllum 
 
2.2.3 Extraction and Isolation 
2.2.3.1 Preparation of the extract of L. macrophyllum for on-flow and stop-flow 
HPLC-NMR analysis 
The specimen of L. macrophyllum (50 g) was roughly chopped and extracted with 3:1 
methanol:dichloromethane (1 L). This extract was then decanted and concentrated under 
reduced pressure and was then sequentially partitioned (trituated) into dichloromethane 
followed by methanol. The extracts were then analysed by analytical HPLC using the 
gradient described in the Experimental chapter Section 7.1.2, which led to the development 
of the HPLC gradient described in Section 2.2.1. A portion of the methanol soluble fraction 
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(72 mg) was re-solubilised in 1 mL 50:50 CH3CN:D2O and filtered through a 0.45 m PTFE 
membrane filter (HP045 Advantec, Japan). For both the on-flow and stop-flow HPLC-NMR 
experiments, 50 L (3,600 g) of the methanol extract was injected and monitored at max 
254 and 315 nm. The HPLC-NMR analyses were performed using the HPLC conditions 
described in Section 2.2.1. 
2.2.3.2 Preparation of the extract for off-line isolation of secondary metabolites from 
L. macrophyllum 
A further extraction of L. macrophyllum (100 g) was carried out with 3:1 MeOH:DCM (2 L). 
This extract was decanted and concentrated under reduced pressure before sequential 
partitioning into DCM (0.9 g) and MeOH (6.0 g) soluble extracts. A portion (800 mg) of the 
MeOH extract subjected to C18 Vacuum Liquid Column (VLC) chromatography using a 25% 
stepwise elution from water to MeOH and then to EtOAc and finally to DCM to afford thirteen 
fractions. Four fractions were combined due to similarities in the analytical HPLC 
chromatograms and 1H NMR spectra, and the combined fraction was filtered through a 0.45 
µm PTFE membrane filter (HP045 Advantec, Japan) and subjected to semi-preparative 
reversed phase HPLC as described in Section 2.2.1 to yield trans-tiliroside (2.12) (26 mg, 
0.05% dry weight), cis-tiliroside (2.13) (6 mg, 0.01%), 4′-methoxy-trans-tiliroside (2.14) (2 mg, 
0.004%) and the previously unreported compound, 4′-methoxy-cis-tiliroside (2.15) (1 mg, 
0.002%). Compound (2.12) had been isolated previously but its structure had been 
incorrectly assigned initially [130] as discussed in Section 2.3. 
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2.3 Results and Discussion 
For the HPLC-NMR chemical profiling, the plant material was extracted and fractionated as 
described in Section 2.2.1. On-flow HPLC-NMR analysis (Figure 2.1 [A]) of the crude 
methanol extract supported the presence of one major compound. From the HPLC 
chromatogram and 2D contour plot from the on-flow HPLC-NMR analysis, it was found that 
along with the major compound (peak 1) three minor compounds (peaks 2 to 4) were also 
observed (Figure 2.2). Similarities in the UV profiles (Figure 2.2) of the four HPLC peaks 
suggested that all four compounds were structurally related. The extracted WET-1D 1H NMR 
spectrum of the major component (Figure 2.1 [B]), corresponding to peak 1 in Figure 2.2 
contained diagnostic 1H NMR signals:  7.88 (d, J = 9 Hz),  7.21 (d, J = 8.5 Hz),  6.83 (d, J 
= 9 Hz) and  6.76 (d, J = 8.5 Hz) which indicated the presence of aromatic proton 
resonances;  7.24 (d, J = 16 Hz) and  5.92 (d, J = 16 Hz), indicating the presence of a 
trans double bond; and  5.03 (d, J = 7.5 Hz),  4.11 (d, J = 5.5 Hz),  3.38 (m),  3.32 (m) 
and  3.21 (m), which were supportive of a sugar moiety. From this the compound was 
suggested to be an aromatic compound with an attached sugar moiety. 
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Figure 2.1. [A] 2D HPLC-NMR contour plot showing the major compound (2.12) (on-flow HPLC-NMR) and [B] Extracted WET-1D 1H NMR 
spectra of compounds (2.12-2.14) (stop-flow HPLC-NMR). 
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On the basis of this NMR data and the fact that the family Malvaceae is known to produce 
flavonoid glycosides [118, 122, 124, 131, 132], this compound was tentatively suggested to 
be trans-tiliroside (2.12). Given the relatively poor S/N obtained for the 1H NMR spectrum of 
peak 1 in the on-flow HPLC-NMR analysis, together with the fact that the 1H NMR spectra for 
the other peaks could not be detected, it was necessary to carry out stop-flow HPLC-NMR 
analyses. Stop-flow HPLC-NMR analysis enabled extended acquisition times (typically from 
20 mins to 16 h) for the WET-1D 1H NMR experiments. 
 
 
Figure 2.2. HPLC chromatogram and 2D PDA plot of on-flow HPLC-NMR analysis of L. 
macrophyllum. 
 
The 30 minutes acquisition time resulted in a significantly improved S/N WET-1D 1H NMR 
spectrum for the major peak, trans-tiliroside (2.12), as well as allowing the detection of WET-
1D 1H NMR spectra of HPLC peaks 2 and 3 (Figure 2.2), as shown in Figure 2.1 [B]. 
The WET-1D 1H NMR spectra of peaks 1-3 (Figure 2.1) all exhibited resonances consistent 
with the presence of olefinic and aromatic methines, along with signals associated with a 
sugar moiety. The elution times of peaks 1 and 2 were very similar, resulting in some 
overlapping and thus the appearance of signals due to peak 1 (compound 2.12) in the WET-
1D 1H NMR spectrum of peak 2 (Figure 2.1). However, marked differences in the intensities 
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of the two sets of 1H NMR signals made it clear which signals belonged to which HPLC peak. 
Diagnostic 1H NMR chemical shift differences for peak 2 were observed at  6.62 (d, J = 14.5 
Hz) and  5.41 (d, J = 14.5 Hz), supporting the presence of cis double bond geometry and 
suggesting that this component was cis-tiliroside (2.13). Although the WET-1D 1H NMR S/N 
for peak 3 was relatively poor (1.5 h acquisition) in comparison with those of compounds 
2.12 and 2.13, several diagnostic features could be extracted. The poor S/N meant that the 
coupling constant associated with the olefinic signals [ 7.33 (d, J ~ 14 Hz) and  6.01 (d, J ~ 
14 Hz)], could only be estimated and this was similar to that of the cis double bond protons in 
2.13. However, the chemical shifts were consistent with the trans double bond geometry 
seen in 2.12 and these, together with the presence of a methoxy signal [ 3.72, s] indicated 
that peak 3 was most likely a methoxy derivative of trans-tiliroside (2.12). Thus peak 3 was 
tentatively assigned the structure 4′-O-methoxy-trans-tiliroside (2.14). 
Even the prolonged analysis times afforded by stop-flow HPLC-NMR were inadequate to 
detect the 1H NMR spectrum of the fourth component (peak 4), although the presence of 
characteristic UV chromophores at 269 nm and 317 nm indicated that this compound was 
probably also a related flavonoid glycoside, which was later identified as compound (2.15). 
To unequivocally identify the four secondary metabolites (2.12-2.15), off-line purification 
employing reversed phase HPLC was undertaken. 
For the off-line HPLC purification, the plant material was extracted and subjected to the 
fractionation methodology as described in Section 2.2.3.2. Analytical HPLC and 1H NMR 
analysis of the methanol-soluble extract confirmed the presence of the flavonoid glycosides 
that were previously observed in the HPLC-NMR analysis, and from this the isolation of 2.12-
2.15 was carried out as described in Section 2.2.3.2. 
The structure of 2.12 (HPLC peak 1) was confirmed on the basis of 1D (1H NMR shown in 
Figure 2.3) and 2D NMR spectroscopy (Table 2.1) and mass spectrometry. The HR-ESI-MS 
of 2.12 displayed an m/z at 593.1308 [M-H]- (calcd. for C30H25O13: m/z 593.1295) and an m/z 
at 595.1440 [M+H]+ (calcd. for C30H27O13: m/z 595.1452) consistent with eighteen degrees of 
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unsaturation and a molecular formula of C30H26O13. The 
13C NMR spectrum of 2.12 showed 
the presence of twenty-six discrete signals [thirteen methines (four of these being overlapped 
and each accounting for two aromatic methines), one methylene and twelve quaternary 
carbons], as supported by the gHSQCAD 2D NMR experiment. The 1H NMR spectrum 
(Figure 2.3) and the 2D gCOSY NMR spectrum identified the presence of the following 
moieties: a set of meta coupled aromatic methines [ 6.15, d, J = 2 Hz (H-6) and  6.38, d, J 
= 2 Hz (H-8)]; two 1,4-disubstituted aromatic rings [ 7.98, dd, 2H, J = 1.5, 9 Hz (H-2′/H-6′) 
and  6.85, dd, 2H, J = 1.5, 9 Hz (H-3′/H-5′)] and [ 7.37, d, 2H, J = 8.5 Hz (H-2′′′/H-6′′′) and  
6.78, d, 2H, J = 8.5 Hz (H-3′′′/H-5′′′)]; a pair of olefinic methines [ 7.34, d, J = 16 Hz (H-7′′′) 
and  6.12, d, J = 16 Hz (H-8′′′)] with trans coupling and, finally, a sugar moiety containing 
five deshielded methines [ 5.45, d, J = 7.5 Hz (H-1′′) and those occurring between  3.16 
and  3.37, (H-2′′, H-3′′, H-4′′, H-5′′)] and one deshielded methylene [ 4.02, dd, J = 6.5, 12 
Hz (H-6a′′) and  4.26, dd, J =1.5, 12 Hz (H-6b′′)]. 
A number of 2D gHMBC NMR experiments were conducted using a range of coupling 
constants (J = 2 Hz, 4 Hz, 6 Hz, 8 Hz, 10 Hz and 12 Hz) in order to optimise the number of 
HMBC correlations. On the basis of these experiments it was concluded that, for HMBC 
purposes, the optimal J value for observing correlations in the sugar moiety was 4 Hz, while 
for the aromatics it was 10 Hz.  
In combination with the 13C NMR spectrum, the 2D gHSQC and gHMBC NMR experiments 
allowed for the complete assignment of 2.12. The sugar moiety was concluded to be 
disubstituted at both the anomeric and methylene carbon on the basis of the HMBC 
correlations observed to both of these carbons. The deshielded sugar methylene resonances 
at  4.02 (H-6a′′) and  4.26 (H-6b′′) showed an HMBC correlation to 166.2 ppm (C-9′′′) (see 
Figure 2.4), supporting an ester linkage to C-6” of the sugar.  
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Figure 2.3. 1H NMR (500 MHz, d6-DMSO) spectrum of trans-tiliroside (2.12).
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Figure 2.4. Key HMBC correlations for trans--tiliroside (2.12). 
 
Further HMBC correlations observed between this ester carbon 166.2 ppm (C-9′′′) and the 
olefinic methines at  7.34 (H-7′′′) and  6.12 (H-8′′′) (See Figure 2.4) unambiguously placed 
the trans double bond adjacent to this ester. This structure fragment could be extended 
further by considering the HMBC correlations between the aromatic protons at  7.37 (H-
2′′′/H-6′′′) and the olefinic methine carbon at 144.6 ppm (C-7′′′). A further HMBC correlation 
between the other methine proton at  6.12 (H-8′′′) and the quaternary carbon at 124.9 ppm 
(C-1′′′) suggested a connection of the alkene to one of the two 1,4-disubstituted aromatic 
rings. This 1,4-disubsituted aromatic ring was probably substituted with a hydroxyl group due 
to a lack of resonances that would support an alkoxyl group, as supported by the HMBC 
correlation between its aromatic protons  7.37 (H-2′′′) and  6.78 (H-3′′′) and the carbon at 
159.8 ppm (C-4′′′). Together, these HMBC correlations permitted this first structure fragment, 
attached to a central sugar moiety, to be identified as a trans-p-coumaroyl moiety as shown 
in Figure 2.5. 
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Figure 2.5. Fragments linked to the sugar for the major component (2.12). 
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A second ether linkage from the sugar moiety was identified on the basis of the HMBC 
correlation observed from the anomeric proton at  5.45 (H-1′′) to a quaternary carbon at 
133.1 ppm (C-3) (See Figure 2.4). No other HMBC correlations were observed to C-3, 
suggesting a high degree of substitution in this portion of the structure. The second of the 
1,4-disubstituted aromatic rings was also suggested to be substituted with a hydroxyl moiety 
on the same basis as that for compound (2.12), with correlations observed from the aromatic 
methines  7.98 (H-2′) and  6.85 (H-3′) to the deshielded carbon at 160.0 ppm. A further 
HMBC correlation, from  7.98 (H-2′) to 156.4 ppm (C-2), suggested that the 1,4-
disubstituted aromatic ring was connected to a deshielded olefinic carbon atom (C-2) as 
shown in Figure 2.4.  
The remaining pair of aromatic protons at  6.15 (H-6) and  6.38 (H-8) were only meta 
coupled (J = 2 Hz) to each other and thus were concluded to be part of a 1,2,3,5tetra-
substituted aromatic ring. These protons displayed HMBC correlations to the quaternary 
carbons at 103.9 ppm (C-10) and 156.3 ppm (C-9) (Figure 2.5). In addition to the carbon at 
133.1 ppm (C-3), a further quaternary carbon at 177.4 ppm (C-4) was observed in the 13C 
NMR spectrum, suggesting that this substructure, attached to the anomeric proton of the 
sugar moiety, was the flavonol kaempferol (Figure 2.5).  
The complete NMR data (as given in Table 2.1) unequivocally confirmed the structure of 
2.12 to be trans-tiliroside, a known flavonol glycoside first isolated from Tilia argenta [133]. 
Trans-tiliroside was initially reported as compound 2.16 before structural revisions, 
conducted in 1964 [130], ultimately reassigned it to structure 2.12. Prior to this structural 
revision of trans-tiliroside, a compound named tribuloside was reported and assigned 
structure 2.12 in recognition of its difference to structure 2.16 [134]. The revision made it 
clear that “tribuloside” and the compound initially given structure 2.16 were the same 
compound, trans-tiliroside (2.12) [135]. Since this early revision, the “real” compound 2.16 
has been isolated from multiple sources [136-140], with the structure determined by 1D and 
2D NMR spectroscopy [139].  
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Table 2.1. 1H (500 MHz) and 13C (125 MHz) NMR spectroscopic data of trans-tiliroside (2.12) in d6-DMSO. 
Position H, J C
a gCOSY gHMBC (4 Hz) gHMBC (8 Hz) gHMBC (10 Hz) 
1 - - - - - - 
2 - 156.4, s - - - - 
3 - 133.1, s - - - - 
4 - 177.4, s - - - - 
5 - 161.2, s - - - - 
6 6.15, d, J = 2 Hz 98.8, d H-8 C-5, C-7, C-8, C-10 C-5, C-7, C-8, C-10 C-5, C-7, C-8, C-10 
7 - 164.2, s - - - - 
8 6.38, d, J = 2 Hz 93.7, d H-6 C-6, C-7, C-9, C-10 C-6, C-7, C-9, C-10  C-6, C-7, C-9, C-10 
9 - 156.3, s - - - - 
10 - 103.9, s - - - - 
1’ - 120.8, s - - - - 
2’ 7.98, dd, J = 1.5, 9 Hz 130.9, d H-3’ C-2, C-4’, C-6’ C-2, C-4’, C-6’  C-2, C-3, C-4’, C-6’ 
3’ 6.85, dd, J = 1.5, 9 Hz 115.1, d H-2’ C-4’, C-5’ C-1’, C-4’, C-5’  C-1’, C-4’, C-5’ 
4’ - 160.0, s - - - - 
5’ 6.85, dd, J = 1.5, 9 Hz 115.1, d H-6’ C-3’, C-4’ C-1’, C-3’, C-4’ C-1’, C-3’, C-4’ 
6’ 7.98, dd, J = 1.5, 9 Hz 130.9, d H-5’ C-2, C-2’, C-4’ C-2, C-2’, C-4’ C-2, C-2’, C-4’, C-5’ 
1’’ 5.45, d, J = 7.5 Hz 101.0, d H-2’’ C-3, C-2’’, C-3’’ C-3 C-3 
2’’ 3.21
b
, m 74.1, d H-1’’, 2’’-OH C-1’’, C-3’’ C-1’’, C-3’’ C-1’’, C-3’’ 
3’’ 3.24
b
, m 76.2, d 3’’-OH C-1’’, C-2’’, C-4’’ C-1’’, C-4’’ C-1’’, C-2’’, C-4’’ 
4’’ 3.16
b
, m 69.9, d 4’’-OH C-3’’, C-5’’, C-6’’ C-3’’ C-3’’, C-5’’, C-6’’ 
5’’ 3.37
b
, m 74.2, d H-6a’’, H-6b’’ C-1’’ C-4’’ C-1’’, C-3’’, C-4’’ 
6a’’ 4.02, dd, J = 6.5, 12 Hz 63.0, t H-5’’, H-6b’’ C-5’’, C-9’’’ C-4’’, C-5’’, C-9’’’ C-5’’, C-9’’’ 
6b’’ 4.26, dd, J = 1.5, 12 Hz  H-5’’, H-6a’’ C-4’’, C-5’’, C-9’’’ C-4’’, C-5’’, C-9’’’ C-4’’, C-9’’’ 
1’’’ - 124.9, s - - - - 
2’’’ 7.37, d, J = 8.5 Hz 130.2, d H-3’’’ C-4’’’, C-7’’’ C-3’’’, C-4’’’ C-6’’’, C-7’’’ C-3’’’, C-4’’’, C-7’’’ 
3’’’ 6.78, d, J = 8.5 Hz 115.8, d H-2’’’ C-1’’’, C-4’’’, C-5’’’ C-1’’’, C-4’’’, C-5’’’  C-1’’’, C-4’’’, C-5’’’ 
4’’’ - 159.8, s - - - - 
5’’’ 6.78, d, J = 8.5 Hz 115.8, d H-6’’’ C-1’’’, C-3’’’, C-4’’’ C-1’’’, C-3’’’, C-4’’’ C-1’’’, C-3’’’, C-4’’’ 
6’’’ 7.37, d, J = 8.5 Hz 130.2, d H-5’’’ C-4’’’, C-7’’’ C-2’’’, C-4’’’, C-5’’’, C-7’’’ C-4’’’, C-5’’’, C-7’’’ 
7’’’ 7.34, d, J = 16 Hz 144.6, d H-8’’’ C-2’’’/C-6’’’, C-8’’’, C-9’’’ C-2’’’/C-6’’’, C-8’’’, C-9’’’ C-2’’’/C-6’’’, C-8’’’, C-9’’’ 
8’’’ 6.12, d, J = 16 Hz 113.6, d H-7’’’ C-1’’’, C-9’’’ C-1’’’, C-9’’’ C-1’’’, C-9’’’ 
9’’’ - 166.2, s - - - - 
5-OH 12.58, s - - C-5, C-6, C-7, C-10 C-5, C-6, C-10 C-5, C-6, C-7, C-10 
7-OH 10.88, bs - - - - - 
4’-OH 10.18, bs - - - - - 
2’’-OH 5.48, d, J = 4.5 Hz - H-2’’ C-1’’, C-2’’, C-3’’ C-1’’, C-2’’, C-3’’ C-1’’, C-2’’, C-3’’ 
3’’-OH 5.19, d, J = 5.5 Hz - H-3’’ C-2’’, C-3’’, C-4’’ C-2’’, C-3’’, C-4’’ C-2’’, C-3’’, C-4’’ 
4’’-OH 5.24, d, J = 4.5 Hz - H-4’’ C-3’’, C-4’’ C-5’’ C-3’’, C-4’’ C-5’’ C-3’’, C-4’’ C-5’’ 
4’’’-OH 10.05, bs - - - - - 
a Carbon assignments based on gHSQCAD and gHMBC NMR experiments. b Signals overlapped 
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A comparison of the NMR data for 2.12 (Table 2.1 and Experimental chapter Section 7.2) 
with those reported in the literature (d6-DMSO and CD3OD) confirmed that the compound 
corresponding to HPLC peak 1 was trans-tiliroside (2.12) [135, 141, 142]. Although the 
complete 2D NMR assignment of 2.12 is documented in the literature [142], it is worth noting 
that on one occasion prior to this 2D assignment [143], several of the carbon NMR 
assignments (namely positions C-5, C-6, C-8 and C-9) were incorrect. The carbon chemical 
shift assignments were confirmed by our gHSQCAD and gHMBC NMR experiments and are 
consistent with all other literature NMR reports for 2.12 [135, 141, 142]. The sugar moiety in 
compound 2.12 was concluded to be a β-D-glucopyranoside on the basis of a comparison of 
the NMR chemical shifts for this moiety with the literature data [141]. The absolute 
configuration of the sugar moiety in compound 2.12 has been previously established by both 
acid and alkali hydrolyses [130, 144]. Trans-tiliroside (2.12) is known to occur in other 
Malvaceae species [126, 131, 132, 145-147]. 
The negative ESI-MS of HPLC peak 2 (2.13) was identical to that of 2.12 in that it showed 
the presence of an ion at m/z 593 [M-H]-, while the positive mode showed the presence of 
ions at m/z 595 [M+H]+ and m/z 617 [M+Na]+. The 1H NMR spectrum of 2.13 was also very 
similar to that of 2.12. Comparison of the spectrum of 2.13 with that of 2.12 indicated that 
both compounds contained the same kaempferol and glycoside moieties (Table 2.2).  
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Table 2.2. 1H (500 MHz) and 13C (125 MHz) NMR spectroscopic data of cis-tiliroside (2.13) in 
d6-DMSO. 
Position H, J  C
a gCOSY gHMBC 
1 - - - - 
2 - 156.5, s - - 
3 - 133.1, s - - 
4 - ND - - 
5 - 161.1, s - - 
6 6.17, d, J = 2.0 Hz 98.5, d H-8 C-5, C-7, C-8, C-10 
7 - 164.3, s - - 
8 6.32, d, J = 2.0 Hz 93.5, d H-6 C-6, C-7, C-9, C-10  
9 - 156.4, s - - 
10 - 103.7, s - - 
1’ - 120.6, s - - 
2’ 7.95, d, J = 9.0 Hz 130.6, d H-3’ C-2, C-4’, C-6’  
3’ 6.84, d, J = 9.0 Hz 115.0, d H-2’ C-1’, C-4’, C-5’  
4’ - 159.7, s - - 
5’ 6.84, d, J = 9.0 Hz 115.0, d H-6’ C-1’, C-3’, C-4’ 
6’ 7.95, d, J = 9.0 Hz 130.6, d H-5’ C-2, C-2’, C-4’ 
1’’ 5.40, d, J = 7.5 Hz 101.5, d H-2’’ C-3’’ 
2’’ 3.20
b
, m 73.8, d H-1’’ - 
3’’ 3.24
b
, m 75.9, d 3’’-OH - 
4’’ 3.15
b
, m 69.7, d 4’’-OH - 
5’’ 3.37
b
, m 74.2, d H-6a’’ - 
6a’’ 4.07, dd, J = 6.0, 11.0 Hz 63.0, t H-5’’, H-6b’’ C-9’’’ 
6b’’ 4.15, dd, J = 2.0, 11.0 Hz  H-6a’’ - 
1’’’ - 125.4, s - - 
2’’’ 7.55, d, J = 8.5 Hz 132.4, d H-3’’’ C-4’’’, C-6’’’, C-7’’’ 
3’’’ 6.69
b
, d, J = 8.5 Hz 114.6, d H-2’’’ C-1’’’, C-4’’’, C-5’’’ 
4’’’ - 158.8, s - - 
5’’’ 6.69
b
, d, J = 8.5 Hz 114.6, d H-6’’’ C-1’’’, C-3’’’, C-4’’’ 
6’’’ 7.55, d, J = 8.5 Hz 132.4, d H-5’’’ C-2’’’,C-4’’’, C-7’’’ 
7’’’ 6.67
b
, d, J = 12.5 Hz 143.5, d H-8’’’ C-2’’’, C-6’’’, C-9’’’ 
8’’’ 5.46
b
, d, J = 12.5 Hz 114.3, d H-7’’’ C-1’’’ 
9’’’ - 165.6, s - - 
5-OH 12.55, s - - - 
4’-OH 10.16, bs - - - 
2’’-OH 5.45
b
, d, J = 4.5 Hz - H-2’’ - 
3’’-OH 5.17, d, J = 5 Hz - H-3’’ - 
4’’-OH 5.22, d, J = 5.5 Hz - H-4’’ C-5’’ 
a Carbon assignments based on gHSQCAD and gHMBC NMR experiments 
b Signals overlapped 
ND indicates signals were not detected 
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Differences were evident in the olefinic methines of the coumaroyl moiety, with a shift from  
7.34, d, J = 16 Hz (H-7′′′) and  6.12, d, J = 16 Hz (H-8′′′) in 2.12 to  6.67, d, J = 12.5 Hz (H-
7′′′) and  5.46, d, J = 12.5 Hz (H-8′′′) in 2.13 as shown in Figure 2.6. This change was 
consistent with a cis double bond in the coumaroyl moiety (Figure 2.6). In addition, the sugar 
methylene signals at  4.02, dd, J = 6.5, 12 Hz (H-6a′′) and  4.26, dd, J = 1.5, 12 Hz (H-6b′′) 
in 2.12 shifted to  4.07, dd, J = 6, 11 Hz (H-6a′′) and  4.15, dd, J = 2, 11 Hz (H-6b′′) in 2.13, 
which was also consistent with a change from trans to cis in the double bond geometry of the 
coumaroyl moiety. On this basis compound 2.13 was concluded to be cis-tiliroside, which 
was first reported in a mixture with trans-tiliroside (2.12) in 1995 [148]. The first isolation and 
characterization of 2.13 was reported in 2004 [142]. Comparison of the NMR data obtained 
from this study as a mixture with 2.12 in CD3OD (see Experimental chapter Section 7.2) for 
HPLC peak 2 with that in the literature (reported in CD3OD) confirmed that this compound 
was cis-tiliroside (2.13) [142]. 
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Figure 2.6. Fragments linked to the sugar for the major component (2.13). 
 
The negative ESI-MS of the compound responsible for HPLC peak 3 showed the presence of 
an ion at m/z 607 [M-H]-, 14 mass units higher than that of 2.12 and 2.13 and consistent with 
a molecular formula of C31H28O13 and eighteen degrees of unsaturation. The 
1H NMR 
spectrum was very similar to that of 2.12. Once again, the presence of a trans-p-coumaroyl 
moiety was indicated by the chemical shifts and coupling constants of the olefinic protons [ 
7.35, d, J = 16 Hz (H-7′′′) and  6.17, d, J = 16 Hz (H-8′′′)]. The 1H NMR chemical shifts of the 
1,4-disubstituted aromatic ring associated with the kaempferol moiety [ 8.06, d, 2H, J = 8 Hz 
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(H-2′/H-6′) and  6.99, d, 2H, J = 8 Hz (H-3′/H-5′)] as shown in Table 2.3. This evidence and 
the presence of a deshielded methyl resonance [ 3.70, s, 3H, (4′-OCH3)], indicated that 2.14 
was a methoxy derivative of 2.12. 
The methoxyl group was positioned on the 1,4-disubstituted aromatic ring of the kaempferol 
moiety on the basis of the HMBC correlations observed from the methoxyl protons  3.70 (4′-
OCH3) and the aromatic protons  8.06 (H-2′/H-6′) to 161.3 ppm (C-4′) (Figure 2.7 and Table 
2.3). In turn the aromatic protons  8.06 (H-2′/H-6′) showed a key correlation to 156.1 ppm 
(C-2), thereby supporting the positioning of the methoxyl on C-4’ of the kaempferol moiety as 
shown in Figure 2.7.  
On the basis of this data (Table 2.3), it was concluded that HPLC peak 3 was kaempferol-4′-
methyl ether-3-O-β-D-(6-O-trans-p-coumaroyl)-glucopyranoside (2.14), which was first 
reported in 2007 by Morales-Escobar et al. [125]. However, the 1H NMR chemical shifts 
reported by this group [125] for the meta-coupled aromatic methines in the methoxyl 
kaempferol moiety ( 6.50, H-6 and 6.68, H-8) were markedly higher than those typically 
observed for kaempferol glycosides, namely  6.15 and  6.35 [149, 150]. In contrast, the 1H 
NMR analysis of 2.14 (Table 2.3) is consistent with the typical kaempferol glycoside 
chemical shifts ( 6.15 and  6.35). A closely related compound, 6′-O-(4’’’-methoxy-trans-
cinnamoyl)-kaempferol-3-β-D-glucopyranoside (2.17), reported in 2009 by Choudhary et al. 
[151], for which 2D NMR correlations formed the basis of the structure elucidation argument 
[151] and their positioning of the methoxyl group on the cinnamoyl moiety was based on a 
HMBC correlation observed from the methoxyl protons at  3.89 to a peak assigned to C-4’’’ 
at 161.5 ppm as shown in Figure 2.8 [151]. The position of attachment of the methoxy 
moiety in this compound is not unequivocal since no further HMBC correlations from the 
associated aromatic ring to the remaining section of the cinnamoyl moiety were reported 
[151].  
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Table 2.3. 1H (500 MHz) and 13C (125 MHz) NMR spectroscopic data of 4′-methoxy-trans-
tiliroside (2.14) in d6-DMSO. 
Position H, J  C
a gCOSY gHMBC 
1 - - - - 
2 - 156.1, s - - 
3 - 133.4, s - - 
4 - ND - - 
5 - 161.1, s - - 
6 6.15, s 98.7, d H-8 C-5, C-7, C-8, C-10 
7 - 164.7, s - - 
8 6.38, d 93.6, d H-6 C-6, C-7, C-9, C-10  
9 - 156.4, s - - 
10 - 103.9, s - - 
1’ - 122.4, s - - 
2’ 8.06, d, J = 7.5 Hz 130.4, d H-3’ C-2, C-4’, C-6’  
3’ 6.99, d, J = 8.5 Hz 113.3, d H-2’ C-1’, C-4’, C-5’  
4’ - 161.3, s - - 
5’ 6.99, d, J = 7.5 Hz 113.3, d H-6’ C-1’, C-3’, C-4’ 
6’ 8.06, d, J = 7.5 Hz 130.4, d H-5’ C-2, C-2’, C-4’ 
1’’ 5.45, d, J = 8.0 Hz 101.8, d H-2’’ C-3 
2’’ 3.23
b
, m 73.8, d H-1’’, 2’’-OH C-1’’, C-3’’ 
3’’ 3.28
b
, m 75.7, d 3’’-OH C-4’’, C-1’’ 
4’’ 3.25
b
, m 69.5, d 4’’-OH C-3’’ 
5’’ 3.37
b
, m 73.8, d H-6a’’ C-4’’ 
6a’’ 4.02, dd, J = 5.0, 11.0 Hz 62.4, t H-5’’, H-6b’’ C-4’’, C-5’’, C-9’’’ 
6b’’ 4.28, d, J = 11.5 Hz  H-6a’’ C-4’’, C-5’’, C-9’’’ 
1’’’ - 125.0, s - - 
2’’’ 7.40, d, J = 8.0 Hz 130.0, d H-3’’’ C-3’’’, C-4’’’, C-7’’’ 
3’’’ 6.78, d, J = 7.5 Hz 115.5, d H-2’’’ C-1’’’, C-4’’’, C-5’’’ 
4’’’ - 159.8, s - - 
5’’’ 6.78, d, J = 7.5 Hz 115.5, d H-6’’’ C-1’’’, C-3’’’, C-4’’’ 
6’’’ 7.40, d, J = 8.0 Hz 130.0, d H-5’’’ C-4’’’,C-5’’’, C-7’’’ 
7’’’ 7.35, d, J = 16.0 Hz 144.4, d H-8’’’ C-2’’’/C-6’’’, C-8’’’, C-9’’’ 
8’’’ 6.17, d, J = 16.0 Hz 113.4, d H-7’’’ C-1’’’, C-9’’’ 
9’’’ - 166.2, s - - 
4’-OCH3 3.70, s 54.9, q  C-4’ 
5-OH 12.55, bs - - C-5, C-6, C-10 
2’’-OH 5.46, m - H-2’’ C-1’’, C-2’’, C-3’’ 
3’’-OH 5.22, m - H-3’’ C-2’’, C-3’’, C-4’’ 
4’’-OH 5.26, m - H-4’’ C-3’’, C-4’’, C-5’’ 
a 
Carbon assignments based on gHSQCAD and gHMBC NMR experiments 
b 
Signals overlapped 
ND indicates signals were not detected 
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Figure 2.7. 2D gHMBC NMR spectrum of 4′-methoxy-trans-tiliroside (2.14), showing key correlations. 
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Figure 2.8. HMBC NMR correlation of compound (2.17). 
 
In our study, the original NMR spectra for 2.14 were obtained in d6-DMSO. The chemical 
shifts reported for both 2.14 and 2.17 in the literature [125, 151] were from NMR spectra 
obtained in CD3OD. In order to better compare the NMR data, the spectra for 2.14 were re-
run in CD3OD. Comparison of the NMR data obtained for 2.14 in CD3OD (see Experimental 
chapter Section 7.2.2 and Table 2.4) with that reported in the literature for compounds 2.14 
and 2.17, indicated that both literature structures had been assigned incorrectly.  
The structure of the compound originally reported as 6′-O-(4’’-methoxy-trans-cinnamoyl)-
kaempferol-3-β-D-glucopyranoside (2.17), should be revised to kaempferol-4′-methyl ether-3-
O-β-D-(6-O-trans-p-coumaroyl)-glucopyranoside (2.14), on the basis of NMR chemical shift 
comparisons with the data obtained for 2.14 as shown in Table 2.4.  
The compound reported in the literature [125] as kaempferol-4′-methyl ether-3-O-β-D-(6-O-
trans-p-coumaroyl)-glucopyranoside (2.14) also requires a structure re-assignment. This 
structure revision is based on the chemical shifts of the meta coupled aromatic protons ( 
6.50 (H-6) and  6.68 (H-8)) of the flavonoid moiety [125]. Comparison with literature NMR 
data [152, 153] for other closely related metabolites (see Figure 2.9), shows that these 1H 
NMR chemical shifts are not consistent with a structure which has two hydroxyl groups at 
positions 5 and 7 ( 6.15 (H-6) and  6.40 (H-8)). Without access to an authentic sample of 
the compound incorrectly reported as kaempferol-4′-methyl ether-3-O-β-D-(6-O-trans-p-
coumaroyl)-glucopyranoside (2.14), only a tentative structure re-assignment can be 
proposed for this compound, which is discussed below [125].  
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Table 2.4. Chemical shift comparison of 2.14 and literature reports of 2.17 and 2.14 in 
CD3OD. 
 2.14 literature 2.17 [151] literature 2.14 [125] 
Position H C
 H, J C H, J C 
1 - - - - - - 
2 - 158.5, s - 159.2, s - 159.3, s 
3 - ND - 135.1, s - 136.0, s 
4 - ND - 179.5, s - 179.8, s 
5 - ND - 158.5, s - 163.5, s 
6 6.16, d 99.7, d 6.11, d, J = 1.8 Hz 100.3, d 6.50, d, J = 2.0 Hz 99.4, d 
7 - 165.6, s - 162.9, s - 165.8, s 
8 6.35, d 94.6, d 6.29, d, J = 1.8 Hz 95.0, d 6.68, d, J = 2.0 Hz 95.0, d 
9 - 157.9, s - 159.0, s - 158.9, s 
10 - ND - 105.2, s - 106.0, s 
1’ - 123.4, s - 122.4, s - 122.0, s 
2’ 8.08, d 131.7, d 7.99, d, J = 8.6 Hz 132.1, d 7.95, d, J = 8.0 Hz 129.6, d 
3’ 6.93, d 114.3, d 6.80, d, J = 8.4 Hz 116.8, d 7.08, d, J = 8.0 Hz 115.7, d 
4’ - 162.6, s - 161.2, s - 159.0, s 
5’ 6.93, d 114.3, d 6.80, d, J = 8.4 Hz 116.8, d 7.08, d, J = 8.0 Hz 115.7, d 
6’ 8.08, d 131.7, d 7.99, d, J = 8.6 Hz 132.1, d 7.95, d, J = 8.0 Hz 129.6, d 
1’’ 5.26, d 103.8, d 5.22, d, J = 7.1 Hz 104.0, d 5.27, d, J = 7.8 Hz 103.5, d 
2’’ 3.46
b
, m 75.4, d 3.43, dd, d, J = 9.1,  
7.5 Hz 
75.8, d 3.54, dd, d, J = 9.5,  
7.8 Hz 
74.0, d 
3’’ 3.44
b
, m 77.5, d 3.47, d, J = 7.8 Hz 77.7, d 3.50, t, J = 9.5 Hz 77.8, d 
4’’ 3.38
b
, m 71.2, d 3.38, t, J = 9.0 Hz 71.7, d 3.39, t, J = 9.5 Hz 71.6, d 
5’’ 3.41
b
, m 75.4, d 3.49, m 78.0, d 3.60, m 75.4, d 
6a’’ 4.19, m 63.7, t 4.17, dd, J = 13.0,  
3.8 Hz 
64.2, t 4.34, dd, J = 12.0, 4.5 Hz 64.5, t 
6b’’ 4.30, d  4.27, dd, J = 12.5,  
4.4 Hz 
- 4.24, dd, J = 12.0, 3.0 Hz - 
1’’’ - 126.4, s - 127.0, s - 125.0, s 
2’’’ 7.35, d 130.9, d 7.32, d, J = 8.4 Hz 131.2, d 7.95, d, J = 8.0 Hz 129.7, d 
3’’’ 6.82, d 116.5, d 6.78, d, J = 8.4 Hz 116.0, d 6.83, d, J = 8.0 Hz 116.2, d 
4’’’ - 160.6, s - 161.5, s - 159.5, s 
5’’’ 6.82, d 116.5, d 6.78, d, J = 8.4 Hz 116.0, d 6.83, d, J = 8.0 Hz 116.2, d 
6’’’ 7.35, d 130.9, d 7.32, d, J = 8.4 Hz 131.2, d 7.95, d, J = 8.0 Hz 129.7, d 
7’’’ 7.42, d 146.1, d 6.08, t, J = 16.0 Hz 146.5, d 7.65, d, J = 16.0 Hz 146.0, d 
8’’’ 6.10, d 114.5, d 7.40, d, J = 15.8 Hz 114.3, d 6.42, d, J = 16.0 Hz 116.1, d 
9’’’ - 166.3, s - 168.7, s - 168.3, s 
4’-OCH3 3.72, s 55.5, q   3.90, s 58.5, q 
4’’’-OCH3   3.89, s 56.0, q   
a Carbon assignments based on correlations from gHSQCAD and gHMBC NMR spectra 
b Sugar moiety proton signals assigned from gHSQCAD NMR spectrum 
ND – Not detected in gHMBC NMR experiment 
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A 1H NMR comparison of multiple compounds (2.18-2.22) from the literature [150, 152] 
indicated that for the meta coupled protons, a hydroxyl or methoxyl substitution at the C-4’ or 
C-3 positions only has a small effect on the chemical shifts of the meta coupled aromatic 
protons as shown in Figure 2.9, whereas substitution (methyl-prop-1-enoxyl or methoxyl) at 
the C-7 position has a significant effect on these protons as shown in Figure 2.9 [150, 152]. 
The reported HMBC correlations for the compound reported by Morales-Escobar et al. [125], 
and assigned the structure (2.14) showed a correlation from the anomeric proton of the sugar 
moiety to a quaternary carbon at 133.6 ppm. This correlation immediately eliminated the 
possibility of the glycoside being substituted at position C-7 (see below).  
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Figure 2.9. Comparison of NMR data for structurally related flavonoids. 
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As shown in Figure 2.10, the chemical shift reported for compound (2.23) [154] indicate that 
a sugar-substituted C-7 quaternary signal would appear near 163 ppm, which is quite 
different to that of the 133.6 ppm observed for compounds with the sugar moiety attached to 
C-3 of the kaempferol moiety. The chemical shifts of the methylene protons of the sugar 
moiety ( 4.34,  4.24) were typical of those of a sugar esterified at C-6” (see compound 2.24 
in Figure 2.10) and were much higher than those of a terminal sugar moiety (see compound 
2.25 in Figure 2.10) [155]. This, together with the reported HMBC correlations from the sugar 
methylene protons to the ester carbon at 168.3 ppm, confirmed that the p-coumaroyl moiety 
was indeed attached at C-6’’ of the sugar as depicted in compounds (2.12-2.14) and 
compound (2.24) (Figure 2.10) [153]. Thus, the compound reported by Morales-Escobar et 
al. [125] has the same sugar linkages as 2.14. Consequently, only a few possibilities remain 
which could explain the significant differences observed for the meta coupled aromatic 
protons. 
One possibility considered was that of a 6,8-dihydroxy-substituted flavonoid instead of a 5,7-
dihydroxy-substituted flavonoid. However, neither the 1H nor the 13C NMR chemical shifts 
associated with the meta coupled aromatic protons ( 6.50, H-8;  6.68, H-6 and 99.4 ppm, 
C-6; 95.0 ppm C-8) [125] were in accordance with the literature [156] NMR data reported for 
6,8-dihydroxy-substituted flavonoids such as compound (2.27) (Figure 2.10) [156]. In 6,8-
dihydroxy flavonoid 2.27, the aromatic methines in question appear at  6.90 (H-5)/104.7 
ppm (C-5) and  6.81 (H-7)/114.7 ppm (C-7). These large differences in both the 1H and 13C 
NMR chemical shifts rule out a 6,8-dihydroxy flavonoid moiety in any revised structure being 
proposed. 
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Figure 2.10. Comparison of NMR data for structurally related flavonoids. 
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After consideration of the NMR data of closely related flavonoids [157], it was concluded that 
the most likely structure of the compound originally reported as 2.14 by Morales-Escobar et 
al. [125] is kaempferol-7-methyl ether-3-O-β-D-(6-O-trans-p-coumaroyl)-glucopyranoside 
(2.28) [157] (Figure 2.10). This structure satisfactorily explains the differences observed in 
chemical shifts for the meta coupled aromatic protons on the kaempferol moiety and also 
supports all the reported HMBC correlations [125]. This proposed structure revision 
corresponds to a known compound. However a direct NMR comparison was hampered by 
the use of CD3OD as the NMR solvent for the compound reported as 2.14 by Morales-
Escobar et al. [125] and d6-DMSO for 2.28 [157]. For an unequivocal revision to the structure 
of the compound reported as 2.14, a complete HMBC re-assessment of an authentic sample 
would be required. 
The HR-ESI-MS of HPLC peak 4 displayed an m/z at 607.1461 [M-H]- (calcd. for C31H27O13: 
m/z 607.1452) consistent with a molecular formula C31H28O13 and eighteen degrees of 
unsaturation. The 1H NMR and gHSQCAD spectrum (Figure 2.11) spectra of peak 4 were 
very similar to that of 2.13, with the only noticeable difference being the presence of a new 
methoxyl resonance ( 3.77, s, 3H). Like that of cis-tiliroside (2.13), the 1H NMR spectrum of 
peak 4 also indicates the presence of a cis-p-coumaroyl moiety [ 6.67, (H-7′′′) and  5.49, d, 
J = 13.5 Hz (H-8′′′)]. The coupling constant for the proton at  6.67 could not be measured 
accurately as it was overlapped with the H-3’’’/H-5’’’ aromatic protons. The location of the 
methoxyl moiety was again established on the basis of key HMBC correlations observed 
from the methoxyl protons at  3.77 (4′-OCH3) and the aromatic methines  8.03 (H-2′/H-6′) 
to the carbon at 161.2 ppm (C-4′). The additional HMBC correlation from the aromatic 
methines  8.03 (H-2′/H-6′) to the C-2 carbon at 156.0 ppm allowed the methoxyl to be 
positioned, once again, on the kaempferol moiety. As such, compound 2.15 was identified to 
be kaempferol-4′-methyl ether-3-O-β-D-(6-O-cis-p-coumaroyl)-glucopyranoside. To the best 
of our knowledge, this represents a new flavonoid glycoside derivative. 
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A feature that was noted for both the purified trans-tiliroside (2.12) and cis-tiliroside (2.13) 
was that both converted to an equilibrium mixture of the two compounds. This mixture was 
reminiscent of the initial ratio of the two compounds that occurred in the crude extract 
(approximately 4:1 trans-tiliroside to cis-tiliroside). The conversion was much more rapid in 
CD3OD than in d6-DMSO and cis-tiliroside (3 days) converted to a mixture much more rapidly 
than trans-tiliroside (>3 weeks in CD3OD). A study was undertaken to determine the stability 
of trans-tiliroside (2.12) at different temperatures and various solvents. The conversion was 
monitored using analytical HPLC, with the most rapid conversion occurring in the presence of 
methanol at room temperature, where a sample of pure trans-tiliroside (2.12) converted to a 
mixture of both isomers. The presence of cis-tiliroside (2.13) could be detected in this 
conversion after about 3 weeks. Pure samples of trans-tiliroside (2.12) in methanol and in 
ethanol were subjected to UV light (254 nm and 365 nm) for 24 hours at each wavelength, 
resulting in the ratio of trans-tiliroside (2.12) to cis-tiliroside (2.13) isomers increasing from 
approximately 4:1 to almost 1:1 in both solvents as shown by the analytical HPLC 
chromatogram of the mixture of trans-tilirosde (2.12) and cis-tiliroside (2.13) in Figure 2.12. 
Due to this conversion, particularly in CD3OD, the optimal NMR solvent for this class of 
compounds is d6-DMSO as the conversion is substantially slower in this solvent. It is worth 
noting that most of the literature NMR data for this class of compounds has been reported in 
CD3OD. 
In order to determine if the methoxy tiliroside derivatives 2.14 and 2.15 were natural products 
or artefacts of the isolation procedure, two separate small scale (5 g) extractions were 
conducted in MeOH and EtOH. Both afforded compounds 2.14 and 2.15 in a similar ratio to 
that detected initially in the crude extract obtained using 3:1 MeOH:DCM, while no ethoxy 
derivatives were observed in either extraction. This demonstrated that compounds 2.14 and 
2.15 are natural products and not artefacts of the isolation procedure. 
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Figure 2.11. 2D gHSQCAD NMR spectrum of kaempferol-4′-methyl ether-3-O-β-D-(6-O-cis-p-coumaroyl)-glucopyranoside (2.15). 
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Figure 2.12. Analytical HPLC chromatogram of the UV exposed mixture of 2.12 and 2.13. 
 
Flavonoids and flavonoid glycosides are a class of secondary metabolites recognised for 
their important biological activities (Introduction Section 1.2) [18, 118, 158]. Trans-tiliroside 
(2.12) has been reported to display anti-oxidative properties [159], inhibits cAMP 
phosphodiesterase [143], exhibits anti-complement, anti-inflammatory and free radical 
scavenging activities, potent activity towards d-GalN-induced cytotoxicity in hepatocytes, 
displays cytotoxicity against specific leukaemia cell lines, and also exhibits moderate anti-
bacterial activity [132, 147]. It has also been observed that trans-tiliroside (2.12) can 
modulate the activity of known anti-bacterial agents, with a reduction of minimum inhibitory 
concentration (MIC) of at least two fold when trans-tiliroside (2.12) was incorporated into the 
growth medium at 32 µg/mL [147]. Mixtures of trans-tiliroside (2.12) and cis-tiliroside (2.13) 
show significant toxicity towards brine shrimp, as well as displaying potent inhibition towards 
CYP3A4 [142]. The anti-bacterial activity displayed by a mixture of the two compounds has 
been suggested to be due to the cis isomer. In a separate study it was demonstrated that 
compounds containing the cis-coumaroyl moiety are more active than those with the 
corresponding trans-coumaroyl moiety [153, 159]. The crude extract of L. macrophyllum 
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displayed modest cytotoxicity. Owing to the observed tendency of the isolated flavonoid 
glycosides to form equilibrium mixtures, no cytotoxicity testing was conducted on the isolated 
secondary metabolites. 
 
2.4 Concluding Remarks 
This study demonstrated that on-line and off-line chemical profiling techniques are 
complementary. The on-line profiling by HPLC-NMR was used to tentatively identify the two 
major components of the methanol extract of L. macrophyllum, as well as one of the minor, 
related, components. On-line HPLC-NMR provided a chemical profile of the crude methanol 
extract of the Australian plant L. macrophyllum, resulting in the tentative identification of 
trans-tiliroside (2.12), cis-tiliroside (2.13) and 4′-methoxy-trans-tiliroside (2.14). Subsequent 
off-line purification permitted the complete structural elucidation of the four flavonoid 
glycosides (2.12-2.15). Compound 2.15 was established to be a new flavonoid glycoside 
structural derivative. This represents the first report of the isolation of flavonoid glycosides 
from the genus Lasiopetalum. The off-line purification of these compounds was particularly 
important since the NMR assignment of 2.14, as reported in the literature, was found to be 
inconclusive in terms of the position of attachment for the methoxy moiety. Upon detailed 
examination of the literature NMR data and that obtained for 2.14, it was concluded that the 
structures of the two literature compounds reported as kaempferol-4′-methyl ether-3-O-β-D-
(6-O-trans-p-coumaroyl)-glucopyranoside and 6′-O-(4’’-methoxy-trans-cinnamoyl)-
kaempferol-3-β-D-glucopyranoside should be revised. A series of stability studies undertaken 
concluded that compounds 2.14 and 2.15 interconverted but were not artefacts of the 
extraction procedure with methanol. The use of HPLC-NMR was found to be particularly 
suited to the analysis of unstable compounds that convert to equilibrium mixtures, such as 
those investigated in this study. 
97 
 
Chapter 3  
Phenylphenalenones and 
Oxabenzochrysenones from the Australian 
plant Haemodorum simulans 
3.1 Introduction 
Phenylphenalenones (Figure 3.1) are secondary metabolites of phenylpropanoid origin 
which have been found exclusively in the plant families Haemodoraceae, Musaceae, 
Pontederiaceae and Strelitziaceae [160]. The family Haemodoraceae is predominantly found 
in the southern hemisphere, with genera such as Haemodorum being endemic to Australia 
and Papua New Guinea [161]. Tetraoxygenated phenylphenalenones and related 
compounds modified by the formation of an ether bridge between ring A and ring D result in 
the formation of oxabenzochrysenone (naphthoxanthenones) type structures (Figure 3.1). 
The oxabenzochrysenone structure class of secondary metabolites has also been shown to 
occur almost exclusively in the family Haemodoraceae [160, 162-167]. The occurrence of the 
phenylphenalenones and oxabenzochrysenones in families of plants such as Musaceae and 
Haemodoraceae illustrates their close structural relationship and their importance in being 
potential chemotaxonomic markers for these families of plants [164, 168].  
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Figure 3.1. General structures and numbering of phenylphenalenones and 
oxabenzochrysenones. 
 
The number of oxabenzochrysenones (3.1-3.11) isolated is far fewer than that of the 
phenylphenalenones (including phenylbenzoisochromenones) (3.12-3.19) with the additional 
fused ring in the former structure class limiting the sites for substitution [162]. The main 
differences for phenylphenalenones and related compounds are the positioning of the aryl 
substituent, and degree of oxygenation and functionality, while anhydrides and esters in the 
B ring also occur. Typically, in the most common phenylphenalenones that have been 
isolated, the aryl ring is attached to position 7 (3.15-3.19) or position 9 (3.12) within the D 
ring, however aryl attachment at position 4 (3.13-3.14, 3.20-3.21) and position 8 (3.22) have 
also been identified, along with diphenylphenalenones (3.23-3.24). 
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3.1.1 Biosynthesis of phenylphenalenones 
The biosynthetic pathway for the formation of phenylphenalenones was first reported as 
incorporating phenylalanine and tyrosine from the shikimate pathway [169]. This was 
different to that of the fungal phenalenones which were formed by the acetate-polymalonate 
pathway [169, 170]. The incorporation of carbon labelled phenylalanine was used to show 
that the polymalonate pathway was involved in the biosynthesis of phenylphenalenones, with 
up to 3.8% incorporation of labelled phenylalanine detected [171, 172]. The intermediates 
involved in the biosynthesis of phenylphenalenones were not discovered until Hölscher and 
Schneider provided experimental evidence for a diarylheptanoid intermediate [173]. They 
observed that twenty-four hours after addition of [2-13C] cinnamic acid (3.25) in root cultures 
of Anigozanthos preisii (Haemodoraceae), isolated anigorufone (3.26) showed the presence 
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of enhanced 13C NMR signals at C-5 and C-8, thereby providing direct evidence of the 
biosynthetic pathway derived of the phenylalanine pathway [173]. This evidence also 
supported that the biosynthesis occurs via the diarylheptanoid pathway (Scheme 3.1), which 
was further proved by the addition of [2-13C] 1-phenyl-7-(3,4-diacetoxyphenyl)hepta-1,3-dien-
5-one (3.27) to cultured roots of A. preisii. When anigorufone (3.26) was then isolated 
enhancements in the 13C NMR signal at C-8 were observed, providing evidence of the 
diarylheptanoid intermediate [173]. The speed at which incorporation of the labelled 
precursors was found to occur (within twenty-four hours), would explain why no 
diarylheptanoid compounds have been isolated from organisms containing 
phenylphenalenones, as this rapid cyclisation occurs so readily [173].  
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HO
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The origin of the carbon at C-6a in the phenylphenalenone structure class, which 
corresponds to C4 in the diarylheptanoid intermediate (see Figure 3.2), was thought to have 
come from the incorporation of C-2 from an acetate molecule (Figure 3.2), as this carbon 
could not have come from the p-coumaric acid (Figure 3.2) molecules in the 
phenylphenalenone biosynthesis [174]. Multiple experiments using labelled [13CH3] 
methionine, [2-13C] acetate and [2-13C] malonate allowed for the determination of the origin of 
the C-6a of the phenylphenalenone nucleus [174]. The incorporation of [2-13C] acetate into 
multiple phenylphenalenones showed that acetate is involved in the biosynthesis of 
phenylphenalenones (Scheme 3.1) [174]. 
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phenylphenalenone diarylheptanoid acetate p-coumaric acid  
Figure 3.2. Positions corresponding to the acetate incorporation in the biosynthesis of 
phenylphenalenones. 
 
This led to further studies into the biosynthesis of the phenylphenalenones as there was still 
uncertainty arising from the incorporation of the saturated phenylpropanoic moiety by either 
dihydrocinnamic acid or from cinnamic acid (Figure 3.3) followed by a post condensation 
hydrogenation with a second cinnamate moiety [175]. In vivo feeding experiments of cultures 
of A. preisii resulted in the identification of reversible interconversions of phenylpropanoids 
into dihydrophenylpropanoids (Figure 3.3), which have roles in the biosynthesis of the 
phenylphenalenones [175]. The reversible interconversions of the phenyl- and 
dihydrophenyl- propanoids could lead to the variable ratio of different phenylphenalenones 
produced [175].  
 
O
OH
O
OH
cinnamic acid dihydrocinnamic acid  
Figure 3.3. Example of the interconversion of a phenylpropanoid into a 
dihydrophenylpropanoid. 
 
However, the phenylphenalenone biosynthetic pathway would not result in the formation of 
related phenylphenalenone-type structures such as the phenylbenzoisochromenone (3.16). 
The formation of these phenylbenzoisochromenones was suggested to occur via an oxidative 
step in the phenylphenalenone biosynthetic pathway, or via a Diels-Alder cycloaddition of an 
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ester intermediate [176]. The use of 13C labelled phenylalanine determined that like that of 
phenylphenalenones, phenylbenzoisochromenones were formed through a late branching of 
the diarylheptanoid pathway [176]. 8-Phenylphenalenones (3.22) follow the same 
biosynthetic pathway, with a diarylheptanoid intermediate, however it was hypothesised that 
after an intramolecular cycloaddition, a 1,2-aryl migration occurs (Scheme 3.1) [177]. Further 
oxygenation of phenylphenalenones originates from the hydroxyl group of the 4-coumaroyl 
moiety and is incorporated at the stage of the linear diarylheptanoid, while hydroxyl groups at 
C-2 are introduced later during the phenylphenaleneone biosynthesis [178]. 
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4CL - 4-coumarate CoA ligase; C4H - cinnamate 4-hydroxylase; PAL - phenylalanine ammonia lyase ; PKS III – 
polyketide synthase type III; a) putative reductase (possibly chalcone reductase); b) putative dehydrogenation; c) 
putative CYP or phenol oxidase; d) putative cyclase (possibly diels-alderase); e) reduction and dehydrogenation; 
f) putative oxidative phenol coupling. 
Scheme 3.1. The biosynthetic pathway for phenylphenalenones (sourced from Schmitt and 
Schneider [175], Hölscher and Schneider [177], Munde and Maddula et al [178], Schmitt and 
Hölscher et al [179] and Brand and Hölscher et al [180]) 
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3.1.2 Biological activity of phenylphenalenones 
The biological activity of phenylphenalenones has not been thoroughly studied. The activity 
of phenylphenalenones such as 3.28 and derivatives has been studied more thoroughly, with 
anti-oxidant activity [181], anti-protozoal activity [182], inhibition of eukaryotic DNA 
polymerases [183] and inhibition of HIV-1 integrase [184] reported. The first reports of 
biological activity of phenylphenalenones (3.26, 3.29-3.35), isolated from Musa acuminate or 
derivatives of phenylphenalenones isolated, included growth inhibition of the germination 
tubes of the fungus Fusarium oxysporum f. sp. cubense race 4, which is the fungus that 
causes Panama disease, with increased activity under light exposure [185-188]. Further anti-
fungal activity of phenylphenaleneones isolated from Musa species and synthetic structural 
derivatives was reported against Mycosphaerella fijiensis, with 1H-phenalen-1-one (3.28) 
displaying potent activity, while anigorufone (3.26) was the most active natural 
phenylphenalenone [189, 190]. The anti-parasitic activity of the phenylphenalenones (3.26, 
3.31-3.37) was evaluated against Leishmania donovani promastigotes and L. infantum 
amastigotes, with 3.26 and 3.31 being the most active against L. donovani promastigotes 
(IC50 12.0 g/mL and 10.3 g/mL respectively) while 3.26, 3.31, 3.36 and 3.37 possessed 
activity against L. infantum amastigotes (IC50 13.3 g/mL, 10.5 g/mL, 15.6 g/mL and 17.2 
g/mL respectively) [191]. The plant M. basjoo was found to contain phenylphenalenones 
that exhibit anti-oxidant (3.21) and -glucosidase inhibitory (3.38-3.39) activity [192]. Anti-
bacterial activity of compound 3.40 was reported against Bacillus cereus [193]. 
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In the current study crude extracts originating from two collections of the Australian plant H. 
simulans were selected for chemical investigation on the basis of the presence of minor 
phenylphenaleneone constituents detected from an initial study of this plant species together 
with the biological activity observed for the crude extracts of the plant [194]. 
 
3.2 Experimental 
3.2.1 General Experimental 
For detailed information on the general experimental procedures and spectroscopic 
techniques please see the Experimental chapter Section 7.1. Both on-flow and stop-flow 
HPLC-NMR analyses of the 100% hexane silica column fraction were performed using 70% 
CH3CN:D2O, while the HPLC-NMR analyses of the combined 20:80 hexane:DCM and 100% 
DCM silica column fractions were conducted using 50% CH3CN:D2O. Both HPLC-NMR 
analyses were carried out with detection at max 254 and 290 nm. Semi-preparative reversed 
phase HPLC was conducted using the methods described in Section 3.2.3.2. 
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3.2.2 Plant material 
The plant specimens were collected by Mr. Allan Tinker from the Western Flora Caravan 
Park, 22 km north of Eneabba (Irwin botanical province), Western Australia (plant license 
SW008335). The first collection (aerial parts and bulbs) was conducted on the 20th of 
January 2005 and initially identified as H. simplex. This taxonomic classification was 
subsequently revised to H. simulans. A second collection of the bulbs of this plant was 
conducted on the 20th of February 2007. Voucher specimens designated the codes 2005-01a 
(bulbs), 2005-01b (aerial parts) and 2007-01 (bulbs) respectively are deposited at the School 
of Applied Sciences (Discipline of Applied Chemistry), RMIT University.  
 
 
H. simulans (Voucher code: 2005-01)  
(only aerial parts shown) 
 
 Kingdom: Plantae 
 Phylum: Magnoliophyta 
 Class:  Liliopsida 
 Order: Commelinidae 
 Family: Haemodoraceae 
 Genus:  Haemodorum 
 Species: simulans 
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H. simulans (Voucher code: 2007-01)  
 
A 2 g portion of the initial collection of the H. simulans specimen (aerial parts and bulbs) was 
extracted separately with 3:1 MeOH:DCM (40 mL) and evaluated in several assays (anti-
tumour, anti-viral and anti-microbial) at a concentration of 50 mg/mL at the University of 
Canterbury, Christchurch, New Zealand. The crude extract of the aerial parts displayed 
moderate cytotoxicity towards P388 with an IC50 of 105 g/mL, while the bulbs displayed 
potent cytotoxicity with an IC50 of <4.9 g/mL. Both the aerial parts and the bulbs displayed 
cytotoxicity towards the BSC-1 cells, and thus it could not be concluded if Herpes simplex or 
Polio virus were inhibited (details in the Experimental chapter Section 7.1.4). Similar levels 
of anti-microbial activity were observed between the aerial parts and the bulbs of the plant. 
Moderate anti-fungal activity towards Trichophyton mentagrophytes was observed for both 
components, with the bulbs being more active of the two, with a zone of inhibition of 5 mm, 
while a zone of inhibition of 1 mm was observed for the aerial parts. It was also determined 
that both the aerial parts and bulbs displayed a zone of inhibition of 3 mm against Bacillus 
subtilis. For both extracts it was found that there was no activity towards Escherichia coli, 
Pseudomonas aeruginosa, Candida albicans or Cladosporium resinae. 
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3.2.3 Extraction and Isolation 
3.2.3.1 Preparation of the extract of H. simulans for on-flow and stop-flow 
HPLC-NMR analysis 
The first collection of the H. simulans bulbs 2005-01a (22 g) was extracted with 3:1 
MeOH:DCM (400 mL). This extract was decanted and concentrated under reduced pressure 
and then subjected to sequential partitioning (trituated) into DCM (97.7 mg) and MeOH (2.24 
g) soluble extracts respectively. These bulbs were then re-extracted with a 1:1 mixture of 
MeOH:DCM (400 mL) and then combined with the initial extract. The second collection of the 
H. simulans bulbs, 2007-01 (36 g) was extracted with 3:1 MeOH:DCM (400 mL). Analysis of 
the subsequent DCM and MeOH extracts generated from this second collection of the bulbs, 
indicated that both fractions displayed very similar analytical HPLC chromatograms and 1H 
NMR spectra to those obtained from the first collection of the bulbs. On this basis, the DCM 
and MeOH soluble extracts from the 2007-01 bulbs sample were combined with the DCM 
and MeOH soluble extracts of the 2005-01 bulbs sample. A portion of the DCM soluble 
extract (205 mg) was subjected to silica flash chromatography using a 20% stepwise elution 
as described in the Experimental chapter Section 7.1, resulting in fifteen fractions. The 
enriched 100% hexane fraction (51 mg) and the combined 20:80 hexane:DCM and 100% 
DCM fractions (36 mg) were selected for HPLC-NMR analysis as shown in Scheme 3.2. The 
100% hexane fraction was re-solubilised in 1 mL of 70% CH3CN:D2O and the combined 
fraction was re-solubilised in 1 mL of 50% CH3CN:D2O and each filtered through a 0.45 m 
PTFE membrane filter (HP045 Advantec, Japan). For the HPLC-NMR experiments of the 
enriched 100% hexane fraction obtained from flash silica chromatography, 50 L (4,120 g) 
was injected, while for the combined fraction as detailed above, 50 L (3,360 g) was 
injected. The HPLC-NMR analyses were carried out using the methods described in Section 
3.2.1. 
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Scheme 3.2. Isolation and purification scheme for the partial identification of secondary 
metabolites by HPLC-NMR analysis.  
 
3.2.3.2 Preparation of the extract for off-line isolation of secondary 
metabolites from the bulbs of H. simulans 
Following the HPLC-NMR analyses, the 100% hexane silica column fraction was subjected 
to semi-preparative reversed phase HPLC using an isocratic 80% CH3CN:H2O solvent 
system, leading to the isolation of 5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-
dione (3.44) (21.0 mg, 0.10%) and haemodordioxolane (3.45) (13.5 mg, 0.06%). Semi-
preparative reversed phase HPLC was then carried out on the combined fraction that was 
subjected to HPLC-NMR analysis, using an isocratic 70% CH3CN:H2O solvent system, 
leading to the isolation of haemoxiphidone (3.42) (7.8 mg, 0.03%) and haemodorone (3.41) 
(7.5 mg, 0.03%). Semi-preparative reversed phase HPLC was also conducted on the 80:20 
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DCM:EtOAc fraction using 70% CH3CN:H2O, resulting in the isolation of 5-methoxy-1H-
naphtho[2,1,8-mna]xanthen-1-one (3.2) (5.3 mg, 0.02%), while the combined 40:60 and 
20:80 DCM:EtOAc fractions was subjected to semi-preparative reversed phase HPLC using 
isocratic 60% CH3CN:H2O conditions to afford 5-hydroxy-2-methoxy-1H-naphtho[2,1,8-
mna]xanthen-1-one (3.4) (8.3 mg, 0.04%).  
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3.2.3.3 Preparation of the extract for off-line isolation of secondary 
metabolites from the aerial parts of H. simulans 
The aerial parts of the first collection of H. simulans, 2005-01b (26 g) were subjected to the 
same extraction procedure as the initial extraction of the bulbs described in Section 3.2.3.21. 
The DCM-soluble fraction was subjected to flash silica chromatography using the same 20% 
stepwise elution profile adopted for the fractionation of the bulbs extract, resulting in fifteen 
fractions. Subsequent semi-preparative reversed phase HPLC of the 80:20 DCM:EtOAc 
fraction using isocratic 70% CH3CN:H2O conditions yielded 5-methoxy-1H-naphtho[2,1,8-
mna]xanthen-1-one (3.2) (8.6 mg, 0.11%), which was also present in the DCM-soluble 
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fraction of the bulbs of the H. simulans. The MeOH soluble extract was subjected to C18 
Vacuum Liquid Chromatography (VLC) using a 25% stepwise elution from H2O to MeOH to 
EtOAc and finally to DCM resulting in ten fractions. The 100% MeOH and 80:20 MeOH:H2O 
fractions were subjected to semi-preparative reversed phase HPLC using 40% CH3CN:H2O 
to afford haemodoroxychrysenose (3.46) (23.5 mg, 0.31%). 
3.2.4 Acid hydrolysis 
Approximately 0.5 mg of haemodoroxychrysenose (3.46) was treated with 10 mL of 15% 
aqueous HCl. The reaction mixtures were heated to 90C and stirred for six hours. The 
solution was neutralised by drop-wise addition of 5% aqueous NaOH to which EtOAc was 
then added. The aqueous partition was evaporated under reduced pressure and the residue 
spotted on aluminium-backed silica gel TLC plates along with standard samples of -ᴅ-
glucopyranose, -ᴅ-galactose, -ᴅ-rhamnose, and -ᴅ-xylose. The TLC plate was developed 
with n-butanol:HOAc:H2O (3:1:1), air dried and then sprayed with 10% aqueous H2SO4, 
followed by heating in an oven at 110C. The hydrolysis products from 3.46 exhibited a 
characteristic spot (Rf = 0.63) that was identical with that observed for -ᴅ-glucopyranose. 
3.2.5 Crystallography 
Crystallographic diffraction data were collected with an Oxford SuperNova diffractometer 
using Cu radiation ( = 1.54184 Å) by Dr Jonathan White at the University of Melbourne. 
Data were reduced using the CrysalisPRO software. The temperature of the data collection 
was maintained at 130 K, using an Oxford Cryostream cooling device. The structure was 
solved by direct methods, and difference Fourier synthesis and was refined on F2 (SHELXL-
97) [195]. Thermal ellipsoid plot was generated using program ORTEP-3 [196] integrated 
within the WINGX program suite [197]. 
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3.3 Results and Discussion 
As a result of combining extracts of the bulbs of H. simulans as well as subsequent silica 
flash column chromatography fractions as described in Section 3.2.3.2 and from the 
subsequent 1H NMR and analytical HPLC analyses, selected enriched fractions were 
subjected to HPLC-NMR analysis. On-flow HPLC-NMR analysis of the 100% hexane silica 
column fraction was carried out as described in Section 2.2.1 and the results of this can be 
seen in Figure 3.4. On the basis of the on-flow HPLC-NMR analysis of this fraction, two 
principal compounds were observed, while subsequent stop-flow analysis of this fraction 
permitted longer acquisition times. The later eluting compound exhibited 1H NMR resonances 
and a UV profile consistent with the phenylphenalenone structure class with a maxima at 348 
nm (as shown in Figure 3.5), while methoxy resonances at  3.95 and  3.27, together with 
its extraction characteristics (from 100% hexane fraction of silica column), suggested that 
this compound could possibly be 5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-
dione (3.44), previously isolated from H. simulans [194].  
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Figure 3.4. [A] 2D HPLC-NMR contour plot showing compounds (3.44 and 3.45) (on-flow HPLC-NMR) and [B] Extracted WET-1D 1H NMR 
spectra of compounds (3.44 and 3.45) (stop-flow HPLC-NMR).
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The earlier eluting compound displayed the same UV maxima (348 nm) to that of the later 
eluting compound (see Figure 3.5), suggestive of this compound being a 
phenylphenalenone, together with an unusual singlet at  6.03, which integrated as two 
protons, suggesting the possible presence of a highly deshielded methylene. A literature 
structure search of the phenylphenalenone structure class returned no matches for such a 
structural feature [22], suggesting the possibility of a new compound. To determine the 
identity of this possible new compound, off-line isolation and characterisation would be 
required. 
 
 
Figure 3.5. UV profiles of 3.44 and 3.45 extracted from HPLC-NMR analysis. 
 
As with the 100% hexane fraction, the combined fraction was also subjected to HPLC-NMR 
analysis. On-flow analysis and the characteristic UV profile (349 nm for both compounds 
present) indicated that two phenylphenalenones were present as shown in Figure 3.6. 
Following stop-flow HPLC-NMR analysis, which allowed for improved S/N to be achieved for 
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the two compounds present, the presence of a methoxy resonance at  3.16 together with its 
extraction characteristics (from combined 20:80 hexane:DCM and 100% DCM fractions), 
suggested that this compound could possibly be haemodorone (3.41), previously isolated 
from H. simulans [194], however off-line isolation and characterisation was required to 
unequivocally identify this compound and the second compound present. 
Off-line isolation of secondary metabolites from the 100% hexane silica fraction was carried 
out as described in Section 3.2.3.2, resulting in the isolation of the known compound 5,6-
dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione (3.44) and the new compound 
haemodordioxolane (3.45). The combined fraction that was analysed by HPLC-NMR was 
subjected to semi-preparative reversed phase HPLC to give the known compound 
haemodorone (3.41) and the new compound haemoxiphidone (3.42). The 80:20 and 60:40 
DCM:EtOAc silica column fractions were combined and semi-preparative reversed phase 
HPLC using the method described in Section 3.2.3.2 yielded the known 5-methoxy-1H-
naphtho[2,1,8-mna]xanthen-1-one (3.2) along with haemodorone (3.41). Analysis of the 1H 
NMR and analytical HPLC of the 40:60 and 20:80 DCM:EtOAc silica column fractions led to 
these fractions to be combined and subjected to semi-preparative reversed phase HPLC 
using the method described in Section 3.2.3.2, resulting in the isolation of the known 
compound, 5-hydroxy-2-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (3.4).  
Flash silica chromatography was carried out on the DCM extract of the aerial parts of H. 
simulans as described in Section 3.2.3.3 to yield fifteen fractions. On the basis of the 
subsequent analytical HPLC and 1H NMR data, the 80:20 DCM:EtOAc fraction was 
subjected to semi-preparative reversed phase HPLC to afford the known compound 5-
methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (3.2), which was also present in the bulbs of 
the plant. C18 Vacuum Liquid Chromatography (VLC) was carried out on the MeOH extract of 
the aerial parts of H. simulans as described in Section 3.2.3.3. 
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Figure 3.6. [A] 2D HPLC-NMR contour plot (on-flow HPLC-NMR) and [B] Extracted WET-1D 1H NMR spectra of compounds (3.41 and 3.42) 
(stop-flow HPLC-NMR).
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On the basis of 1H NMR and analytical HPLC data of the fractions obtained from the VLC C18 
column chromatography, the 100% MeOH and 80:20 MeOH:H2O fractions were combined 
and subjected to semi-preparative reversed phase HPLC, resulting in the isolation of the new 
compound haemodoroxychrysenose (3.46). 
The structure of the new compound haemoxiphidone (3.42), isolated from the combined 
20:80 hexane:DCM and 100% DCM silica column fractions, was determined using 1D and 
2D NMR spectroscopy (Table 3.1) and mass spectrometry, with the 1H NMR spectrum 
provided in Figure 3.7. The ESI-MS spectrum of haemoxiphidone (3.42) displayed an m/z at 
331 [M-H]-, consistent with a molecular formula of C21H16O4. In the concurrent study, the HR-
ESI-MS analysis was consistent with this mass and molecular formula [198]. 
The same compound (3.42) (based on NMR and HPLC data) was isolated from this plant in 
an earlier study [194], as well as in an independent and concurrent study of a separate 
Haemodorum species (unpublished results). In the initial study conducted on H. simulans this 
compound was assigned the structure 3.43 (xiphidone) although there were anomalies in the 
NMR data compared to that reported by Cremona and Edwards [199]. In addition to this 
anomaly, in two references reporting the structure of xiphidone (3.43), it was unclear as to 
whether this compound was indeed a 7- or a 9- phenylphenalenone [199, 200]. Subsequent 
references to xiphidone showed inconsistencies in the assignment, with references to this 
compound being a 7- phenylphenalenone by Opitz et al. [164] and also assignment as a 9- 
phenylphenalenone by Dora et al. [201]. In the literature for the compound known as 
xiphidone (3.43), the methoxy moieties are located in the 2- and 5- positions and the 1H NMR 
data had been acquired in two different solvents, namely d6-DMSO and d6-acetone (see 
Table 3.2). Based on this, the 1H NMR spectrum of the isolated compound that was originally 
thought to be identical to that of the compound deemed to be xiphidone (3.43) from the initial 
investigation study on this plant [194] was re-acquired in d6-acetone to provide a direct 
comparison to the literature data (Table 3.2). Once again, based on a direct comparison to 
the literature 1H NMR data for xiphidone (3.43) it was concluded that these two compounds 
were different. This meant that a complete structure re-evaluation would be necessary.  
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Table 3.1. 1H (500 MHz) and 13C (125 MHz) NMR data for haemoxiphidone (3.42) in d6-
DMSO. 
Position H, J C
a gCOSY gHMBC 
1 - 178.9, s - - 
2 - 152.3, s - - 
3 7.10, s 111.7, d - C-1, C-2, C-9b 
3a - 124.8, s - - 
4 7.55, s 112.9, d - C-3, C-5, C-6, C-9b 
5 - 146.6, s - - 
6 - 141.2, s - - 
6a - 125.4, s - - 
7 8.37, d, J = 9 Hz 127.2, d H-8 C-6, C-6a, C-9, C-9b 
8 7.49, d, J = 9 Hz 131.2, d H-7 C-6a, C-9a, C-1’ 
9 - 144.1, s - - 
9a - 127.6, s - - 
9b - 119.8, s - - 
1’ - 142.9, s - - 
2’ 7.27, dd, J = 1.5, 8.5 Hz 128.1, d H-3’ C-9, C-3’, C-4’ 
3’ 7.38, dd, J = 6.5, 7.5 Hz 128.0, d H-2’ C-1’, C-2’ 
4’ 7.34, dd, J = 7.0, 7.5 Hz 126.6, d - C-2’, C-3’, C-5’, C-6’ 
5’ 7.27, dd, J = 6.5, 7.5 Hz 128.0, d H-6’ C-1’, 6’ 
6’ 7.27, dd, J = 1.5, 8.5 Hz 128.1, d H-5’ C-9, C-4’, C-5’ 
2-OCH3 3.76, s 55.3, q - C-2 
6-OCH3 3.95, s 61.2, q - C-6’ 
5-OH 10.05, bs - - C-4, C-5, C-6 
a
Carbon assignments based on gHSQCAD and gHMBC NMR experiments 
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Figure 3.7. 1H NMR (500 MHz, d6-DMSO) spectrum of haemoxiphidone (3.42). 
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Table 3.2. 1H NMR (500 MHz) comparison of haemoxiphidone (3.42) and the literature data 
for xiphidone (3.43) in d6-acetone. 
 3.42 in d6-DMSO 3.42 in d6-acetone 
3.43 in d6-acetone 
[201] 
Position H, J H, J H, J 
1 - - - 
2 - - - 
3 7.10, s 7.04, s 7.37, s 
3a - - - 
4 7.55, s 7.57, s 6.89, s 
5 - - - 
6 - - - 
6a - - - 
7 8.37, d, J = 9 Hz 8.42, d, J = 8.0 Hz 8.70, d, J = 7.7 Hz 
8 7.49, d, J = 9 Hz 7.53, d, J = 8.0 Hz 7.55, d, J = 7.7 Hz 
9 - - - 
9a - - - 
9b - - - 
1’ - - - 
2’ 7.27, dd, J = 1.5, 8.5 Hz 7.33, m 7.41* 
3’ 7.38, dd, J = 6.5, 7.5 Hz 7.40, dd, J = 6.5, 8.0 Hz 7.41* 
4’ 7.34, dd, J = 7.0, 7.5 Hz 7.35, m 7.41* 
5’ 7.27, dd, J = 6.5, 7.5 Hz 7.40, dd, J = 6.5, 8.0 Hz 7.41* 
6’ 7.27, dd, J = 1.5, 8.5 Hz 7.33, m 7.41* 
2-OCH3 3.76, s 3.81, s 3.96, s 
6-OCH3 3.95, s 4.04, s - 
5-OH 10.05, bs - - 
5-OCH3   4.02, s 
* signals overlapped 
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The 2D gHMBC NMR analysis conducted in d6-DMSO enabled the unequivocal assignment 
of the new compound haemoxiphidone (3.42). Key HMBC correlations (Figure 3.8) were 
observed from  8.37 (H-7),  7.55 (H-4) and  3.95 (6-OCH3) to 141.2 ppm (C-6), thereby 
placing an aromatic proton at position 7 and a methoxy group at position 6. Further 
correlations from  8.37 (H-7) and  7.49 (H-8) to144.1 ppm, supported the presence of the 
phenyl moiety being located at position 9. In addition, HMBC correlations from the 
exchangeable hydroxyl proton at  10.05 (5-OH) to 122.9 ppm (C-4) and 141.2 ppm (C-6) 
allowed for the positioning of the hydroxyl group at position 5. In an independent and 
concurrent study of a separate Haemodorum species, haemoxiphidone was also isolated 
(unpublished results) and in that study the data was acquired in CDCl3 and a series of single 
irradiation NOE studies conducted. Both studies were able to unequivocally confirm the 
structure of haemoxiphidone (3.42).  
The structure of haemodordioxolane (3.45) was determined on the basis of 1D and 2D NMR 
spectroscopy (Table 3.3), mass spectrometry and UV/Vis spectroscopic analysis. The HR-
ESI-MS of haemodordioxolane (3.45) (see Figure 3.9) displayed an m/z at 319.0603 [M+H]+ 
(calcd. for C19H11O5: m/z 319.0528) consistent with fifteen degrees of unsaturation and a 
molecular formula C19H10O5. The 
1H (Figure 3.10) and gCOSY NMR spectra identified the 
presence of a set of overlapped aromatic protons [ 7.50, m (H-3’/H-5‘) and  7.48, m (H-
2’/H-4’/H-6‘)], one singlet aromatic proton [ 8.25, s (H-4)] and two ortho aromatic protons [ 
7.65, d, J = 7.5 Hz (H-8) and 8.44, d, J = 7.5 Hz (H-9)], along with a singlet proton, which 
integrated for two protons [6.20, s (H-10)], which were all consistent with that of the 
phenylphenalenone structure class. The characteristic UV maximum of 368 nm supported 
the phenylphenalenone structure class [194]. In combination with the 13C NMR data, the 2D 
gHSQCAD (see Figure 3.11) and gHMBC NMR experiments allowed for the complete 
assignment of haemodordioxolane (3.45). 
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Figure 3.8. 2D gHMBC NMR spectrum showing key correlations of haemoxiphidone (3.42). 
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Figure 3.9. HR-ESI-MS (positive mode) spectrum of haemodordioxolane (3.45).  
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Figure 3.10. 1H NMR (500 MHz, CDCl3) spectrum of haemodordioxolane (3.45). 
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It was established through the gHSQCAD NMR experiment that the singlet proton signal at  
6.20 (H-10) was due to the deshielded methylene protons attached directly to a carbon at 
103.2 ppm (C-10), suggestive of a dioxolane moiety. This was confirmed by the HMBC 
correlations observed from the methylene proton signal at  6.20 (H-10) to the aromatic 
carbons at 145.9 ppm and 149.1 ppm (C-5 and C-6). The lack of protons that could be 
accounted for in the B ring of the phenylphenalenone (Figure 3.1) suggested this was due to 
the presence of an anhydride [194]. The protons at  8.25 (H-4) and 8.44 (H-9) displayed 
HMBC correlations to 160.0 ppm (C-3) and 160.8 ppm (C-1) respectively. The coupling of the 
ortho aromatic protons at 7.65 (H-8) and 8.44 (H-9), along with the HMBC correlation of  
8.44 (H-9) to 160.8 ppm (C-1), allowed for the positioning of the phenyl ring at position 7, 
which was also confirmed by the correlations observed from  7.65 (H-8) to 138.9 (C-1’) and 
from  8.44 (H-9) and  7.50 (H-2’/H-6‘) to 143.7 ppm (C-7). This allowed for the unequivocal 
assignment of haemodordioxolane (3.45) as the structure of this compound, which was 
isolated as very fine needle crystals. These crystals were analysed by single crystal X-ray 
analysis at the Australian synchrotron, however the crystals did not diffract and no crystal 
structure could be obtained. 
The compound isolated from the MeOH extract of the stems and leaves, 
haemodoroxychrysenose (3.46) was determined using 1D and 2D NMR spectroscopy (Table 
3.4), along with mass spectrometry and UV-Vis spectroscopy. The HR-ESI-MS of 3.46 
displayed a peak at m/z 479.1337 [M+H]+ (calcd. for C26H23O9: m/z 479.1342) consistent with 
a molecular formula C26H22O9, with 16 degrees of unsaturation. The UV-Vis spectrum 
displayed a maximum at  537 nm, consistent with an oxabenzochrysenone structure class 
[162, 164, 165, 200, 202]. 
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Table 3.3. 1H (500 MHz) and 13C (125 MHz) NMR data for haemodordioxolane (3.45). 
 d6-DMSO CDCl3 
Position H, J C
a 
gCOSY gHMBC H, J C
a 
gCOSY gHMBC 
1 - 160.8, s - - - 160.9, s - - 
2 - - - - - - - - 
3 - 160.0, s - - - 160.1, s - - 
3a - 112.3, s - - - 112.4, s - - 
4 8.25, s 115.0, d - C-3, C-5, C-6, C-9b 8.26 s 116.1, d - C-3, C-5, C-6, C-9b 
5 - 145.9^, s - - - 146.2^, s - - 
6 - 149.1^, s - - - 149.5^, s - - 
6a - 118.3, s - - - 118.8, s - - 
7 - 143.7, s - - - 144.1, s - - 
8 7.65, d, J = 7.5 129.5, d H-9 C-6a, C-9a, C-1’ 7.57 d, J = 7 Hz  129.3, d H-9 C-6a, C-9a, C-1’ 
9 8.44, d, J = 7.5 131.4, d H-8 C-1, C-7, C-9b 8.54 d, J = 7 Hz 132.3, d H-8 C-1, C-7, C-9b 
9a - 115.4, s - - - 116.4, s - - 
9b - 128.3, s - - - 129.5, s - - 
10 6.20, s 103.2, t - C-5, C-6 6.09, s  102.9, t - C-5, C-6 
1’ - 138.8, s - - - 139.1, s - - 
2’ 7.49, m * 127.7, d - C-7, C-4’, C-6’ 7.48 m* 127.8, d
#
 - C-7, C-4’, C-6’ 
3’ 7.52, m ** 129.2, d - C-1’, C-5’ 7.43 m** 128.5, d
##
 - C-1’, C-5’ 
4’ 7.49, m * 127.7, d - C-2’, C-6’ 7.47 m*** 127.8, d
#
 - C-2’, C-6’ 
5’ 7.52, m ** 129.2, d - C-1’, C-3’ 7.43 m** 128.5, d
##
 - C-1’, C-3’ 
6’ 7.49, m * 127.7, d - C-7, C-2’ C-4’ 7.48 m* 127.8, d
#
 - C-7, C-2’ C-4’ 
a
Carbon assignments based on gHSQCAD and gHMBC NMR experiments 
*, **, 
#
 and 
##
 signals overlapped 
^ signals interchangeable 
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Figure 3.11. 2D gHSQCAD NMR spectrum of haemodordioxolane (3.45). 
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Table 3.4. 1H (500 MHz) and 13C (125 MHz) NMR data for haemodoroxychrysenose (3.46) in 
d6-DMSO 
Position H, J  C
a 
gCOSY gHMBC NOESY ROESY 
1 - 182.3, s - - - - 
2 6.72, d, J = 9.5 Hz 126.2, d H-3 C-3a, C-12a H-3 H-3 
3 8.06, d, J = 9.5 Hz 140.9, d H-2 C-1, C-4, C-12b H-2 H-2 
3a - 119.4*, 
s 
- - - - 
4 8.10, s 119.2, d - C-3, C-3a, C-5, C-5a, C-
12b 
5-OCH3 5-OCH3 
5 - 142.2, s - - - - 
5a - 140.8, s - - - - 
6 - - - - - - 
6a - 151.2, s - - - - 
7 7.49, dd, J = 1.5, 8.5 
Hz 
117.0, d H-8 C-6a, C-9, C-10a H-8 H-8 
8 7.59, ddd, J = 1.5, 
8.0, 8.5 Hz 
131.5, d H-7, H-9 C-6a, C-10 H-7, H-9 H-7, H-9 
9 7.37, ddd, J = 1.5, 
8.0, 8.5 Hz 
124.6, d H-8, H-10 C-7, C-10, C-10a H-8, H-10 H-8,  
H-10 
10 9.24, dd, J = 1.5, 8.5 
Hz 
130.0, d H-9 C-6a, C-8, C-10b H-9 H-9 
10a - 118.3, s - - - - 
10b - 119.4*, 
s 
- - - - 
11 - 150.6, s - - - - 
12 8.48, s 119.4*, 
d 
- C-1, C-10a, C-10b, C-11, 
C-12a, C-12b 
- - 
12a - 127.9, s - - - - 
12b - 117.5, s - - - - 
12c - 121.1, s - - - - 
1’ 5.39, d, J = 8.0 Hz 101.3, d 2’ C-11 H-12 H-12,  
H-3’ 
2’ 3.58, m 73.4, d H-1’, H-3’,  
2’-OH 
C-1’ H-3’ 2’-OH 
3’ 3.46, m 77.3, d H-2’, H-4’,  
3’-OH 
- H-2’ - 
4’ 3.32, m 69.2, d H-3’, H-5’,  
4’-OH 
- - - 
5’ 3.42, m 76.6, d H-4’ C-3’ H-6a’ - 
6a’ 3.58, m 60.4, t H-6b’, 6’-OH C-5’ H-5’, H-
6b’ 
- 
6b’ 3.70, m  H-6a’, 6’-OH - H-6a’ - 
5-OCH3 4.08, s 56.7, q - C-5 H-4 H-4 
2’-OH 5.61, d, J = 5.5 Hz - H-2’ C-1’ - - 
3’-OH 5.26, d, J = 4.5 Hz - H-3’ - - - 
4’OH 5.10, d, J = 5.5 Hz - H-4’ - - - 
6’OH 4.56, t, J = 5.5 Hz - H-6a’, H-6b’ - - - 
a
Carbon assignments based on 
13
C, DEPT, gHSQCAD and gHMBC NMR experiments 
* 
13
C at 119.4 ppm overlapped
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The 1H (Figure 3.12) and gCOSY NMR spectra identified the presence of two singlet 
aromatic protons [ 8.10, s (H-4)] and [ 8.48, s (H-12)], a pair of ortho aromatic protons [ 
6.72, d, J = 9.5 Hz (H-2) and  8.06, d, J = 9.5 Hz (H-3)], along with four aromatic protons [ 
7.37, ddd, J = 1.5, 8.0, 8.5 Hz (H-9),  7.49, dd, J = 1.5, 8.5 Hz (H-7), 7.59, ddd, J = 1.5, 8.0, 
8.5 Hz (H-8) and  9.24, dd, J = 1.5, 8.5 Hz (H-10)], a methoxy group [ 4.08, s (5-OCH3)] 
and resonances consistent with a sugar moiety including four methines at [ 5.39, d, J = 8 Hz 
(H-1’) and those occurring between  3.32 and  3.57, (H-2‘’, H-3‘’, H-4‘’, H-5‘’) and one 
methylene [ 3.58, m, (H-6a’) and  3.70, m, (H-6b’)]. Also observed were the exchangeable 
hydroxy moieties of the sugar unit at [ 4.56, t, J = 5.5 Hz (6’-OH),  5.61, d, J = 5.5 Hz (2’-
OH),  5.26, d, J = 4.5 Hz (3’-OH),  5.10, d, J = 5.5 Hz (4’-OH). 
The 2D gHSQCAD and gHMBC NMR experiments allowed for the complete assignment of 
haemodoroxychrysenose (3.46). The HSQCAD (see Figure 3.13) and HMBC correlations 
observed from  8.48 (H-12) allowed for the positioning of the carbonyl moiety at position C-1 
(182.3 ppm) as shown in Figure 3.14. Additional correlations from  8.48 (H-12) to 
quaternary carbons at 119.4 ppm (C-10b) and 150.6 ppm (C-11) (Figure 3.14) showed that 
further substitution of the C ring was present. The ortho-coupled aromatic proton at  8.06 
(H-3) displayed a correlation to 182.3 ppm (C-1) as shown in Figure 3.14, placing both ortho-
coupled aromatic protons  8.06 and  6.72 (H-3 and H-2 respectively) in ring B (Figure 3.1). 
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Figure 3.12. 1H NMR (500 MHz, CDCl3) spectrum of haemodoroxychrysenose (3.46). 
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Figure 3.13. 2D gHSQCAD NMR spectrum of haemodoroxychrysenose (3.46). 
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Correlations from the singlet methine at  8.10 (H-4) to 140.9 ppm (C-3), 140.8 ppm (C-5a) 
and 142.2 ppm (C-5), along with the correlation of the methoxy at  4.08 (5-OCH3) to 142.2 
ppm (C-5), allowed for the positioning around the A ring shown in Figure 3.1. The remaining 
coupled aromatic protons [ 7.49 (H-7),  7.59 (H-8),  7.37 (H-9) and  9.24 (H-10)] were 
found to be due to the D ring of the oxabenzochrysenone-type structure (Figure 3.1). The 
HMBC correlation from  5.39 (H-1’) to 150.6 ppm (C-11) (Figure 3.14) linked the sugar 
moiety to the ring C carbon at position 11 (see Figure 3.1). The positioning of the methoxy 
and sugar moieties was further supported by NOESY and ROESY NMR enhancements 
between  5.39 (H-1’) and  8.48 (H-12), along with correlations between  8.10 (H-4) and  
4.08 (5-OCH3) (see Table 3.4). The TOCSY NMR correlation observed between  8.06 (H-3) 
and  8.10 (H-4) also supported the fact that the sugar moiety was not positioned at the 
alternative 2 position of the oxabenzochrysenone structure, see Figure 3.1. 
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Figure 3.14. [A] Key HMBC correlations and [B] key NOESY and ROESY enhancements 
observed for haemochrysenone (3.46). 
 
The 1D and 2D NMR data, along with ESI-MS data for 5-methoxy-1H-naphtho[2,1,8-
mna]xanthen-1-one (3.2) [162], 5-hydroxy-2-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one 
(3.4) [164], haemodorone (3.41) and 5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-
1,3-dione (3.44) [194], were consistent with literature data. 
5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione (3.44) was isolated from the 
100% hexane fraction from the silica column chromatography, which was the fraction that 
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also contained 3.45 and upon drying, fine fluorescent crystals were obtained. This allowed 
for the first single crystal X-ray diffraction study of 3.44 to be carried out. Compound 3.44 
crystallises as a hemihydrate, with the water oxygen situated on a 2-fold axis of symmetry, 
forming a hydrogen bond with carbonyl oxygen O1: O(6)-H(6') 0.823(5)(9) Å, O1…H6, 
2.174(14) Å, O1…O6 2.982(4) Å and O1…H6…O6 167(6)°. A thermal ellipsoid plot of 3.44 
depicting 20% elliposoids as determined by X-ray crystallographic analysis is given in Figure 
3.15. Full details are provided in Section 3.2.5. 
 
 
Figure 3.15. Single crystal X-ray structure (ORTEP) of 3.44. 
 
3.4 Conclusion 
This study describes the on-line HPLC-NMR profiling of an enriched fraction that led to the 
isolation of the new phenylphenalenones, haemodordioxolane (3.45) and haemoxiphidone 
(3.42), from the bulbs of H. simulans together with the isolation of the new 
oxabenzochrysenone glycoside, haemodoroxychrysenose (3.46) from the aerial parts. 
Several previously reported compounds (3.2, 3.4, 3.41 and 3.44) were also isolated and 
identified. In addition this study has resulted in the first reported single crystal X-ray analysis 
for compound (3.44). The biological activity of all compounds was evaluated in the P388 anti-
tumour assay and concluded that all compounds were inactive in this assay. 
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Chapter 4  
On-line and off-line chemical profiling of the 
Australian plant, Drosera erythrorhiza 
subspecies magna 
4.1 Introduction 
Plants belonging to the family Droseraceae, which consist of three genera (Drosera, Dionaea 
and Aldrovanda), have been used for centuries as traditional medicines [203]. Applications 
include the use of extracts in the treatment of asthma, bronchitis, whooping cough, for 
paroxysmal and hacking coughs, in addition to being used in anticancer treatment [204-209]. 
Drosera is one of the largest genera of carnivorous plants and is commonly known as “the 
sundews”. Members of Drosera spp. secrete a sticky substance from their leaves that traps 
prey [210, 211]. There are greater than one hundred species of Drosera found worldwide, 
with the largest species distribution occurring within Australia. Plants of the Drosera genus 
have been used throughout Europe for the treatment of respiratory problems, whilst the 
Australian Aboriginal people have utilised the bulbs in their dyes [212, 213]. Extracts have 
been shown to possess anti-fertility, anti-inflammatory, spasmolytic and anti-microbial 
activities [214-217]. Plants of the family Droseraceae are known to produce two principal 
classes of secondary metabolites, namely flavonoids such as compounds (1.12, 1.13 and 
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1.16) and naphthoquinones such as compounds (1.186, 1.195, 1.228, 1.267, 1.272 and 4.1-
4.10) [75, 206, 218-221]. 
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In continuing the application of hyphenated spectroscopic approaches to rapidly assess the 
chemistry of Australian plants, crude extracts (from the bulbs and aerial parts) of the 
Australian carnivorous plant D. erythrohiza subspecies magna were assessed for anti-
tumour, anti-viral and anti-microbial activities. This plant was selected for an on-line HPLC-
NMR chemical profiling study on the basis of previous chemistry reported from the family 
Droseraceae as well as the broad range of activity displayed by the crude extracts. 
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4.2 Experimental 
4.2.1 General Experimental 
For all general experimental procedures and spectroscopic methods, see the Experimental 
Chapter Section 7.1. Semi-preparative reversed phase HPLC purification of plumbagin 
(1.267) was conducted using isocratic conditions consisting of 25% CH3CN/H2O, while for the 
remaining compounds, a gradient method of (0 mins 30% CH3CN/H2O; 20 mins 50% 
CH3CN/H2O) was used (monitored at max 254 and 300 nm). Both on-flow and stop-flow 
HPLC-NMR analyses were performed using gradient HPLC conditions (0 mins 30% 
CH3CN/D2O; 20 mins 50% CH3CN/D2O), with detection at max 254 and 300 nm. An authentic 
sample of plumbagin (1.267), derived from Plumbago indica (CAS number 481-42-5) was 
purchased from Sigma Aldrich. 
4.2.2 Plant material 
The plant was identified as D. erythrorhiza subspecies magna (Droseraceae) and collected 
by Mr Allan Tinker on 6th of July 2004, from the Western Flora Caravan Park, 22 km north of 
Eneabba (Irwin botanical district) in Western Australia (plant licence for scientific or other 
prescribed purposes SW008335). The plant material was physically separated into its aerial 
and bulbaceous components. Voucher specimens designated the codes 2004-44a 
(bulbaceous roots) and 2004-44b (aerial parts) are deposited at the School of Applied 
Sciences (Discipline of Applied Chemistry), RMIT University. Samples (2 g) of both the bulbs 
(voucher sample 2004-44a) and aerial (2004-44b) components of the plant were extracted 
with 3:1 MeOH:DCM and sequentially partitioned (trituated) into DCM and MeOH soluble 
crude extracts, which were then evaluated for biological activity as described in the 
Experimental chapter Section 7.1.4. Both extracts showed anti-tumour activity against the 
P388 (Murine leukaemia) cell line (IC50 of 4.9 g/mL for the bulb extract and 8.8 g/mL for 
the aerial component extract) as well as displaying significant anti-viral activity towards 
Herpes simplex type 1 and Polio virus type 1. In addition, both extracts exhibited potent 
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broad spectrum anti-fungal activity towards Candida albicans, Trichophyton mentagrophytes 
and Cladosporium resinae with inhibition zones (radius of inhibition outside the 6 mm 
diameter application disc) of 15, 15 and 10 mm respectively, while exhibiting significant and 
selective anti-bacterial activity towards Bacillus subtilis (10 mm zone of inhibition). Both of 
the crude extracts were inactive against Escherichia coli and Pseudomonas aeruginosa. All 
compounds isolated (1.267 and 4.7-4.10) were evaluated for P388 anti-tumour activity, while 
compounds 1.267 and 4.7-4.8 were assessed for anti-microbial activity and compounds 4.7-
4.8 were tested for anti-viral activity (Table 4.1). 
 
 
D. erythrorhiza subspecies magna (Voucher code: 2004-44) 
 
 Kingdom: Plantae 
 Phylum: Equisetophyta 
 Class:  Equisetopsida 
 Order: Caryophyllales 
 Family: Droseraceae 
 Genus:  Drosera 
 Species: erythrorhiza 
 Subspecies: magna 
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Table 4.1. Biological evaluation of D. erythrohiza subspecies magna compounds isolated. 
Compound 
Anti-tumour 
assay 
Anti-viral assays 
Anti-microbial assays 
(Zone of inhibition in mm) 
P388 
(g/mL) 
HSV HSV Cyt PV PV Cyt BS CA TM CR EC PA 
Plumbagin (1.267) 0.52 NT NT NT NT 12 20 10 3 NT NT 
Droserone (4.7) < 12.5 ND ND 
No virus 
inhibition 
50% cytotoxic 
zone observed 
ND ND ND ND ND ND 
Hydroxydroserone 
(4.8) 
4.25 U 
100% cytotoxic 
zone observed 
U 
100% cytotoxic 
zone observed 
5 ND 6 ND ND ND 
Drosersone-5-O--
glycoside (4.9) 
1.01 NT NT NT NT NT NT NT NT NT NT 
Hydroxydroserone-5-
O--glycoside (4.10) 
3.72 NT NT NT NT NT NT NT NT NT NT 
a
 All compounds tested at 1 mg/mL. 
b
 The inhibition zones are the radius of inhibition outside the 6 mm diameter application disc. 
U = unable to see if there was any virus present because of the cytotoxicity. 
NT = Not tested; ND = No activity detected; Cyt = cytotoxicity; P388 = Murine leukaemia cell line; HSV = DNA Herpes simplex virus type 1; PV = RNA Polio virus type 1;  
BS = Bacillus subtilis; CA = Candida albicans; TM = Trichophyton mentagrophytes; CR = Cladosporium resinae; EC = Escherichia coli; PA = Pseudomonas aeruginosa 
The P388 standard used was mitomycin C (sigma M0503) with an IC50 of 183 ng/mL. 
The anti-viral standard used was 30 L of 0.005 mg/mL didemnum B which displayed cytotoxicity against both viruses at this concentration. 
The standard reference compounds for the anti-microbial assays included 10 g gentamicin (Difco 6423890) which showed a 10 mm zone of inhibition against E. coli and  
P. aeruginosa, 30 g of chloramphenicol (Difco 61338910) which showed a 12 mm zone of inhibition against Bacillus subtilis, and 100 IU units of nystatin (Difco 6753890), 
which showed zones of inhibition of 12 mm, 6 mm and 10 mm against Candida albicans, Trichophyton mentagrophytes, and Cladosporium resinae respectively. 
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4.2.3 Extraction and Isolation 
4.2.3.1 Preparation of the extract of D. erythrorhiza subspecies magna for on-flow 
and stop-flow HPLC-NMR analysis 
A portion of the bulbs of the plant D. erythrohiza subspecies magna (12.67 g) was initially 
extracted using 3:1 MeOH:DCM (400 mL) and then sequentially partitioned (trituated) into 
EtOAc (748 mg) and H2O (204 mg) soluble extracts. The bulbs were then re-extracted using 
3:1 MeOH:DCM (400 mL), before being sequentially partitioned (trituated) into DCM (150 
mg) and MeOH (536 mg) soluble extracts. Analytical HPLC analysis indicated similarities in 
the compounds present in the initial EtOAc extract and the MeOH extract from the re-
extraction and so were combined. Part (96 mg) of this combined extract was dissolved in 
40% CH3CN/D2O and subjected to HPLC-NMR analysis using the method described in 
Section 2.2.1.  
4.2.3.2 Preparation of the extract for off-line isolation of secondary metabolites from 
D. erythrorhiza subspecies magna 
Off-line isolation of the compounds observed in HPLC-NMR analysis was carried out using 
the combined extracts used for HPLC-NMR analysis. A portion of this combined extract (300 
mg) was subjected to size exclusion chromatography using the method described in the 
Experimental chapter Section 7.1 to afford twenty-four fractions. Subsequent analytical 
HPLC and 1H NMR analysis of the fractions led to six fractions being combined and 
subjected to reversed phase semi-preparative HPLC. This was conducted using the gradient 
described in Section 2.2.1, which resulted in the isolation of the four structurally related 
naphthoquinones: droserone (4.7) (15.2 mg, 0.25%), hydroxydroserone (4.8) (13.8 mg, 
0.23%), droserone-5-O-β-glycoside (4.9) (8.6 mg, 0.14%) and hydroxydroserone-5-O-β-
glycoside (4.10) (5.8 mg, 0.10%). The aerial parts of the D. erythrohiza subspecies magna 
plant were extracted using 3:1 MeOH:DCM (300 mL), and then sequentially partitioned 
(trituated) into DCM, MeOH and H2O fractions. Analytical reversed phase HPLC of the MeOH 
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extract of the aerial parts of the plant indicated that a further naphthoquinone was present. 
The MeOH extract was fractionated by size exclusion chromatography as described in the 
Experimental chapter Section 7.1 resulting in five fractions. Two of these fractions were 
combined before being subjected to reversed phase semi-preparative HPLC as described in 
Section 2.2.1, which afforded plumbagin (1.267) (5.4 mg, 0.31%). 
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4.3 Results and Discussion 
The analytical HPLC chromatograms of the crude EtOAc extract and the re-extracted MeOH 
extract were similar and were therefore combined. These extracts both showed the presence 
of two early-eluting compounds, as well as two later-eluting compounds. HPLC-NMR 
analysis was undertaken and on the basis of the on-flow HPLC-NMR analysis three peaks 
were apparent in the HPLC chromatogram (Figure 4.1), whilst in the 2D NMR contour plot 
one major compound was present as well as one further compound (see Figure 4.2). The 
early-eluting peak was not observed in the on-flow HPLC-NMR analysis due to its low 
abundance in the extract. In HPLC-NMR there most often is a requirement to overload the 
analytical HPLC in order to achieve sufficient S/N for the NMR analysis and this frequently 
results in poor resolution/separation in the chromatography, as shown in Figure 4.1.  
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Figure 4.1. HPLC chromatogram obtained from the on-flow HPLC-NMR analysis of the 
crude extract of D. erythrorhiza subspecies magna. 
 
As shown in Figure 4.2, the changing solvent composition associated with the gradient 
method used in the HPLC-NMR analysis results in a chemical shift drift. This is evident for 
the major component which was observed to change in chemical shift by ~0.1 ppm over the 
thirty seconds that it took to elute. This chemical shift drift is expected to occur when 
employing a gradient HPLC method for HPLC-NMR analysis [222]. It was necessary to 
conduct stop-flow HPLC-NMR to permit longer acquisition times for the other two minor 
components observed in the HPLC chromatogram.  
Analysis of the WET-1D 1H NMR spectra (Figure 4.3) from stop-flow HPLC-NMR of the 
early-eluting peak showed the presence of a sugar moiety ( 3.20- 3.80, m) together with 
aromatic resonances ( 6.80- 7.70) as shown in Figure 4.3. A comparison with the initial 
analytical HPLC analysis led to the suspicion that the first, early-eluting peak in the HPLC-
NMR was, in fact, two co-eluting compounds. The 1H NMR spectra of the two later-eluting 
compounds (peak 2 and peak 3 in Figure 4.1) showed some similarities to that of the early 
co-eluting compounds but did not exhibit any resonances associated with a sugar moiety. 
The 1H NMR of the first of the later-eluting compounds (4.7) showed the presence of a set of 
three aromatic protons [ 7.48, t, J = 7 Hz (H-7);  7.34, d, J = 7.5 Hz (H-8) and  6.97, m, J = 
8.5 Hz (H-6)] together with a methyl singlet [ 1.79, (H-9)]. 
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Figure 4.2. On-flow 2D HPLC-NMR contour plot showing the presence of the major compound (4.7) and one of the minor compounds (4.8). 
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Figure 4.3. WET-1D 1H NMR spectra of the peaks observed in the stop-flow HPLC-NMR 
analysis. 
 
The second of the later-eluting compounds (4.8) displayed resonances similar to that of 4.7 
but exhibited only two aromatic protons [ 7.17, d, J = 9 Hz and 7.09, d, J = 9 Hz], along 
with a methyl singlet [ 1.79, s]. These chemical shifts, together with the UV maxima at 
approximately 270 nm (Figure 4.4), were consistent with the naphthoquinone structure class. 
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Given the known chemistry produced by Drosera spp. it was suspected that these two 
compounds were the naphthoquinones, droserone (4.7) and hydroxydroserone (4.8).  
 
 
Figure 4.4. Extracted UV profile of the major component observed in the HPLC-NMR 
analyses. 
 
Off-line isolation was necessary in order to identify which compounds were responsible for 
the biological activity observed in the crude extract. This would also permit an unequivocal 
identification of the four secondary metabolites indicated by the initial analytical HPLC 
analysis. Off-line isolation of compounds from both the bulbs and aerial parts were 
undertaken separately as described in Section 4.2.3.2. The structures of the 
naphthoquinones and the corresponding glycosides (1.267 and 4.7-4.10) were determined 
on the basis of 1D and 2D NMR analysis, along with mass spectrometry.  
The negative mode ESI-MS of the compound isolated from the aerial parts of the plant 
(1.267), displayed an m/z at 187 [M-H]-, consistent with a molecular formula of C11H8O3 and 
eight degrees of unsaturation. Comparison of the 1H and 13C NMR spectra with those of 
naphthoquinones known to occur in Droseraceae, indicated that the secondary metabolite 
was plumbagin (1.267) [223, 224]. An authentic sample of plumbagin was purchased from 
Sigma Aldrich and used to confirm that the compound isolated from the aerial parts of the 
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plant was plumbagin. NMR and mass spectrometric data was identical to that of the authentic 
sample as shown in Table 4.2.  
The negative mode ESI-MS of the second peak detected in the HPLC-NMR analysis (4.7), 
displayed an m/z of 203 [M-H]-, consistent with a molecular formula of C11H8O4 and eight 
degrees of unsaturation. On the basis of the 1D and 2D NMR analyses along with a 
comparison of NMR data to the literature, it was concluded that this secondary metabolite 
was in fact droserone (4.7) [207, 225-227]. While 1H NMR (Figure 4.5) assignments were 
found to be consistent with those in the literature, it was evident that the 13C NMR chemical 
shift literature reassignments for the carbons at positions C-6 and C-8 was necessary (see 
Figure 4.6). 
 
Table 4.2. 1H (500 MHz) and 13C NMR (125 MHz) chemical shift comparison of isolated and 
authentic plumbagin (1.267) in d6-DMSO.  
 Isolated plumbagin Authentic plumbagin 
Position H, J C
 H, J C
 
1 - 184.4, s - 184.4*, s 
2 - 149.4, s - ND 
3 6.98 dd, J = 3.0, 1.5 Hz 135.2, d 6.98 bs 135.2, d 
4 - 190.1, s - 190.1*, s 
4a - 114.9, s - ND 
5 - 160.1, s - 160.1, s 
6 7.32 dd, J = 8.5, 1.0 Hz 123.8, d 7.32 d, J = 7.0 Hz 123.8, d 
7 7.72 dd, J = 8.5, 7.5 Hz 137.0, d 7.73 dd, J = 8.0, 8.0 Hz 136.5, d 
8 7.53 dd, J = 7.5, 1.0 Hz 118.7, d 7.53 d, J = 7.5 Hz 118.7, d 
8a - 132.0, s - 131.9, s 
9 2.09 d, J = 1.5 Hz 16.0, q 2.10 bs 15.9, q 
5-OH 11.86 s - 11.85, s - 
bs indicates a broad singlet 
ND indicates signals were not detected 
* indicates these signals were just visible from the baseline noise 
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Figure 4.5. 1H NMR (500 MHz, d6-DMSO) spectrum of droserone (4.7).  
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In the literature [227], C-6 is assigned as 118.1 ppm while C-8 is assigned as 122.7 ppm. On 
the basis of the direct 1J C-H correlations observed in the gHMBC NMR experiment (Figure 
4.7) the correct assignment of these carbons has been revised to C-6 (122.7 ppm) and C-8 
(118.2 ppm) respectively.  
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Figure 4.6. Literature 13C NMR assignments and re-assignments of positions C-6 and C-8 for 
droserone (4.7). 
 
The second naphthoquinone (4.8) isolated from the bulbs of the plant displayed an m/z of 
219 [M-H]- in the negative mode ESI-MS, which was consistent with C11H8O5 and eight 
degrees of unsaturation. NMR comparison with droserone (4.7) suggested this was 
hydroxydroserone (4.8), while a comparison with literature data confirmed this [219, 228].  
The two glycosides (4.9-4.10) which co-eluted in the HPLC-NMR analysis (Figure 4.3) were 
suggested to be the glycosides of droserone (4.7) and hydroxydroserone (4.8) by 
comparison of the stop-flow WET-1D 1H NMR and off-line 1H NMR spectra and on the basis 
of biosynthetic origin considerations. This was further supported by the negative mode ESI-
MS analyses of 4.9 and 4.10 which displayed an m/z of 365 [M-H]-, and 381 [M-H]-, 
consistent with masses corresponding to the glycosides of droserone (4.7) and 
hydroxydroserone (4.8) respectively. On the basis of direct NMR comparisons to the 
literature [219, 227], it was established that these were in fact droserone-5-O--glycoside 
(4.9) and hydroxydroserone-5-O--glycoside (4.10). 
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Figure 4.7. Expansion of 2D gHMBC NMR spectrum, displaying the direct 1JC-H correlations for the assignment of droserone (4.7). 
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Although 1H NMR chemical shifts for droserone-5-O--glycoside (4.9) were consistent with 
the literature data as shown in Figure 4.8, the data from the gHSQCAD (See Figure 4.9) and 
gHMBC NMR experiments established that the 13C NMR chemical shifts previously assigned 
[227] to positions C-6 and C-8 in the structure of droserone-5-O--glycoside (4.9) should (as 
in the case of droserone (4.7)) be reversed as shown in Figure 4.8.  
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Figure 4.8. Literature 13C NMR assignments and re-assignments of positions C-6 and C-8 for 
droserone-5-O--glycoside (4.9). 
 
The complete assignment of hydroxydroserone-5-O--glycoside (4.10) using 1D and 2D 
NMR analysis (See Table 4.3) confirmed the structure, with the 1H NMR spectrum shown in 
Figure 4.10. The positioning of the sugar moiety was determined on the basis of a chemical 
shift comparison with droserone-5-O--glycoside (4.9), droserone (4.7), hydroxydroserone 
(4.8) as shown in Figure 4.11, and the literature data for hydroxydroserone-5-O--glycoside 
(4.10) [219]. It was observed that when the hydroxy at position C-5 was changed to a sugar 
moiety (for instance in the case of droserone (4.7) and droserone-5-O--glycoside (4.9)), the 
13C NMR chemical shift of the carbonyl at C-4 decreased markedly (Figure 4.11).  
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Figure 4.9. 2D gHSQCAD NMR spectrum of droserone-5-O--glycoside (4.9).  
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Figure 4.10. 1H NMR (500 MHz, d6-DMSO) spectrum of hydroxydroserone-5-O--glycoside (4.10). 
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While the carbon at C-4 was not observed in the NMR experiments of 4.10, the chemical shift 
for C-1 (191.2 ppm) of 4.10 was similar to that of the chemical shift observed for C-1 of 
hydroxydroserone (4.8) (188.8 ppm), indicating that the sugar moiety was not at C-8. This left 
only position C-5 for the positioning of the sugar moiety as illustrated in Figure 4.11. 
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Figure 4.11. Key 13C NMR assignments allowing the sugar moiety for hydroxydroserone-5-
O--glycoside (4.10) to be positioned. 
 
A selective 1D NOE enhancement observed for the proton at  7.56 (H-6) to the anomeric 
proton (H-1’) at  5.02 (Figure 4.12), positioned the sugar moiety adjacent to the proton at  
7.56 (H-6), while from the 2D gCOSY NMR experiment, H-6 was coupled to the proton at  
7.32 (H-7). The HMBC correlations from  13.05 (8-OH) to 113.7 ppm (C-8a), 126.9 (C-7) 
and 156.3 (C-8) (Figure 4.12), enabled unequivocal assignment of hydroxydroserone-5-O--
glycoside (4.10). Based on this data (as well as the gHSQCAD NMR experiment), both 1H 
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and 13C assignments in the literature [219] for positions C-6 and C-7 should be reversed. The 
sugar moieties of 4.10 and 4.11 had been previously established on the basis of a hydrolysis 
and subsequent TLC analysis, together with the interpretation of the coupling constants [219, 
227]. 
 
Table 4.3. 1H (500 MHz) and 13C (125 MHz NMR spectroscopic data of hydroxydroserone-5-
O--glycoside (4.10) in d6-DMSO. 
Position H, J  C
a gCOSY gHMBC 1D NOE 
1 
 
- 191.2, s - - - 
2 - 118.0, s - - - 
3 - 157.9, d - - - 
4 - ND - - - 
4a - 116.9, s - - - 
5 - 152.0, s - - - 
6 7.56 d, J = 9.5 Hz 125.5, d H-7 C-4a, C-5, C-8 H-1’ 
7 7.32 d, J = 9.5 Hz 126.9, d H-6 C-5, C-8, C-8a - 
8 - 156.3, s - - - 
8a - 113.7, s - - - 
9 1.89, s 8.3, q - C-1, C-2, C-3 - 
1’ 5.02 d, J = 7.0 Hz 101.7, d H-2’ C-5 - 
2’ 3.35 m 73.2, d H-1’ C-1’, C-3’ - 
3’ 3.29 m 76.2, d - C-2’, C-4’ - 
4’ 3.19 m 69.2, d H-5’ C-3’, C-6’ - 
5’ 3.37 m 77.0, d H-4’, H-6’b C-6’ - 
6’ 3.47 m 
3.69 dd, J = 11.5, 1.5 Hz 
60.4, t  
H-5’ 
C-5’ - 
3-OH 11.22, s - - - - 
8-OH 13.05, s - - C-7, C-8, C-8a - 
2’-OH ND - - - - 
3’-OH ND - - - - 
4’-OH ND - - - - 
5’-OH ND - - - - 
6’-OH ND - - - - 
ND indicates signals were not detected 
a
 Carbon assignments based on gHSQCAD and gHMBC NMR experiments 
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Figure 4.12. Key HMBC correlations and single irradiation NOE NMR enhancement 
observed in the unequivocal assignment of hydroxydroserone-5-O--glycoside (4.10). 
 
Of the isolated compounds, plumbagin (1.267) displayed the most potent and broad 
spectrum anti-tumour and anti-microbial activity (Table 4.1). It was observed that 
hydroxydroserone (4.8) and its 5-O--glycoside (4.10) had similar P388 activity, while 
droserone-5-O--glycoside (4.9) exhibited a greater than 10 fold increase in P388 activity 
compared to droserone (4.7). While the glycosides were not tested for anti-microbial activity, 
it was observed that hydroxydroserone (4.8) exhibited slight inhibition against Bacillus subtilis 
(5 mm zone of inhibition) and Trichophyton mentagrophytes (6 mm), however droserone 
(4.7), displayed no activity against these strains. Plumbagin (1.267) is well known for its wide 
range of biological activities (See Introduction Section 1.3) including anti-malarial, anti-
microbial, anti-fungal, anti-inflammatory activity and cytotoxicity [75, 229-233]. Droserone 
(4.7) is also known to exhibit slight anti-plasmodial and seed germination activity [231, 232]. 
 
4.4 Concluding Remarks 
In this study, HPLC-NMR was successfully implemented to rapidly profile secondary 
metabolites present in the crude extracts of the bulbs of the Australian carnivorous plant, D. 
erythrohiza subspecies magna, resulting in the partial identification of two naphthoquinones 
(4.7) and (4.8) and a mixture of the two corresponding naphthoquinone glycosides (4.9) and 
(4.10). Subsequent off-line isolation of compounds from the bulb extracts permitted the 
Marine and Terrestrial Natural Products Discovery 
154 
unequivocal identification of compounds 4.7-4.10. As a result of this study, several 13C NMR 
chemical shift reassignments were established for compounds 4.7, 4.9 and 4.10. Chemical 
investigation of the aerial parts of Drosera erythrohiza subspecies magna led to the isolation 
of plumbagin (1.267). Of all the compounds isolated, plumbagin (1.267) was observed to 
possess the greatest anti-tumour and anti-microbial activity, with this potent broad spectrum 
activity being consistent with the known activity of plumbagin (1.267). 
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Chapter 5  
On-line and Off-line Methodologies for the 
Identification of Secondary Metabolites 
from the Marine Red Alga Plocamium 
angustum 
5.1 Introduction 
The marine environment has, to date, proven to be a valuable resource for the search of 
new bioactive secondary metabolites [234-236]. The sheer biodiversity of the marine 
environment has resulted in the discovery of a vast array of unique secondary 
metabolites, many of which possess potent biological activities [10, 11, 234, 236, 237]. 
One feature that differs between marine secondary metabolites compared to plant 
secondary metabolites is the very common incorporation of halogens into marine 
secondary metabolites, especially those derived from marine red algae. 
Crude extracts of marine organisms are frequently composed of a complex mixture of 
compounds, so that any insight into the structure class(es) of the secondary metabolites 
present is invaluable. To assist in the search and identification of new compounds, 
hyphenated methodologies (e.g., GC-MS and HPLC-MS) are often employed. The 
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application of HPLC-NMR has been demonstrated as being able to offer valuable insight 
into the structure class and the range of secondary metabolites present in a crude extract. 
This has been successfully demonstrated in a number of chemical profiling studies 
conducted within the MATNAP research group at RMIT University, both on marine and 
terrestrial extracts and also in monitoring chemical interconversions [238-241]. HPLC-
NMR is advantageous in that it has the ability to separate components in situ and is a 
non-destructive technique. This allows for the full recovery of all components for any 
further studies such as bioassays or mass spectrometry. It is also an invaluable method of 
analysis for compounds that are unstable [242].  
Plocamium is a genus of red algae that has been highly studied, with forty-seven species 
known to date [8, 243, 244]. Some species of Plocamium are found in various worldwide 
locations such as P. cartilagineum, while others such as P. angustum are found in specific 
regions (New Zealand and South Eastern Australia). The genus Plocamium is known to 
produce a vast array of acyclic and cyclic polyhalogenated monoterpenes (5.1-5.21) for 
which the main differences are associated with the position, orientation and degree of 
halogen incorporation [238, 245-260]. Of the species of Plocamium, P. cartilagineum has 
been studied more widely than any other species, with forty-three compounds having 
been reported to date [8]. The first reported acyclic polyhalogenated monoterpene was 
tribromotrichloromonoterpene (5.1), discovered in 1973 from the digestive system of the 
sea hare of Aplysia californica [245]. The structure of this polyhalogenated monoterpene 
was determined on the basis of X-ray diffraction and it was noted that during analysis, 
discolouration of the crystal was observed as it yellowed over time, and reflections 
declined, suggesting decomposition. This was the first naturally occurring compound with 
such a high degree of halogenation, while it was later determined that the true source of 
this polyhalogenated terpene was in fact P. coccineum [246]. 
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The species P. angustum is endemic to New Zealand and Australia and has not been as 
widely studied, with only four secondary metabolites having been reported (5.6, 5.7, 5.20, 
5.21) to date [254, 256]. An extract of the red alga P. angustum was selected for chemical 
investigation on the basis of the potent cytotoxicity and significant anti-microbial activities 
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displayed by the crude extract. In addition, chemical investigation of the alga was 
motivated by the fact that this genus is known to produce a wide array of polyhalogenated 
monoterpenes, some of which possess bioactive properties, together with the fact that this 
species has not been extensively studied [258, 261-267]. 
 
5.2 Experimental 
5.2.1 General Experimental 
For all general experimental procedures and spectroscopic methods, see the 
Experimental chapter Section 7.1. Analytical HPLC method development was conducted 
on the crude DCM extract and isocratic 70% CH3CN:H2O found to be most suited for this 
separation. HPLC-NMR was conducted at 70% CH3CN:D2O with detection at max 254 and 
290 nm. Semi-preparative HPLC was conducted using an isocratic solvent system (65% 
CH3CN/H2O) and UV detection at max 254 nm and 290 nm.  
5.2.2 Algal material 
A specimen of P. angustum was collected on 22nd January 2006 from the Borough of 
Queenscliff near Pt. Lonsdale, Victoria. Two further specimens of the alga were obtained 
on 13th December 2009 from the same location as the initial collection, with this collection 
a targeted collection undertaken by Dr Gerald Kraft. The three separate specimens were 
identified by Dr Gerald Kraft. Voucher specimens designated the codes 2006-04, 2009-14 
and 2009-15 respectively are deposited at the School of Applied Sciences (Discipline of 
Applied Chemistry), RMIT University. A 2 g portion of the frozen P. angustum specimen 
(voucher specimen 2006-04) was extracted with 3:1 MeOH:DCM (40 mL) and evaluated 
for biological activity as described in Section 7.1.4. This crude extract exhibited potent 
cytotoxicity (IC50 <4.9 g/mL, see Table 5.1), broad spectrum anti-fungal activity against 
Candida albicans (10 mm zone of inhibition), Trichophyton mentagrophytes (10 mm zone 
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of inhibition), and Cladosporium resinae (20 mm zone of inhibition) as well as selective 
anti-bacterial activity against Bacillus subtilis (15 mm zone of inhibition). In addition the 
crude extract also showed a 100% cytotoxic zone when tested against Herpes simplex 
type 1 and Polio virus type 1, meaning that it was not possible to distinguish if there was 
any virus inhibition at all. Further collections of P. angustum (voucher codes 2009-14 and 
2009-15) were also subjected to cytotoxicity screening, with one of the two collections 
having an IC50 of <4.9 g/mL, while the other extract possessed an IC50 of 22.7 g/mL. All 
cytotoxicity results are given in Table 5.1. 
 
 
P. angustum (Voucher code: 2006-04) 
 
 Kingdom: Plantae 
 Phylum: Rhodophyta 
 Class:  Florideophyceae 
 Subclass: Rhodymeniophycidae 
 Order: Plocamiales 
 Family: Plocamiaceae 
 Genus:  Plocamium 
 Species: angustum 
 
Collected by Dr Sylvia Urban, Dr Rick Tinker, Dr Daniel Dias and Mrs Priyanka Reddy 
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P. angustum (Voucher code: 2009-14) 
 
 
P. angustum (Voucher code: 2009-15) 
 
Table 5.1. Summary of the P388 cytotoxicity of plocamenone (5.21) and isoplocamenone 
(5.24) isolated from three separate specimens of P. angustum. 
Specimen Voucher Code P388 cytotoxiciy IC50 (g/mL) 
2006-04 (crude extract) <4.9 
2009-14 (crude extract) <4.9 
2009-15 (crude extract) 22.7 
plocamenone (5.21) (obtained from 2006-04) 0.158* 
plocamenone (5.21) (obtained from 2009-14) <0.098 
plocamenone (5.21) (obtained from 2009-15) <0.098 
mixture of 5.21 and 5.24 (obtained from 2009-14) <0.098 
* Purity of isolated plocamenone was lower on this occasion. 
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5.2.3 Extraction and Isolation 
5.2.3.1 Preparation of the extract of P. angustum for on-flow and stop-flow HPLC-
NMR analysis 
The specimen of P. angustum (voucher specimen 2006-04) (50 g) was roughly chopped 
and extracted with 3:1 MeOH:DCM (1 L). This extract was then decanted and 
concentrated under reduced pressure and was then sequentially partitioned (trituated) into 
DCM, MeOH and H2O soluble extracts respectively. A portion of the DCM extract (64.3 
mg) was re-solubilised in 1 mL 70:30 CH3CN:D2O and filtered through a 0.45 m PTFE 
membrane filter (HP045 Advantec, Japan). For both on-flow and stop-flow HPLC-NMR 
analyses 50 L injections (3,217 g per injection) of the DCM extract was injected using 
the conditions described in Section 2.2.1.  
5.2.3.2 Preparation of the extract for off-line isolation of secondary metabolites 
from P. angustum 
The remaining algal material (125 g) was extracted using 1 L of 3:1 MeOH:DCM. The 
crude extract was decanted and concentrated under reduced pressure and then 
sequentially partitioned (trituated) into DCM, MeOH and H2O soluble extracts respectively. 
The DCM extract from the HPLC-NMR analysis was combined with this DCM extract to 
give a combined DCM fraction (510 mg), which was subjected to flash silica column 
chromatography using the method described in Section 7.1, resulting in sixteen fractions. 
On the basis of the analytical HPLC analysis and the 1H NMR spectra one fraction was 
found to contain the two compounds observed from the HPLC-NMR analysis. Subsequent 
off-line purification of this fraction was achieved using semi-preparative reversed phase 
HPLC using the method described in Section 5.2.1, to afford plocamenone (5.21) (30 mg, 
0.15%) and isoplocamenone (5.24) (2 mg, 0.01%). While plocamenone (5.21) was 
observed to be a very stable secondary metabolite, isoplocamenone (5.24) degraded 
rapidly. Further to this, it was found that the latter degraded much more rapidly once 
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purified than when it was present as a mixture with plocamenone (5.21). Owing to the 
degradation observed it was necessary to undertake re-collections of the alga. A separate 
fraction containing a mixture of plocamenone (5.21) and isoplocamenone (5.24) (4:1) was 
obtained from a combination of the two re-collected specimens of the alga, using the 
same isolation procedure as described for the initial isolation (45 mg, 0.38%). This mixture 
was utilised for subsequent NMR analysis, HR-GC-MS analysis as well as for the 
biological screening. 
 
5.3 Results and Discussion 
P. angustum was extracted as outlined in Section 5.2.3.1. 1H NMR analysis showed the 
presence of possibly one major metabolite, while from analytical HPLC analysis, two closely 
eluting peaks were observed. From this, analytical HPLC method development was 
undertaken as shown in Figure 5.1 in order to obtain suitable separation conditions for 
HPLC-NMR analysis to be undertaken.  
 
 
Figure 5.1. Analytical HPLC method development for the DCM extract of P. angustum.
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On the basis of this HPLC method development, taking into consideration the total run time 
and separation, 70% CH3CN:D2O was selected for the HPLC-NMR analyses. Chemical 
profiling was conducted employing HPLC-NMR in an attempt to identify the class of 
secondary metabolites present. HPLC-NMR chemical profiling was achieved using both on-
flow and stop-flow analyses. On-flow HPLC analysis clearly indicated the presence of two 
structurally related secondary metabolites as shown in Figure 5.2. Given that the genus 
Plocamium is known to produce polyhalogenated monoterpenes, it was proposed that the 
compounds present in the crude extract were most likely of this structure class. This was 
also supported by the presence of the deshielded 1H NMR chemical shift at  4.44 which is 
characteristic of a halogenated methine. 
Stop-flow HPLC-NMR analysis was also carried out in an attempt to elucidate the 
structures of the two polyhalogenated monoterpenes, previously observed in the on-flow 
HPLC-NMR analysis. In the stop-flow mode, selected chromatographic peaks can be 
trapped in the HPLC-NMR flow cell for an indefinite period, thereby allowing for extended 
acquisition times and consequently greatly improved sensitivity and resolution in the 
resulting WET-1D 1H NMR spectra. The major secondary metabolite 5.21 present in the 
DCM fraction was now subjected to stop-flow HPLC-NMR analysis, whereby acquisition of 
a WET-1D 1H NMR spectrum (1 min) (Figure 5.2), together with a WET-2D gCOSY (47 
min) (Figure 5.3) and a gHSQCAD (4 h) (Figure 5.4) NMR experiment were carried out. 
On the basis of the WET-2D gCOSY NMR spectrum obtained (Figure 5.3), protons at  
4.44 (H-7),  4.18 (H-8b) and  3.74 (H-8a) all shared correlations, suggestive of a 
methine and methylene with non-equivalent protons. In addition, an aromatic proton at  
6.18 (H-1b) showed a correlation to the terminal singlet methyl at  1.82 (H-9). This NMR 
data was consistent with the acyclic polyhalogenated monoterpene structure class that 
has previously been reported from this red alga genus [235, 250, 264, 268]. 
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Figure 5.2. [A] HPLC chromatogram of the HPLC-NMR analysis (UV detection at max 250 nm), [B] HPLC 2D contour plot of the HPLC-NMR 
analysis (200-400 nm), [C] On-flow HPLC-NMR contour plot of the DCM extract of P. angustum and [D] Stop-flow HPLC-NMR WET-1D 1H 
NMR spectra of compounds (5.21 and 5.24). 
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The WET-2D gHSQCAD NMR experiment (Figure 5.4) showed the presence of an 
olefinic methine ( 6.26 to 134.0 ppm), an exocyclic double bond ( 6.18 and  6.09 to 
133.2 ppm), a deshielded methine ( 4.44 to 63.5 ppm), a deshielded methylene ( 4.18 to 
48.0 ppm) as well as a singlet methyl ( 1.65 to 27.9 ppm), while the peak at  3.74 
observed in the gCOSY was not evident in the WET-1D or gHSQCAD NMR experiments 
was due to this peak being completely suppressed under the residual water suppression 
region. On the basis of the analysis of this NMR data, in consultation with the MarinLit 
database, it was proposed that the major component was plocamenone, an acyclic 
polyhalogenated monoterpene previously isolated from P. angustum (5.21) [255, 269]. For 
this compound to be unequivocally identified, it would be necessary to obtain further NMR 
spectroscopic evidence of the compound’s connectivity, along with mass spectrometric 
data. 
The minor component (5.24) that was observed in the on-flow HPLC-NMR analysis was 
also subjected to stop-flow HPLC-NMR analysis. This allowed for an extended WET-1D 
1H NMR spectrum (20 min) to be acquired (Figure 5.2). It was evident that some of the 
signals in the WET-1D 1H NMR spectrum were either partially or completely suppressed 
(under the suppressed HDO peak). Also the low abundance of 5.24 meant that any further 
WET-2D NMR experiments that were acquired in the stop-flow HPLC-NMR mode failed to 
provide any conclusive connectivity. It was necessary to undertake an off-line isolation 
and analysis of this compound in order for its complete structure to be elucidated. In 
addition, the significant cytotoxicity and anti-microbial activities observed for the crude 
extract of this marine alga further supported the need for an off-line investigation in order 
to evaluate and determine the nature of the bioactive compound(s). 
 
Marine and Terrestrial Natural Products Discovery 
166 
 
Figure 5.3. Stop-flow HPLC-NMR WET-2D gCOSY NMR spectrum of plocamenone (5.21). 
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Figure 5.4. Stop-flow HPLC-NMR WET-2D gHSQCAD NMR spectrum of plocamenone (5.21). 
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The off-line isolation of the secondary metabolites from the red alga P. angustum was 
conducted using the extraction as outlined in Section 5.2.3.2. The DCM partitioned 
fraction was further fractionated by flash silica chromatography to afford sixteen fractions, 
one of which consisted of the two secondary metabolites previously observed in the 
HPLC-NMR analyses. This fraction was further purified using semi-preparative reversed 
phase HPLC (see Figure 5.5) using the conditions described in Section 2.2.1 to afford 
plocamenone (5.21) and the minor structurally related secondary metabolite, 
isoplocamenone (5.24). In the purification of 5.24, the compound was isolated either as a 
separate unstable compound or as a mixture with 5.21, since the stability of 5.24 could be 
prolonged when isolated as a mixture. 
 
 
Figure 5.5. Semi-preparative HPLC chromatogram with 2D contour plot showing the 
isolation of plocamenone (5.21) and isoplocamenone (5.24), as well as the extracted UV 
profile of the major compound, plocamenone (5.21). 
 
The structure of plocamenone (5.21) was established by 1D (1H NMR given in Figure 5.6) 
and 2D NMR analysis (see Table 5.2), along with mass spectrometry. 2D NMR 
experiments confirmed the structure of plocamenone, a marine secondary metabolite 
Marine and Terrestrial Natural Products Discovery 
169 
previously reported as possessing structure (5.24), isolated from P. angustum [254-256, 
269, 270]. 
The structure of plocamenone has been the focus of several structural revisions. 
Plocamenone was first reported in 1979 and proposed as 5.22 [254], but in the same year 
the structure was revised to 5.24 [255]. In 1983 the structure was revised back to 5.22, and 
then in 1984 further revisions to 5.23 were concluded [256, 270]. This structure was 
deemed to be incorrect and was again revised back to 5.24 [269]. In 1997 the structure 
was again incorrectly described as 5.23 [271] and finally in 2010 plocamenone was once 
again reported as 5.24 [272]. While all NMR chemical shifts were consistent with those 
given in literature sources [254, 256, 270], no complete 2D NMR analysis was reported in 
the structural elucidation/revisions. This is the first complete 2D NMR assignment of 
plocamenone, and the first assignment of its double bond geometry, which has revised the 
structure of plocamenone from (5.24) to (5.21). 
 
Table 5.2. 1H (500 MHz) and 13C (125 MHz) NMR data for plocamenone (5.21) in CDCl3. 
position H J  C gCOSY gHMBC 
1 6.13, s 131.3, t H-10 C-2, C-3, C-10 
2 - 141.8, s - - 
3 - 191.5, s - - 
4 - 129.9, s -  
5 6.20, s 133.4, d - C-3, C-4, C-6, C-7, C-9 
6 - 69.0, s - - 
7 4.36, dd, J = 3, 9 Hz 62.2, d H-8a, H-8b C-6, C-8, C-9 
8a 3.72, dd, J = 9, 12 Hz 46.4, t H-7, H-8b C-7 
8b 4.24, dd, J = 3, 12 Hz  H-7, H-8a C-6 
9 1.75, s 26.9, q - C-5, C-6, C-7 
10 1.95, s 16.6, q H-1 C-1, C-2, C-3 
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Figure 5.6. 1H NMR (500 MHz, CDCl3) spectrum of plocamenone (5.21). 
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The assignment of R or S configurations to stereogenic centers in halogenated 
monoterperenes is not a trivial matter. Fortunately, in 1975 Mynderse and Faulkner 
observed, for compounds whose structures were confirmed by X-ray crystallography, that 
the 1H NMR chemical shift of the position 10 methyl varied in a predictable manner 
depending on the relative configurations at positions 6 and 7 [248, 259, 266, 268, 273-
276]. Crews expanded these rules by making use of the more reliable and more 
discernible differences in 13C NMR chemical shifts for the position 10 methyl carbon atom 
[275]. Here a chemical shift difference of 3 ppm between the (R, S) and (R, R) 
configurations have been reported, in particular chemical shifts of ca.  28 and 25 are 
characteristic of 6R*, 7R* (or 6S*, 7S*) and 6S*, 7R* (or 6R*, 7S*) relative configurations, 
respectively [275]. As such the relative configuration for plocamenone was assigned in 1985 
by applying the empirical rules of Mynderse and Faulkner and Crews to the proton and 
carbon chemical shifts of the methyl group (H-10,  1.75; C-10, 26.8 ppm). In particular, 
the chemical shift of  26.8 ppm was consistent with a 6R*, 7R* (or 6S*, 7S*) relative 
configuration. While these chemical shifts supported an RS configuration, attempts to 
employ calculated 1H NMR chemical shifts to resolve the double bond geometry of 
plocamenone were not fruitful [269].  
The minor analogue isoplocamenone (5.24) was subjected to similar analyses to that 
of plocamenone (5.21). However, owing to the instability of this compound, particularly in 
CDCl3, a complete characterisation in this NMR solvent was only possible when acquired 
as a mixture of 5.24 and 5.21 (1H NMR spectrum shown in Figure 5.7). Subsequent re-
isolations of 5.24 were carried out, in an attempt to characterise and identify the 
compound, however the instability of this compound continually resulted in rapid 
degradation being observed after each isolation attempt. ESI-MS analysis of 5.24 was 
only possible if undertaken immediately after semi-preparative reversed phase HPLC 
purification, providing that the fraction containing the compound was not evaporated to 
dryness.  
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Figure 5.7. 1H NMR (500 MHz, CD3OD) spectrum of isoplocamenone (5.24) in a mixture with plocamenone (5.21). 
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Table 5.3. 1H (500 MHz) and 13C (125 MHz) NMR data for isoplocamenone (5.24) in 
CD3OD. 
Position H (J in Hz) C
a, mult gCOSY gHMBC 
1a 5.92, d, J = 2.0 Hz  129.1, t H-10 C-2, C-3, C-10 
1b 6.02, d, J = 2.0 Hz    
2 - 143.3, s - - 
3 - 192.1, s - - 
4 - 133.5, s -  
5 6.85, s 140.9, d - C-3, C-4, C-6, C-7, C-9 
6 - 69.8, s - - 
7 4.97, dd, J = 3.0, 9.0 Hz  61.6, d H-8a, H-8b C-6, C-8, C-9 
8a 3.94, dd, J = 9.0, 12.0 Hz 47.1, t H-7, H-8b C-7 
8b 4.38, dd, J = 3.0, 12.0 Hz   H-7, H-8a C-6 
9 2.05, s 26.3, q - C-5, C-6, C-7 
10 1.98, s 18.0, q H-1 C-1, C-2, C-3 
a
Carbon NMR assignments based on gHSQCAD and gHMBC NMR experiments 
 
The positive mode ESI-MS of 5.24 displayed an m/z of 335 [M+H]+, which was isobaric 
with that observed for plocamenone (5.21), with an isotopic ratio and splitting also 
comparable to that of plocamenone (5.21). HR-GC-MS analysis of 5.24 was carried out on 
a sample also containing 5.21 with the chromatographic peak of 5.24 displaying an m/z of 
298.9397 [M-Cl]+, consistent with C10H12O
35Cl2
81Br (calculated for 298.9403). It was noted 
that this compound’s stability could be prolonged when isolated in the presence of 
plocamenone (5.21) and so it was decided that this minor secondary metabolite would be 
isolated as a mixture with 5.21 to permit further characterisation and identification to be 
carried out. It must be noted that even in a mixture, this minor compound degraded within 
two weeks. On the basis of the NMR analyses conducted on the mixture of plocamenone 
(5.21) and isoplocamenone (5.24) in CD3OD, complete characterisation was possible by 
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NMR analysis. Extensive analysis of the 1D and 2D NMR data (Table 5.3), in combination 
with the mass spectrometric evidence, established that the minor analogue had the same 
connectivity as that of plocamenone (5.21) and was an isomer of this compound.  
Owing to the instability of 5.24, any further separation and characterisation could not be 
conducted as a means to ascertain the structure of this minor structural analogue. 
Comparison of the NMR data indicated that the most significant chemical shift differences 
for plocamenone (5.21) and the minor analogue 5.24 in CD3OD (Table 5.4) were observed 
for the 1H NMR chemical shifts at positions 1a, 1b, 5, 7 and 10, whilst the greatest 
differences in the 13C NMR chemical shifts were evident at positions 1, 4 and 5. 
 
Table 5.4. 1H and 13C NMR chemical shift differences for plocamenone (5.21) and 
isoplocamenone (5.24) (500 MHz, CD3OD). 
 plocamenone (5.21) isoplocamenone (5.24) 
Differences 
(ppm) 
Position H C 
a H C 
a H C 
1a 6.17, s 132.3, (t) 5.91, s 129.0, (t) +0.26 +3.3 
1b 6.23, s  6.00, s  +0.23  
2 - 143.3, (s) - 143.5, (s)  −0.2 
3 - 193.2, (s) - 192.3, (s)  +0.9 
4 - 130.5, (s) - 133.7, (s)  −3.2 
5 6.39, s 134.7, (d) 6.84, s 140.8, (d) −0.45 −6.1 
6 - 70.7, (s) - 69.7, (s)  +1.0 
7 4.57, dd, (3, 9.5) 63.5, (d) 4.97, dd, (2.5, 9) 61.5, (d) −0.40 +2.0 
8a 3.80, dd, (9.5, 12) 47.6, (t) 3.93, dd, (9, 13) 47.1, (t) −0.13 +0.5 
8b 4.27, dd, (3, 12)  4.37, dd (2.5, 13)  −0.10  
9 1.93 16.6, (q) 1.97, s 18.0, (q) −0.04  −1.4 
10 1.76 27.6, (q) 2.05, s 26.2, (q) −0.29 +1.4 
a
 Carbon assignments based on gHSQCAD and gHMBC NMR experiments. 
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Inspection of 1H and 13C NMR chemical shifts reported for structurally related halogenated 
terpenes such as compounds (5.25-5.28) (Figure 5.8) established that a configurational 
change of the stereogenic centers only results in small chemical shift differences being 
observed [248, 250, 275]. Given that the 1H and 13C NMR chemical shift differences 
between plocamenone (5.21) and the minor analogue 5.24 (Table 5.4) were much greater 
than for those observed for changes around stereogenic centers, it was concluded that 
the structures of 5.21 and 5.24 did not differ by a relative configuration change. This 
ultimately led to the conclusion that the two structures differed in terms of their double 
bond geometry. Since the double bond geometry of plocamenone had not been previously 
established, the isolation of this isomer provided an opportunity to resolve this structural 
feature. 
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Figure 5.8. 1H and 13C NMR chemical shift comparisons of configurational isomers. 
 
A change in the double bond geometry from E to Z can have a significant effect on 1H 
NMR chemical shifts. This was apparent when comparing the NMR data for the 
polyhalogenated compounds (5.29–5.31) [248]. From these compounds (5.29-5.31) it was 
observed that once again a configurational change had little effect on surrounding 
chemical shifts when comparing compounds 5.29 and 5.30, while comparison of the 
chemical shifts of compounds 5.30 and 5.31, the change in double bond geometry from E 
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to Z has a significant effect on surrounding chemical shifts, with a difference of 0.26 ppm 
observed for the  position between compounds 5.30 and 5.31 [248]. 
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Figure 5.9. 1H NMR comparison of configurational and double bond isomers. 
 
In trisubstituted olefins it has been documented that the olefinic carbons of the E isomer 
reside at a higher field [277] and in the case of 1,2-disubstituted ethylenes the rule E < 
Z is observed in the 13C NMR data of the olefinic carbons [278, 279]. In addition, the 
regiochemistry of furoplocamioids A to C (5.32–5.34), which possess a 1,2-dihalovinyl 
system were determined on the basis of the 13C NMR chemical shits of the substituted 
vinyl carbon [280]. 
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A range of model compounds clearly established that the chemical shift of the olefinic 
proton and associated carbon resonance in trisubstituted olefinic systems are deshielded 
for compounds with Z geometry. This trend is in line with the differences observed in the 
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1H and 13C NMR chemical shifts of plocamenone (5.21) and isoplocameone (5.24), for the 
olefinic H-5 and the associated olefinic carbon resonances at C-4 and C-5 (Table 5.4). 
Further to this, the geometry of the double bond could be assigned by comparison of the 
observed chemical shifts for the olefinic H-5 to those calculated either through NMR 
prediction software such as Advanced Chemistry Development (ACD) labs™ and 
ChemDraw™ [281, 282] or those calculated from tables of substituent shielding constants 
which support compound (5.24) as being the Z isomer of plocamenone (5.21) [247, 283-
285]. This trend for both the 1H and 13C NMR chemical shifts for the E isomer to be more 
shielded than for the corresponding Z isomer is also evident in the structure of 
cartilagineal (5.3) [247].  
On the basis of the significant chemical shift differences observed for the olefinic 1H and 
13C NMR resonances for plocamenone (5.21) and the minor analogue as seen in Table 
5.4, it was concluded that the minor analogue 5.24 was the Z double bond geometric 
isomer of plocamenone (5.21). This meant that the double bond geometry that had been 
previously depicted in the structure of plocamenone should now be revised to an E 
configuration. This isomer 5.24 has been attributed the name isoplocamenone and on 
biosynthetic grounds the same relative configuration is assigned to both isoplocamenone 
(5.24) and plocamenone (5.21). The 1H and 13C NMR chemical shifts of the position 10 
methyl support an RS configuration for both compounds [248]. 
It is worth noting that HPLC-NMR analysis of P. angustum was essential in recognising 
the existence of the closely related plocamenone structural analogue 5.24 and greatly 
assisted in the eventual isolation and identification of this unstable compound. It may be 
speculated that isoplocamenone (5.24) could potentially arise as an artefact formed under 
the extraction conditions. To study this phenomenon, a portion of the frozen alga was 
extracted with DCM and immediately analysed by analytical HPLC. This confirmed the 
presence of both plocamenone (5.21) and isoplocamenone (5.24) in the crude extract. 
This was also supported by the detection of both compounds in the crude extracts 
analysed by HPLC-NMR which were also conducted on the frozen alga and immediately 
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analysed. On the basis of this evidence, it is suggested that both compounds are natural 
products. The isolation of double bond isomers from the one organism has been 
documented on other occasions especially in marine algae [248, 286, 287].  
Plocamenone (5.21) has been previously reported to exhibit cytotoxicity in the AMES test, 
as well anti-bacterial activity towards Eschericha coli [255, 271]. Plocamenone (5.21) as 
well as a mixture of plocamenone (5.21) and isoplocamenone (5.24) were subjected to 
biological screening as detailed in Section 5.2.2. It was observed that the initial 
plocamenone (5.21) isolated possessed significant cytotoxicity in the P388 murine 
leukemia cell assay, with an observed IC50 of 0.158 g/mL (Table 5.1). The IC50 for the 
anti-tumour compound adriamycin, also known as doxorubicin, was 0.031 g/mL in this 
assay. Plocamenone (5.21) also showed activity when tested as an inhibitor of bacterial 
and fungal pathogens. It was observed that at a concentration of 30 μg/mL, plocamenone 
(5.21) inhibited the growth of Bacillus subtilis, Candida albicans and Cladosporium resinae 
with inhibition zones (radius of inhibition outside the 6 mm diameter application disc) of 
10, 2 and 6 mm zones respectively. At a concentration of 30 μg/mL the standard 
compound chloramphenicol had an inhibition zone of 12 mm against B. subtilis and the 
standard compound nystatin had inhibition zones of 12 mm against both C. albicans and 
C. resinae. The reported activity towards E. coli of plocamenone (5.21) [271] was not 
observed in this biological activity screening of plocamenone (5.21), however the reason 
for this is unclear.  
Subsequent biological testing of a highly purified sample of plocamenone (5.21) isolated 
from the two re-collected specimens of the alga, along with a mixture of plocamenone 
(5.21) and isoplocamenone (5.24) (present in a ratio of approximately 4:1) both displayed 
an IC50 of <97.5 ng/mL (Table 5.1). Owing to the instability of isoplocamenone (5.24), this 
compound was only able to be tested as a mixture with plocamenone (5.21). However, 
given the greater abundance of 5.21 (4:1), the activity observed for the mixture of the two 
compounds is presumed to be due to the major compound, plocamenone (5.21).  
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5.4 Concluding Remarks 
HPLC-NMR chemical profiling of the red alga P. angustum with subsequent off-line HPLC 
isolation resulted in the identification of plocamenone (5.21), together with a new, unstable 
double bond isomer, isoplocamenone (5.24). The complete structures of plocamenone 
(5.21) and isoplocamenone (5.24) were established on the basis of extensive 2D NMR 
analysis and by recognising chemical shift trends for closely related trisubstituted olefins. 
This represents the first complete structure assignment for plocamenone (5.21) leading to 
a structural revision for this compound, along with its selective anti-bacterial activity 
towards Bacillus subtilis and moderate broad spectrum anti-fungal activity. The use of 
HPLC-NMR to conduct this study clearly demonstrated that it is an invaluable method for 
the analysis of unstable compounds. 
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Chapter 6  
HPLC-NMR Chemical Profiling and 
Dereplication Studies of the Marine Brown 
Alga, Cystophora torulosa 
6.1 Introduction 
To date, the genus Cystophora consists of twenty-six accepted species, all of which have 
been extensively studied [288]. The genus is endemic to Australasia with most species 
only found around Australia [289]. A range of structural classes of compounds have been 
reported from various species of Cystophora including polyenes (6.1-6.3), phloroglucinol 
derivatives (6.4-6.7), polyprenyl chromans (6.8-6.11), resorcinol derivatives (6.12-6.15), 
farnesylacetone derivatives (6.20-6.31), carotenoids (6.32), steroids (6.33), 
meroditerpenes (6.34), isoprenoid dihydroquinones (6.35-6.37), tetraprenyltoluquinols 
(6.38-6.39) amongst others [289-292]. 
The first study conducted on a species of the genus Cystophora was in 1977, with four 
classes of compounds reported [293]. This included two polyenes (6.1-6.2), a 
phloroglucinol derivative (6.4), five polyprenyl chromans (6.5-6.9) and four resorcinols 
(6.12-6.15), which were all isolated from Cystohora torulosa [293]. In an earlier report of 
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the isolation of secondary metabolites from the brown alga Sargassum tortile, it was 
established that polyprenyl chromans similar to compounds 6.8 and 6.9 stimulate the 
settling and metamorphosis of Coryne uchidai larvae [294]. 
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Later it was discovered that the farnesylacetone epoxide (6.20) reported from C. 
moniliformis, displayed anti-convulsant activity in mice [295]. The phloroglucinol 
derivatives (6.5-6.6) isolated form C. moniliformis displayed potent inhibition of oxidative 
phosphorylation, while the resorcinol derivative (6.14) from C. torulosa showed only slight 
inhibition of oxidative phosphorylation [296]. The study of four different species of 
Marine and Terrestrial Natural Products Discovery 
182 
Cystophora afforded many secondary metabolites [297], including phloroglucinol 
derivatives (6.5-6.6) from C. monilifera and polyenes (6.1-6.2) as well as the 
phloroglucinol (6.5) from C. congesta [297]. Within the same study, it was found that C. 
expansa contained the phloroglucinols (6.4-6.5), as well as -tocotrienol (6.8), while C. 
scalaris afforded the phloroglucinols (6.4-6.5) [297]. The isoprenoid dihydroquinones 
(6.35-6.37) were isolated from an unknown species of Cystophora from Western Australia 
[298]. A further study of C. moniliformis afforded -tocotrienol (6.10) as well as 
compounds (6.22-6.25 and 6.40-6.46) [299]. The crude extract of C. congesta was found 
to possess cardiovascular activity in hypertensive rats [300], however it was from an 
inactive fraction that the phloroglucinol trimer (6.47) was isolated [300], with a separate 
report of polymeric phloroglucinol derivatives similar to that of 6.47 being isolated from the 
same species [301]. The sperm attraction of cystophorone (6.3), isolated from C. 
siliquosa, was established in 1984 [302] with activity within the range of other hormone 
systems in brown algae [302]. A number of carotenoids such as 6.32 were then isolated in 
1987 from the two species C. retroflexa and C. torulosa [303]. A year later, a number of 
sesquiterpenes (6.26-6.28), related to farnesylacetone as well as the cyclic sesquiterpene 
(6.48) were isolated from C. moniliformis, where preliminary feeding studies suggested 
that geranylacetone (6.29) was a deterrent of Tripnerstes gracilis and Subninella undulata 
[304].  
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C. torulosa and C. retroflexa were also found to contain a number of phlorotannins such 
as 6.49 [305-308], while steroids like 6.33 and meroditerpenes such as 6.34 were isolated 
in 1998 from C. brownii [291]. In 2006, a study of C. fibrosa from South Africa yielded the 
tetraprenyltoluquinols (6.38-6.39) [292], however it was suggested by the authors that the 
species C. fibrosa should be moved into the Cystoseira genus due to the presence of 
these secondary metabolites [292]. The first report of the isolation of compounds from the 
species C. harveyi was in 2007 with the isolation of atractylochromene (6.11), a known 
anti-inflammatory agent, pycnanthuquinone C (6.50), as well as (6.35 and 6.37) [309]. In 
this latter study [309] it was also reported that extracts containing atractylochromene 
(6.11) have been used in the treatment of rheumatic diseases, digestive ailments, mild 
diarrhoea and influenza, while extracts known to contain (6.35) have been used for the 
treatment of dysentery, fever, arthritis and apoplexia [309]. The related 
pycnanthuquinones A (6.51) and B (6.52), isolated from the African plant, Pycnanthus 
angolensis were shown in a previous report to possess anti-hyperglycemic activity in mice 
[310]. The highly studied C. monoliformis was studied further in 2008, with the isolation of 
the two new epimeric terpene diols, namely monilforminol A and B (6.53-6.54) along with 
a farnesylacetone derivative (6.30) [311]. In this study it was established that a mixture of 
compounds 6.41 and 6.42 displayed moderate P388 anti-tumour activity and moderate 
anti-fungal activity towards Trichophyton mentagrophytes. In 2010, the farnesylacetone 
epoxide (6.31) from C. moniliformis and the phloroglucinol derivative (6.7) were reported 
from C. scalaris [312]. 
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Databases are an invaluable resource to assist in the dereplication of compounds that are 
present in an organism (marine or terrestrial). In particular, databases such as the 
Dictionary of Natural Products [7] and the MarinLit database [8] are extremely useful due 
to their ability to search using structural information (e.g. UV profiles, molecular mass, 
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NMR spectra, etc.), structures/substructures and/or taxonomic classification, or on the 
basis of other bibliographic information. While the Dictionary of Natural Products has a 
very broad scope in that it allows searches to be conducted for both marine and terrestrial 
organisms (~170,000 compounds) [7], the MarinLit database is more specific in that it 
deals only with the literature for compounds that have been reported from marine sources 
and comprises >5,200 compounds isolated from approximately 6,000 species, spanning 
2,200 genera and thirty-nine phyla [8]. The use of the MarinLit database in assisting to 
determine the structure class(es) of compound(s) that are present in specific 
genera/genus and species can provide insight into the classes of compounds that are 
likely to be present/occur in a specific organism and is therefore an invaluable aid in the 
dereplication of marine natural products . 
In this chapter, a dereplication exercise was conducted on the crude extract of the 
southern Australian marine brown alga C. torulosa. The specimen was selected for 
chemical profiling due to the highly studied nature of the genus in an effort to identify the 
class(es) of compounds present and/or rapidly identify these compounds. The crude DCM 
extract was subjected to HPLC-NMR chemical profiling for the rapid determination of the 
class(es) of compounds present in this alga. The dereplication exercise was carried out in 
conjunction with the use of the MarinLit database and was successful in identifying two 
principal classes of secondary metabolites. Following ESI-MS or GC-MS of the small 
scale isolations of the compounds present, a total of nine secondary metabolites could be 
identified.  
 
6.2 Experimental 
6.2.1 General Experimental 
For detailed information on the general experimental procedures and spectroscopic 
techniques refer to the Experimental chapter Section 7.1. Analytical HPLC method 
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development was conducted on the crude DCM extract, using isocratic conditions 
consisting of 80% CH3CN:H2O providing good separation of the early eluting group of 
compounds. For the two later eluting compounds 100% CH3CN provided sufficient 
separation, however this was not suitable for the HPLC-NMR analysis as some D2O is 
required to maintain a lock. It was established that 90% CH3CN:H2O was suitable for the 
HPLC-NMR analysis of these later components. On-flow HPLC-NMR analyses were 
conducted on the crude DCM extract using isocratic HPLC conditions obtained via 
analytical HPLC method development (80% CH3CN:D2O for the identification of the early 
eluting compounds and 90% CH3CN:D2O for the identification of the later eluting 
compounds), with detection at max 230 and 254 nm. A single analytical reversed phase 
HPLC collection was conducted to isolate a small quantity of the minor secondary 
metabolites (6.1-6.2, 6.12, 6.15-6.19) to permit ESI-MS or GC-MS analyses to be carried 
out. These analytical HPLC collections were conducted using 90% CH3CN:H2O for the off-
line isolation of 6.12, 6.15-6.19 and 100% CH3CN for the isolation of 6.1-6.2 with detection 
at max 220 and 254 nm in both cases. Semi-preparative reversed phase HPLC was 
conducted using isocratic conditions consisting of 90% CH3CN:H2O for the off-line 
isolation of the major secondary metabolite (6.14) with detection at max 220 and 254 nm. 
6.2.2 Algal material 
A specimen of C. torulosa was collected on 22nd of January 2006 from the Borough of 
Queenscliff near Pt. Lonsdale, Victoria, Australia and the specimen was identified by Dr 
Gerald Kraft. A voucher specimen designated the code 2006-10 is deposited at the 
School of Applied Sciences (Discipline of Applied Chemistry), RMIT University. For 
detailed information on the biological assays refer to the Experimental chapter Section 
7.1.4. A 2 g sample of the C. torulosa specimen was extracted using 3:1 MeOH:DCM and 
evaluated for biological activity. The crude extract displayed cytotoxicity against the P388 
(Murine leukaemia) cell line with an IC50 of 23.9 g/mL. The extract also showed a 25% 
anti-viral zone of inhibition for Herpes simplex type 1 and a 75% zone of inhibition against 
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the Polio virus type 1. The crude extract showed no anti-microbial activity against 
Eschericha coli, Bacillus subtilis, Pseudomonas aeruginosa, Candida albicans, 
Trichophyton mentagrophytes and Cladosporium resinae. 
 
 
C torulosa (Voucher code: 2006-10) 
 
 Kingdom: Chromista 
 Phylum: Ochrophyta 
 Class:  Phaeophyceae 
 Order: Fucales 
 Family: Sargassaceae 
 Genus:  Cystophora 
 Species: torulosa 
 
Collected by Dr Sylvia Urban, Dr Rick Tinker, Dr Daniel Dias and Mrs Priyanka Reddy 
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6.2.3 Extraction and Isolation 
6.2.3.1 Preparation of the crude extract of C. torulosa for on-flow HPLC-
NMR analysis 
A frozen sample of C. torulosa (120 g) was extracted with 3:1 MeOH:DCM (1 L). This 
extract was decanted and concentrated under reduced pressure and sequentially 
partitioned (trituated) into DCM (748.4 mg) and MeOH (1.2 g) soluble fractions 
respectively. A portion of the DCM fraction (112 mg) was concentrated under reduced 
pressure and then re-solubilised using 100% HPLC-NMR grade CH3CN and then filtered 
through a 0.45 m PTFE membrane filter (HP045 Advantec, Japan). For on-flow HPLC-
NMR experiments 50 L (5,600 g) of the DCM extract was injected using the conditions 
described in Section 6.2.1. 
6.2.3.2 Preparation of the crude extract of C. torulosa for off-line isolation 
of secondary metabolites from C. torulosa 
A portion of the crude DCM extract (50 mg) that was used to conduct the HPLC-NMR 
analysis was also subjected to a single analytical reversed phase HPLC collection using 
the methods described in Section 6.2.1 to conduct a small scale isolation of the resorcinol 
derivatives (6.12, 6.14-6.19) and polyenes (6.1-6.2). This was undertaken to permit ESI-
MS or GC-MS analyses to be conducted for each of the secondary metabolites. After the 
dereplication exercise had been completed a further portion of the DCM extract (100 mg) 
was subjected to semi-preparative reversed phase HPLC in an effort to conduct off-line 
isolation and structure confirmation of the major component (6.14). Semi-preparative 
reversed phase HPLC was conducted using the methods as described in Section 6.2.1 to 
afford compound (6.14) (6.8 mg, 0.04%).  
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6.3 Results and Discussion 
The marine alga C. torulosa was extracted as outlined in Section 6.2.3.1. The analytical 
HPLC chromatogram showed the presence of what appeared to be one main class of 
compounds, while a second class was present as shown in Figure 6.1. This was 
concluded on the basis of the extracted UV profiles of the major compound and a minor 
late eluting compound as shown in Figure 6.2. On this basis, separate analytical HPLC 
methods were developed for each of the two classes of compounds present as described 
in Section 6.2.1. Chemical profiling methodologies were undertaken to identify firstly the 
classes of compounds present and to attempt to identify each component present. The 
methodology used for this chemical profiling is given in Scheme 6.1. 
 
 
Figure 6.1. Analytical HPLC chromatogram of the crude DCM extract of C. torulosa 
showing the presence of two distinct classes of compounds. 
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Scheme 6.1. Methodologies used for the chemical profiling of C. torulosa. 
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Figure 6.2. Extracted UV profiles of the two classes of compounds observed in the 
analytical HPLC analysis of the crude extract. 
 
On-flow HPLC-NMR chemical profiling of the earlier eluting compounds (Figure 6.3) was 
undertaken using the DCM extract and the method described in Section 6.2.1. 
On the basis of the 2D contour plot (Figure 6.3) obtained from the on-flow HPLC-NMR 
analysis of the crude extract, five secondary metabolites were detected. It could be 
concluded these five compounds were structurally related, as they had very similar WET-
1D 1H NMR spectra as illustrated in Figure 6.3, as well as similar UV profiles. In the on-
flow HPLC-NMR trace, the major compound (6.14) displayed the presence of a 
characteristic triplet methyl signal at  0.86, two aromatic singlets at  6.07 and  6.01, 
overlapping proton signals at  2.70 and  5.28, and signals consistent with a straight 
chain alkane between  2.40 and  1.25.  
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Figure 6.3. [A] On-flow 2D HPLC-NMR contour plot showing the presence of five structurally related compounds (6.14-6.18) and [B] Extracted 
WET-1D 1H NMR spectra of compounds (6.14-6.18) from the on-flow HPLC-NMR analysis.  
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On the basis of this information, the MarinLit database [8] was used to conduct searches 
of marine natural products reported from brown algae of the genus Cystophora that 
contained the diagnostic triplet methyl. This search profile is given in Figure 6.4 and it can 
be seen that six possible compounds were identified, with both resorcinol and 
phloroglucinol derivatives displaying the characteristic triplet methyl and aromatic moieties 
that were observed in the on-flow HPLC-NMR analysis. In the major compound the two 
aromatic protons present in the NMR spectrum integrated for a total of three aromatic 
protons. This indicated that the major compound was in fact a resorcinol derivative as 
given in Figure 6.5, which shows two different types of aromatic protons whilst 
phloroglucinol derivatives only possess one distinct aromatic proton chemical shift 
integrating for a total of two protons (Figure 6.5). Owing to the similarities for the 
remaining compounds observed in the HPLC-NMR analysis, this allowed the five early 
eluting secondary metabolites to be identified as being structurally related resorcinol 
derivatives. It was however not possible to unequivocally identify each resorcinol 
derivative definitively without a corresponding mass. 
A small-scale off-line isolation of the compounds present would be required in order to 
identify each of the resorcinol derivatives present. This would then permit either ESI-MS 
or GC-MS analyses to be conducted to obtain a most likely molecular mass of each of the 
compounds. For this, a single analytical reversed phase HPLC injection was undertaken 
to obtain sufficient quantities for ESI-MS. Upon acquisition of the ESI-MS it was observed 
that the negative mode ESI-MS of the major secondary metabolite (6.14) exhibited an [M-
H]- at an m/z of 339, indicating a molecular weight of 340 g/mol. This mass was added to 
the previous search criteria (ie. taxonomy and characteristic triplet methyl from the WET-
1D 1H NMR spectrum) in the MarinLit database. This reduced the number of possibilities 
to a single resorcinol derivative (6.14) as given in Figure 6.6.  
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Figure 6.4. [A] Search parameters input into the MarinLit database for the class of 
compounds observed from the HPLC-NMR analysis [B] Compounds in the MarinLit 
database that conform to the search parameters in [A]. 
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The off-line small scale analytical HPLC isolation resulted in a total of seven resorcinol 
derivatives being isolated, two more than were observed by HPLC-NMR analysis and 
were subjected to ESI-MS analysis. These two further secondary metabolites were 
present in the extract in very low quantities which is why they were not observed in the 
HPLC-NMR analysis. These two minor additional compounds had the same UV profile as 
the other resorcinol derivatives. 
 
HO
OH
OOH
HO OH
resorcinol phloroglucinol  
Figure 6.5. Resorcinol and phloroglucinol derivatives 
 
When the WET-1D 1H NMR and/or ESI-MS results for each of the minor resorcinol 
derivatives were entered into the MarinLit database without specifying the genus 
Cystophora so as to broaden the search profile, the compounds were identified as 6.12 
and 6.15-6.19 as shown in Figure 6.7 and Table 6.1 [293, 313]. The NMR and ESI-MS 
data for 6.14 was in accordance with the previously reported data for this compound [293]. 
The resorcinol derivatives (6.12, 6.14-6.15) had been previously reported from C. torulosa 
[293], while compounds (6.16-6.19) were described from the sponge Haliclona sp. [313]. 
The identity of the two compounds that were not visible from the HPLC-NMR analysis, but 
were isolated off-line for ESI-MS analysis (6.12 and 6.19), were tentatively assigned as 
indicated in Table 6.1. 
In order to validate and confirm the identity of these resorcinol derivatives, as determined 
from the chemical profiling of the crude extract by HPLC-NMR, it was decided that the 
major compound would be subjected to off-line purification by semi-preparative reversed 
phase HPLC followed by a complete characterisation by NMR spectroscopy and mass 
spectrometry. Following the purification, a complete 2D NMR characterisation of the major 
secondary metabolite was achieved as shown in Table 6.2.  
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Figure 6.6. [A] Search parameters from the MarinLit database for the major compound 
observed in the HPLC-NMR analysis including ESI-MS mass [B] Single compound from 
MarinLit that conformed to the search parameters entered for the major compound. 
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Figure 6.7. HPLC chromatogram showing the seven compounds (see Table 6.1) 
collected from the analytical HPLC, resulting in the identification of the resorcinols (6.12, 
6.14-6.19). 
 
Given the overlapped nature of the aliphatic region of compound 6.14, the 2D H2BC 
spectrum was utilised to confirm the results obtained from the gCOSY. The H2BC was 
especially useful in the assignment of positions 4, 5, 15 and 16, where overlap in the 1H 
NMR chemical shifts means that interpretation of the gCOSY spectrum is impossible due 
to this overlap. While the 1H NMR chemical shifts were overlapped, the corresponding 13C 
NMR chemical shifts were different, allowing positions 4, 5, 15 and 16 to be assigned. 
A comparison of the WET-1D 1H NMR spectrum and the off-line purified 1H NMR, along 
with the ESI-MS of the major component are provided in Figure 6.8. This showed that the 
on-line WET-1D 1H NMR was comparable to that of the off-line 1H NMR spectrum for this 
compound. The 2D NMR and ESI-MS unequivocally confirmed the structure of the major 
compound (6.14) deduced from the dereplication exercise.  
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Table 6.1. Resorcinol derivatives as isolated from the crude extract of C. torulosa with the 
seven compounds collected (see Figure 6.7), their mass from ESI-MS and their identified 
structure based on MarinLit database searching. 
Peak 
number 
Compound Mass Structure 
1 6.14 340 
HO
OH  
2 6.16 366 
HO
OH  
3 6.15 342 
HO
OH  
4 6.17 368 
HO
OH  
5 6.12* 292 
HO
OH  
6 6.18 344 
HO
OH  
7 6.19* 392 
HO
OH  
* not observed in the HPLC-NMR analysis 
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Table 6.2. 1H (500 MHz) and 13C (125 MHz) NMR spectroscopic data of the major 
resorcinol derivative (6.14) in CDCl3. 
Position H, J  C
a 
gCOSY gHMBC 
1 2.50, t, J = 7.5 Hz 35.6, t H-2 C-2, C-3, C-1’, C-2’, C-6’ 
2 1.60, tt, J = 7.5, 7.5 Hz 30.6, t H-1, H-3 C-1, C-3, C-4, C-1’ 
3 1.39, tt, J = 7.5, 7.5 Hz 29.1, t H-2, H-4 C-1, C-2, C-4, C-5 
4 2.09
b
, dt, J = 7.5, 7.0 Hz 27.0, t H-3, H-5 C-2, C-3, C-5, C-6 
5 5.37
b
, m
 
130.0, d H-4 C-3, C-4 
6 5.37
b
, m 127.8, d H-7 C-4 
7 2.83
b
, m 25.6
c
, t H-6, H-8 C-5, C-9 
8 5.37
b
, m 127.9
 c
, d H-7 - 
9 5.37
b
, m 128.4
 c
, d H-10 - 
10 2.83
b
, m 25.5
 c
, t H-9, H-11 C-8, C-12 
11 5.37
b
, m 128.5
 c
, d H-10 - 
12 5.37
b
, m 128.0
 c
, d H-13 - 
13 2.83
b
, m 25.6
 c
, t H-12, H-14 C-11, C-15 
14 5.37
b
, m 127.0, d H-13 C-16 
15 5.37
b
, m 132.1, d H-16 C-16, C-17 
16 2.07
b
, dq, J = 7.5, 7.0 Hz 20.5, t H-15, H-17 C-14, C-15, C-17 
17 0.97, t, J = 7.5 Hz 14.3, q H-16 C-15, C-16 
1’ - 145.8, s - - 
2’ 6.23, s 108.0, d - C-1. C-3’, C-4’, C-6’ 
3’ - 156.6, s - - 
4’ 6.17, bs 100.2, d - - 
5’ - 156.6, s - - 
6’ 6.23, s 108.0, d - C-1, C-2’, C-4’, C-5’ 
a Carbon assignments based on gHSQCAD and gHMBC NMR experiments 
b Signals overlapped 
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Figure 6.8. [A] WET-1D 1H NMR spectrum of the major compound (6.14) [B] Off-line 1H 
NMR (500 MHz, d6-DMSO) spectrum of compound (6.14) and [C] ESI-MS (negative 
mode) of compound (6.14). 
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The on-flow HPLC-NMR analysis of the later eluting compounds was undertaken using 
the method as described in Section 6.2.1, with the analytical HPLC obtained from HPLC 
method development given in Figure 6.9.  
 
 
Figure 6.9. Analytical HPLC chromatogram (100% CH3CN) of the later eluting compounds 
(6.1 and 6.2) in the crude extract of C. torulosa. 
 
It was evident that the resorcinol derivatives observed in the previous on-flow HPLC-NMR 
analysis were overlapped between 4 and 6 minutes as shown in Figure 6.9. On the basis 
of the on-flow HPLC-NMR analysis it was recognised that the two compounds were 
structurally related to one another as shown in Figure 6.10. These two compounds 
shared similarities with that of the resorcinol derivatives, primarily the presence of the 
triplet methyl signal in the 1H NMR spectrum, however they did not contain the aromatic 
protons at approximately  6.00 and  6.10. On the basis of the lack of these signals, it 
was suggested that these compounds were most likely of the polyene structure class.  
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Figure 6.10. [A] On-flow 2D HPLC-NMR contour plot showing the two structurally related compounds (6.1 and 6.2) and [B] Extracted WET-1D 
1H NMR spectra of compounds (6.1 and 6.2) from the on-flow HPLC-NMR analysis. 
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The MarinLit database confirmed that this structure class had been previously reported 
from the Cystophora genus. This is illustrated in Figure 6.4 whereby the triplet methyl 
signal and the Cystophora genus were entered into the search profile in the MarinLit 
database to give the polyene structure class (6.3) as one of the six possibilities.  
The crude extract was then subjected to analytical reversed phase HPLC in order to 
isolate a small quantity of the polyenes for GC-MS analysis using the method described in 
Section 6.2.1 (GC-MS of 6.1 shown in Figure 6.11). By searching the diagnostic triplet 
methyl NMR signal and the mass obtained from GC-MS the identification of the polyenes 
as (6.1 and 6.2) was possible as shown in Table 6.3. The WET-1D 1H NMR spectra and 
GC-MS analyses were comparable with the literature data [293]. However, the MarinLit 
database indicated that these compounds had not been reported from the genus 
Cystophora (see Figure 6.4), but it did indicate that the polyenes 6.1 and 6.2 had been 
previously reported from the brown alga Fucus vesiculosus [314] as shown in Figure 
6.12. A further review of the literature using Scifinder Scholar [22] established that these 
compounds had actually been isolated and reported from a Cystophora sp. [293]. 
 
Table 6.3. Polyenes isolated and identified from C. torulosa. 
Compound GC-MS Structure 
6.1 284  
6.2 286  
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Figure 6.11. Mass Spectrum obtained from the GC-MS of the polyene (6.1) 
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Figure 6.12. [A] Search parameters from the MarinLit database entered for the first polyene (6.1) observed in the HPLC-NMR analysis [B] 
Compounds in the MarinLit database that conform to the search parameters entered [C] Reference details of the polyene (6.1) matching search 
criteria and [D] The two polyenes (6.1 and 6.2) identified from matching reference. 
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The limitation of databases such as MarinLit, is that while the polyenes had actually been 
previously isolated from Cystophora spp. [293], only one polyene (6.3), that was not isolated 
in this study, appeared in the MarinLit database search profile for the triplet methyl signal 
observed for all of the compounds observed from HPLC-NMR analysis as given in Figure 
6.4. Anomalies such as this one are common when searching specific databases and it 
serves as a warning to be thorough with the use of various databases and to search the 
literature extensively for all possible compounds.  
Due to the fact that the secondary metabolites identified in this study were only isolated in 
minute quantities (sufficient for on-line HPLC-NMR and ESI-MS or GC-MS), together with the 
fact that the major compound (6.14) was found to degrade over time, these compounds were 
not evaluated for any biological activity. 
 
6.4 Concluding remarks 
This study utilised on-line HPLC-NMR as a means of chemical profiling a crude DCM soluble 
extract of the brown algae C. torulosa. On the basis of two separate on-flow HPLC-NMR 
analyses of the crude extract, it was concluded that two classes of compounds were present 
in the crude extract. Analysis of the earlier eluting compounds led to the partial identification 
of the major component, namely the resorcinol derivative (6.14) with the assistance of the 
MarinLit database, while the additional compounds present also possessed similar 1H NMR 
spectra, suggestive of a group of structurally related resorcinol derivatives being present. 
Analysis of the later eluting compounds allowed for the partial identification of the two 
compounds as being of the polyene structure class. Subsequent small-scale analytical HPLC 
collections and analyses of these two classes of compounds permitted the ESI-MS or GC-
MS spectra to be obtained, which, in turn allowed for the determination of the compounds as 
being the polyenes (6.1 and 6.2), and the resorcinol derivatives (6.12, 6.14-6.19) in 
conjunction with the use of the MarinLit database. To confirm that the dereplication exercise 
was successful semi-preparative reversed phase HPLC was employed to obtain sufficient 
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quantities of the major resorcinol derivative (6.14) that permitted a complete 2D NMR 
assignment of this compound to be carried out. All the compounds identified in this 
Cystophora sp. had been previously reported from other Cystophora spp. 
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Chapter 7  
Experimental 
7.1 General Experimental 
All organic solvents used were Analytical Reagent (AR), UV Spectroscopic, HPLC or HPLC-
NMR grades, with milli-Q water also used. Silica flash chromatography was carried out with 
Merck™ silica gel (60-120 mesh), using a 20% stepwise solvent elution system from 100% 
hexane to 100% DCM to 100% EtOAc and finally 100% MeOH, unless otherwise specified. 
C18 Vacuum Liquid Chromatography (VLC) was performed using a 25% stepwise elution 
using 100% H2O to 100% MeOH and finally to 100% DCM. Size exclusion chromatography 
was performed using Sephadex LH-20 (Sigma™) using 100% MeOH as the eluent. Melting 
points (uncorrected) were determined on a Gallenkamp Melting Point apparatus. All % yields 
of compounds isolated were calculated using dry weight of the organism. 
7.1.1 Spectroscopic Analyses 
Optical rotation measurements were carried out using either a Jasco DIP-1000 digital 
polarimeter with 1.2 mL cell, set to Na 589 nm wavelength, or a Perkin-Elmer 241 MC 
polarimeter, at the sodium wavelength of 589 nm, a slit width of 1 nm and an integral of 1 
second per reading. UV-Vis spectra were obtained on a Varian Cary 50 Bio 
Spectrophotometer or on a Varian 1C Spectrophotometer, while UV profiles were also 
Marine and Terrestrial Natural Products Discovery 
209 
extracted from HPLC (PDA detection) in the way of a 2D contour plot (both from a Dionex 
analytical HPLC system or a Varian semi-preparative HPLC system). IR spectra were 
obtained as a film using NaCl discs (CHCl3 or dried EtOH as solvent, then solvent 
evaporated) on a Perkin-Elmer, Spectrum One FTIR Spectrometer. NMR spectra (1H, 500 
MHz and 13C, 125 MHz) were acquired on a 500 MHz Varian INOVA NMR Spectrometer, 
using referencing for each of the solvent signals, CDCl3 ( 7.26, 77.0 ppm), CD3OD ( 3.31, 
49.0 ppm), d6-acetone ( 2.05) and d6-DMSO ( 2.50, 39.5 ppm). 1D and 2D NMR included 
1H, 13C, DEPT, 1D NOE, gCOSY, gHSQCAD, gHMBC, NOESY, ROESY, TOCSY and 
CIGAR experiments. ESI-MS analyses were conducted on a Micromass Platform II Mass 
Spectrometer, equipped with a LC-10AD Shimadzu solvent pump, using a solvent system of 
50% CH3CN/H2O at a flow rate of 0.2 mL/min. The analyses were conducted in both positive 
and negative ionisation modes and a cone voltage of 20 V-30 V. HR-ESI-MS was carried out 
on an Agilent 6200 Series TOF system (ESI operating conditions of 8 L/min N2, 350°C drying 
gas and 4000 V capillary voltage) with an Agilent 1200 Series LC solvent pump (100% 
CH3OH at a flow rate of 0.1 mL/min) in positive or negative ionisation modes (where the 
instrument was calibrated with the Agilent Tuning Mix using purine and HP-0921 as 
reference compounds). GC-MS analyses were carried out on two instruments, the first being 
a Hewlett Packard 56890/5973 GC-MS Mass Selective Detector using a BPX 5 30 m x 0.25 
mm ID df of 0.25  GC column at a constant column flow of 1.0 mL/min, with a temperature 
program (0-1 min 70°C, 22-27 min 280°C). The parameters for the GC included an injector 
temperature of 250°C, detector temperature of 260°C with injector port set to standard 
split/splitless mode, while the mass spectrometer was set to electron impact (EI) analysing 
over the mass range of m/z 40-600. The second GC-MS system utilised was a Varian Saturn 
2200 GC-MS-MS and Varian CP-3800 Gas Chromatograph using a Varian VF-5ms 30 m x 
0.25 mm ID df of 0.25  GC column at a constant flow of 1.0 mL/min, using a temperature 
gradient (0-1 min 60°C, 20-30 min 260°C). The GC parameters included an injector 
temperature of 250°C, with the injector port using the standard split/splitless mode, while the 
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mass spectrometer was set to electron impact (EI) analysing over the mass range of m/z 40-
400. HR-GC-MS analysis was carried out on a Waters GCT Premier GC-Time-of-Flight 
(TOF) system using a BPX5 30 m x 0.25 mm ID column with a column flow of 1.0 mL/min 
and a temperature method (0-0.5 min 40°C, 18-24 min 320°C). The GC parameters included 
an injector temperature of 250°C with injector port set to standard split/splitless mode, while 
mass spectrometer was set to the electron impact (EI) analysing over the mass range of m/z 
40-500. Crystallographic diffraction data were collected with an Oxford SuperNova 
diffractometer using Cu radiation ( = 1.54184 Å) by Dr Jonathan White at the University of 
Melbourne. Data were reduced using the CrysalisPRO software. The temperature of the data 
collection was maintained at 130 K, using an Oxford Cryostream cooling device. The 
structure was solved by direct methods, and difference Fourier synthesis and was refined on 
F2 (SHELXL-97) [195]. Thermal ellipsoid plot was generated using program ORTEP-3 [196] 
integrated within the WINGX program suite [197]. 
7.1.2 Analytical and semi-preparative HPLC 
All analytical and semi-preparative HPLC analyses were conducted in the reversed phase 
(RP) mode. Analytical HPLC analyses were performed on a Dionex P680 pump with a 
PDA100 UV detector, using Chromeleon software. All analytical HPLC was initially 
conducted using the gradient (0-2 min 10% CH3CN/H2O; 14-24 min 75% CH3CN/H2O; 26-30 
min 100% CH3CN; 32-40 min 10% CH3CN/H2O) as outlined in Figure 7.1, unless otherwise 
stated. These analyses were carried out using a Phenomenex Prodigy ODS (3) C18 100Å 
250 mm x 4.6 mm (5 ) column, Phenomenex Gemini ODS (3) C18 100Å 250 x 4.6 mm (5 ) 
or a Phenomenex Luna ODS (3) C18 100Å 250 mm x 4.6 mm (5 ) column and a flow rate of 
1.0 mL/min. Semi-preparative HPLC was conducted on two instruments, the first being a 
Varian Prostar 210 pump equipped with a Varian Prostar 355 PDA detector using STAR LC 
Workstation Version 6.0 software, with a Phenomenex Prodigy ODS (3) C18 100Å 250 mm x 
10 mm (5 ) column and a flow rate of 3.5 mL/min. The second semi-preparative HPLC 
system used was a Dionex P680 pump with a UVD340U PDA detector and a Foxy Jr. 
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fraction collector. The HPLC column was a Phenomenex Gemini C18 100Å 250 mm x 4.6 mm 
(5 ) column. 
 
 
Figure 7.1. Analytical HPLC gradient used for all initial analytical HPLC analyses. 
 
7.1.3 HPLC-NMR 
HPLC-NMR solvents used were HPLC-NMR grade CH3CN (Chromasol V
®), and D2O 
(99.9%). HPLC-NMR analyses were carried out on a Varian Unity INOVA 500 MHz NMR 
Spectrometer, with a Varian 1H[13C] pulsed field gradient flow-probe with a 60 L flow cell, 
connected to a Varian Prostar 230 pump with a Varian Prostar 335 PDA detector and a 
Prostar AS430 Autosampler (injection volume of 50 L). The CORBA™ server 
communication was used between the HPLC pump and NMR and then operated using the 
VNMRJ software (version VNMRJ 2.1b). All HPLC-NMR analyses were conducted on a 
Varian Polaris C18 150 mm x 4.6 mm (5 ) column at either a flow rate of 0.8 mL/min or 1.0 
mL/min. Varian WET solvent suppression [315] was used to supress the CH3CN and its 
satellites, as well as the residual water peaks arising from D2O. 
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7.1.4 Biological Activity Assays 
For all biological activity assays, crude extracts were tested at 50 mg/mL and individual 
compounds tested at 1 mg/mL unless otherwise specified. The three types of activity 
assessed included anti-tumour (P388 Murine Leukaemia cell line), anti-viral (Herpes simplex 
type 1 and Polio type 1) and anti-microbial (three anti-bacterial and three anti-fungal assays). 
All activity studies were conducted at the University of Canterbury, Christchurch, New 
Zealand, by Ms Gill Ellis. 
7.1.4.1 Anti-tumour (P388 Murine Leukaemia Cell Line) Assay 
Anti-tumour activity was determined by use of a two-fold dilution series of the crude extract or 
compound, and incubated for 72 hours with P388 cells. The concentration required of the 
given sample was determined using the absorbance values from when yellow MTT 
tetrazolium dye is reduced by healthy cells to purple MTT formazan as shown in Figure 7.2, 
expressed as an IC50 (ng/mL). This is achieved by determination of the concentration 
required to inhibit P388 cell growth by 50% compared to the control cells. For referencing 
purposes, the standard P388 inhibitor mitomycin C (M0503) was used, which has an IC50 
value of 0.183 µg/mL. 
 
 
Figure 7.2. Micro-titre (96 well) plate with control and test dilutions showing the colour 
change due to inhibition. 
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7.1.4.2 Anti-microbial Activity Assays 
The three anti-bacterial assays included inhibition of Escherichia coli (G-ve ATCC 25922), 
Bacillus subtilis (G+ve ATCC 19659) and Pseudomonas aeruginosa (G-ve ATCC 27853), 
while the three anti-fungal assays assessed inhibition towards Candida albicans (ATCC 
14053), Trichophyton mentagrophytes (ATCC 28185) and Cladosporium resinae. Both anti-
bacterial and anti-fungal activities were determined using the same procedure. The inoculum 
was prepared when a loop of the specific assay cells were transferred from a fresh culture in 
10 mL of sterile water. After vortexting the vial until a cell density of 108 colony forming units 
per mL was formed, which was done by comparison with 5% BaCl2 standard. The inoculated 
sample was then added to 100 mL of Müller Hinton or Potato Dextrose agar and mixed, 
allowing for a final cell density of 107 colonies per mL of solution. Five mL of this solution was 
added to an 85 mm petri dish and allowed to cool. The crude extracts and compounds were 
pipetted onto 6 mm discs of filter paper and allowed to dry. Upon drying the discs were 
placed on the petri dishes, as well as controls, and incubated for 24 hours. The zone of 
inhibition for each assay was determined in millimetres from the edge of the disc as shown in 
Figure 7.3. For referencing of anti-bacterial activity, gentamicin (10 g) (Difco 6423890) 
displays zones of inhibition of 10 mm against E. coli and P. aeruginosa, while 
chloramphenicol (30 g) (Difco 61338910) displays a zone of inhibition of 12 mm against 
Bacillus subtilis. For anti-fungal activity, nystatin (100 IU units) (Difco 6753890) displays 
zones of inhibition of 12 mm, 6 mm and 10 mm against Candida albicans, Trichophyton 
mentagrophytes and Cladosporium resinae respectively. 
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Figure 7.3. Zones of inhibition of anti-microbial assays. 
 
7.1.4.3 Anti-viral (Herpes simplex virus and Polio virus) Assays 
Anti-viral activity was established by pipetting the crude extract or compound on a 6 mm 
diameter filter paper disc and the solvent evaporated. The disc was then placed onto BSC-1 
cells (African Green Monkey kidney) that had been infected with the Herpes simplex virus 
type 1 or RNA Polio virus type 1 and incubated. The radius of the anti-viral activity and/or 
cytotoxic zones, as well as the type of cytotoxicity were examined with an inverted 
microscope after 24 hours. As a reference, didemnum B (30 L of 0.005 mg/mL) displays 
activity against both Herpes simplex and Polio viruses at this concentration. 
7.1.5 Miscellaneous 
7.1.5.1 Photography 
All photos of organisms were taken by Dr Sylvia Urban, Mr Allan Tinker, Dr Rick Tinker, Dr 
Gerald Kraft and Mr Michael Timmers. 
7.1.5.2 Chemical Structures  
Structures were drawn using ChemDraw Ultra Version 10.0, for details see 
http://www.cambridgesoft.com. 
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7.1.5.3 Crystal structure data analysis 
For crystal structure data obtained, Mercury 3.0 was used to visualise the structure in 3D. 
For further information regarding the Mercury program, see 
http://www.ccdc.cam.ac.uk/free_services/mercury/. Associate Professor Jonathan White 
(School of Chemistry, The University of Melbourne, Victoria, 3010, Australia) conducted all 
single X-ray analyses and lodged the cif data with the Cambridge Crystallographic Data 
Centre (CCDC). 
 
7.2 Chapter 2 Experimental 
7.2.1 Chapter 2 HPLC-NMR Characterisation (from stop-flow HPLC-NMR) 
Trans-tiliroside (2.12) 
HPLC-NMR (WET-1D, 500 MHz,  7.88 (2H, d, J = 9 Hz, H2′/H6′), 7.24 (1H, d, J = 16 Hz, 
H7′′′), 7.21 (2H, d, J = 8.5 Hz, H2′′′/H6′′′), 6.83 (2H, d, J = 9 Hz, H3′/H5′), 6.76 (2H, d, J = 8.5 
Hz, H3′′′/H5′′′), 6.20 (1H, d, J = 1.5 Hz, H8), 6.07 (1H, d, J = 1.5 Hz, H6), 5.92 (1H, d, J = 16 
Hz, H8′′′), 5.03 (1H, d, J = 7.5 Hz, H1′′), 4.11 (2H, d, J = 5.5 Hz, H6′′), 3.38 (2H, m, H3′′/H5′′), 
3.23 (1H, m, H2′′), 3.21 (1H, m, H4′′). 
 
Cis-tiliroside (2.12) 
HPLC-NMR as a mixture with 2.12 in a ratio of 1:4 [compound 2.13:compound 2.12] (WET-
1D, 500 MHz, ) 7.83 (d, J = 9 Hz, H2′/H6′), 6.62 (d, J = 14.5 Hz, H7′′′), 6.60 (d, J = 9 Hz, 
H3′/H5′), 6.45 (s, H8), 6.18 (s, H6), 5.41 (d, J = 14.5 Hz, H8′′′), 4.96 (d, J = 7.5 Hz, H1′′), 4.06 
(d, J = 5 Hz, H6′′), 3.43-3.20 (m, H2′′/H3′′/H4′′/H5′′), remaining signals overlapped with 2.12 
or suppressed, while integration was not possible. 
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4′-Methoxy-trans-tiliroside (2.14) 
HPLC-NMR (WET-1D, 500 MHz, ) 8.02 (d, J = 8.5 Hz, H2′/H6′), 7.33 (d, J = 14.5 Hz, H7′′′), 
7.31 (d, J = 7.5 Hz, H2′′′/H6′′′), 6.97 (d, J = 8.5 Hz, H3′/H5′), 6.83 (d, J = 7.5 Hz, H3′′′/H5′′′), 
6.33 (s, H8), 6.18 (s, H6), 6.01 (d, J = 14.5 Hz, H8′′′), 5.13 (d, J = 7.5 Hz, H7′′′), 3.72 (s, 4′-
OCH3), 3.44 (m), 3.25 (m), all other signals suppressed, while integration was not possible. 
 
7.2.2 Chapter 2 Off-line Characterisation  
Trans-tiliroside (2.12), also known as kaempferol-3-O-β-D-(6-O-trans-p-coumaroyl)-
glucopyranoside  
O
O
HO
OH
O
O
OH
HO
OH
OH
O
O
HO
2
3'''
1'''
7'''
9'''
8
6
6''
1''
4'2'
 
 
Isolated as yellow fibrous crystals; m.p. 260-265°C; []21
D
 -33° (c 0.164, MeOH); IR (film) 
maxcm
-1: 3367, 1655, 1605, 1509, 1443, 1359, 1260, 1207, 1179; UV (EtOH) max (nm) 205, 
229 shoulder (sh), 269, 300 sh, 317, 350 sh ( = 3924, 2488, 2049, 2400, 2665, 1434 
respectively); 1H NMR (500 MHz, d6-DMSO) and 
13C NMR (125 MHz, d6-DMSO) are detailed 
in Table 2.1; 1H NMR present as a mixture with 2.13 (500 MHz, CD3OD, ) 7.99 (2H, d, J = 9 
Hz, H-2′/H-6′), 7.40 (1H, d, J = 16 Hz, H-7′′′), 7.32 (2H, d, J = 9 Hz, H-2′′′/H-6′′′), 6.82 (2H, d, J 
= 9 Hz, H-3′/H-5′), 6.80 (2H, d, J = 9 Hz, H-3′′′/H-5′′′), 6.32 (1H, s, H-8), 6.13 (1H, s, H-6), 
6.07 (1H, d, J = 16 Hz, H-8′′′), 5.24 (1H, d, J = 7 Hz, H-1′′), 4.29 (1H, d, J = 11.5 Hz, H-6b′′), 
4.19 (1H, m, H-6a′′), 3.44* (1H, m, H-2′′), 3.43* (1H, m, H-3′′), 3.39* (1H, m, H-5′′), 3.31* (1H, 
m, H-4′′) * indicates overlapping signals; 13C NMR (obtained from gHSQCAD and gHMBC 
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NMR experiments, CD3OD, ppm) 161.4 (C, C-4′), 161.0 (C, C-4′′′), 159.1 (C, C-2), 146.5 (CH, 
C-7′′′), 131.9 (CH, C-2′/C-6′), 130.9 (CH, C-2′′′/C-6′′′), 126.9 (C, C-1′′′), 116.4 (CH, C-3′′′/C-
5′′′), 115.8 (CH, C-3′/C-5′), 114.4 (CH, C-8′′′), 103.7 (CH, C-1′′), 99.9 (CH, C-6), 94.6 (CH, C-
8), 77.6 (CH, C-3′′), 75.5 (CH, C-2′′/C-5′′), 71.4 (CH, C-4′′), 63.9 (CH2, C-6′′), all other carbons 
were not detected; ESI-MS (negative): m/z 593 [M-H]-, (positive): m/z 595 [M+H]+, 617 
[M+Na]+; HR-ESI-MS displayed an m/z at 593.1308 [M-H]- (calcd. for C30H25O13: m/z 
593.1295) and an m/z at 595.1440 [M+H]+ (calcd. for C30H27O13: m/z 595.1452).  
 
Cis-tiliroside (2.13) also known as kaempferol-3-O-β-D-(6-O-cis-p-coumaroyl)-
glucopyranoside 
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Isolated as a yellow powder; 1H NMR (500 MHz, d6-DMSO) and 
13C NMR (125 MHz, d6-
DMSO) are detailed in Table 2.2; 1H NMR present as a mixture with 2.12 (500 MHz, CD3OD, 
) 7.96 (2H, d, J = 9 Hz, H-2′/H-6′), 7.51 (2H, d, J = 8.5 Hz, H-2′′′/H-6′′′), 6.82 (2H, d, J = 9 Hz, 
H-3′/H-5′), 6.69 (1H, d, J = 12.5 Hz, H-7′′′), 6.67 (2H, d, J = 8.5 Hz, H-3′′′/H-5′′′), 6.32 (1H, s, 
H-8), 6.19 (1H, s, H-6), 5.50 (1H, d, J = 12.5 Hz, H-8′′′), 5.20 (1H, d, J = 7.5 Hz, H-1′′), 4.29 
(1H, d, J = 11.5 Hz, H-6b′′), 4.19 (1H, m, H-6a′′), 3.44* (1H, m, H-2′′), 3.43* (1H, m, H-3′′), 
3.39* (1H, m, H-5′′), 3.31* (1H, m, H-4′′) * indicates overlapping signals; 13C NMR (obtained 
from gHSQCAD NMR experiment present as a mixture with 2.12 in a ratio of 1:2 [compound 
2.13: compound 2.12], CD3OD, ppm): 145.0 (CH, C-7′′′), 133.5 (CH, C-2′′′/C-6′′′), 131.9 (CH, 
C-2′/C-6′), 115.8 (CH, C-3′/C-5′), 115.8 (CH, C-8′′′), 115.4 (CH, C-3′′′/C-5′′′), 103.6 (CH, C-1′′), 
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99.7 (CH, C-6), 94.5 (CH, C-8), 77.6 (CH, C-3′′), 75.4 (CH, C-2′′/C-5′′), 71.4 (CH, C-4′′), 63.9 
(CH2, C-6′′), all other carbons were not detected; ESI-MS (negative): m/z 593 [M-H]
-, 
(positive): m/z 595 [M+H]+, 617 [M+Na]+. 
 
4′-Methoxy-trans-tiliroside (2.14) also known as kaempferol-4′-methyl ether 3-O-β-D-(6-O-
trans-p-coumaroyl)-glucopyranoside  
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Isolated as a yellow powder; 1H NMR (500 MHz, d6-DMSO, ) 12.51 (brs, 5-OH), 8.06 (2H, d, 
J = 8 Hz, H-2′/H-6′), 7.40 (2H, d, J = 8 Hz, H-2′′′/H-6′′′), 7.35 (1H, d, J = 16 Hz, H-7′′′), 6.99 
(2H, d, J = 8 Hz, H-3′/H-5′), 6.78 (2H, d, J = 8 Hz, H-3′′′/H-5′′′), 6.38 (1H, s, H-8), 6.17 (1H, d, 
J = 16 Hz, H-8′′′), 6.15 (1H, s, H-6), 5.46 (1H, m, 2′′-OH), 5.45 (1H, d, J = 8 Hz, H-1′′), 5.26 
(m, 4′′-OH), 5.22 (m, 3′′-OH), 4.28 (1H, d, J = 11.5 Hz, H-6b′′), 4.02 (1H, dd, J = 5.0, 11 Hz, 
H-6a′′), 3.70 (3H, s, 4′-OCH3), 3.37* (1H, m, H-5′′), 3.28* (1H, m, H-3′′), 3.25* (1H, m, H-4′′), 
3.23* (1H, m, H-2′′) * indicates overlapping signals; 13C NMR (125 MHz, d6-DMSO, ppm): 
166.2 (C, C-9′′′), 164.7 (C, C-7), 161.3 (C, C-4′), 161.1 (C, C-5), 159.8 (C, C-4′′′), 156.4 (C, C-
9), 156.1 (C, C-2), 144.4 (CH, C-7′′′), 133.4 (C, C-3), 130.4 (CH, C-2′/C-6′), 130.0 (CH, C-
2′′′/C-6′′′), 125.0 (C, C-1′′′), 122.4 (C, C-1′), 115.5 (CH, C-3′′′/C-5′′′), 113.4 (CH, C-8′′′), 113.3 
(CH, C-3′/C-5′), 103.9 (C, C-10), 101.8 (CH, C-1′′), 98.7 (CH, C-6), 93.6 (CH, C-8), 75.7 (CH, 
C-3′′), 73.8 (CH, C-2′′/C-5′′), 69.5 (CH, C-4′′), 62.4 (CH2, C-6′′), 54.9 (CH3, 4′-OCH3), not 
detected (C-4); 1H NMR present as a mixture with 2.15 (500 MHz, CD3OD, ) 8.08 (2H, d, J = 
9 Hz, H-2′/H-6′), 7.42 (1H, d, J = 16 Hz, H-7′′′), 7.35 (2H, d, J = 9 Hz, H-2′′′/H-6′′′), 6.93 (2H, 
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d, J = 9 Hz, H-3′/H-5′), 6.82 (2H, d, J = 9 Hz, H-3′′′/H-5′′′), 6.35 (1H, d, J = 1.5 Hz, H-8), 6.16 
(1H, d, J = 1.5 Hz, H-6), 6.10 (1H, d, J = 16 Hz, H-8′′′), 5.26 (1H, d, J = 6.5 Hz, H-1′′), 4.30 
(1H, d, J = 11.5 Hz, H-6b′′), 4.19 (1H, m, H-6a′′), 3.72 (3H, s, 4’-OCH3), 3.46* (1H, m, H-2′′), 
3.44* (1H, m, H-3′′), 3.41* (1H, m, H-5′′), 3.38* (1H, m, H-4′′) * indicates overlapping signals; 
13C NMR (obtained from gHSQCAD and gHMBC NMR experiments, CD3OD, ppm): 166.3 (C, 
C-9′′′), 165.6 (C, C-7), 162.6 (C, C-4′), 160.6 (C, C-4′′′), 158.5 (C, C-2) , 157.9 (C, C-9), 146.1 
(CH, C-7′′′), 131.7 (CH, C-2′/C-6′), 130.9 (CH, C-2′′′/C-6′′′), 126.4 (C, C-1′′′), 123.4 (C, C-1′), 
116.5 (CH, C-3′′′/C-5′′′), 114.5 (CH, C-8′′′), 114.3 (CH, C-3′/C-5′), 103.8 (CH, C-1′′), 99.7 (CH, 
C-6), 94.6 (CH, C-8), 77.5 (CH, C-3′′), 75.4 (CH, C-2′′/C-5′′), 71.2 (CH, C-4′′), 63.7 (CH2, C-
6′′), 55.5 (CH3, 4′-OCH3), C3, C4, C5 and C10 not detected; ESI-MS (negative): m/z 607 [M-
H]-. 
 
4′-Methoxy-cis-tiliroside (2.15), kaempferol-4′-methyl ether-3-O-β-D-(6-O-cis-p-coumaroyl)-
glucopyranoside  
 
 
 
Isolated as a yellow powder; IR (film) maxcm
-1: 3342, 2919, 2851, 1651, 1605, 1510, 1456, 
1371, 1358, 1302, 1259, 1181; UV (MeOH) max (nm) 204, 224 sh, 268, 299 sh, 313, 354 sh 
( = 4522, 2899, 2254, 2238, 2389, 1357 respectively); 1H NMR (500 MHz, d6-DMSO, ): 
12.48 (brs, 5-OH), 8.03 (2H, d, J = 9 Hz, H-2′/H-6′), 7.55 (2H, d, J = 8 Hz, H-2′′′/H-6′′′), 6.99 
(2H, d, J = 8.5 Hz, H-3′/H-5′), 6.67* (1H, H-7′′′), 6.67* (2H, d, J = 9 Hz, H-3′′′/H-5′′′), 6.30 (1H, 
O
O
HO
OH
O
O
OH
HO
OH
OCH3
O
O
OH
2
3'''
1'''
7''' 9'''
8
6
6''
1''
4'2'
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s, H-8), 6.14 (1H, s, H-6), 5.49 (1H, d, J = 13.5, H-8′′′), 5.48 (1H, m, 2′′-OH), 5.38 (1H, d, J = 
7.5 Hz, H-1′′), 5.26 (m, 4′′-OH), 5.20 (m, 3′′-OH), 4.15 (1H, m, H-6b′′), 4.06 (1H, dd, J = 5.5, 
11.5 Hz H-6a′′), 3.77 (3H, s, 4′-OCH3), 3.36* (1H, m, H-5′′), 3.24* (1H, m, H-3′′), 3.23* (1H, m, 
H-2′′), 3.16* (1H, m, H-4′′) * indicates overlapping signals; 13C NMR (obtained from 
gHSQCAD and gHMBC NMR experiments, d6-DMSO, ppm): 165.5 (C, C-9′′′), 161.2 (C, C-
4′), 158.8 (C, C-4′′′), 156.7 (C, C-9), 156.0 (C, C-2), 143.5 (CH, C-7′′′), 133.3 (C, C-3), 132.5 
(CH, C-2′′′/C-6′′′), 130.4 (CH, C-2′/C-6′), 125.3 (C, C-1′′′), 122.4 (C, C-1′), 114.5 (CH, C-3′′′/C-
5′′′), 114.3 (CH, C-8′′′), 113.3 (CH, C-3′/C-5′), 103.5 (C, C-10), 101.2 (CH, C-1′′), 99.0 (CH, C-
6), 93.8 (CH, C-8), 75.9 (CH, C-3′′), 73.9 (CH, C-2′′), 73.7 (CH, C-5′′), 69.5 (CH, C-4′′), 62.4 
(CH2, C-6′′), 55.2 (CH3, 4′-OCH3), not detected (C-4, C-5, C-7); 
1H NMR present as a mixture 
with 2.14 in a ratio of 1:2 [compound 2.15: compound 2.14] (500 MHz, CD3OD, ) 8.04 (2H, 
d, J = 9 Hz, H-2′/H-6′), 7.55 (2H, d, J = 8.5 Hz, H-2′′′/H-6′′′), 6.93 (2H, d, J = 9 Hz, H-3′/H-5′), 
6.72 (1H, d, J = 13 Hz, H-7′′′), 6.69 (2H, d, J = 8.5 Hz, H-3′′′/H-5′′′), 6.35 (1H, d, J = 2 Hz, H-
8), 6.21 (1H, d, J = 2 Hz, H-6), 5.53 (1H, d, J = 13 Hz, H-8′′′), 5.17 (1H, d, J = 7 Hz, H-1′′), 
4.17 (2H, m, H-6′′), 3.77 (3H, s, 4’-OCH3), 3.30-3.47* (4H, m, H-2′′/H-3′′/H-4′′/H-5′′) * indicates 
overlapping signals; 13C NMR present as a mixture with 2.14 in a ratio of 1:2 [compound 
2.15: compound 2.14] (obtained from gHSQCAD NMR experiment, CD3OD, ppm): 145.1 
(CH, C-7′′′), 133.6 (CH, C-2′′′/C-6′′′), 131.7 (CH, C-2′/C-6′), 115.6 (CH, C-8′′′), 115.4 (CH, C-
3′′′/C-5′′′), 114.3 (CH, C-3′/C-5’), 104.0 (CH, C-1′′), 99.7 (CH, C-6), 94.6 (CH, C-8), 63.7 
(CH2, C-6′′), 54.3 (CH3, 4′-OCH3), all other carbons were not detected; HR-ESI-MS 
(negative): m/z at 607.1461 [M-H]- (calcd. for C31H27O13: m/z 607.1452); ESI-MS (negative): 
m/z 607 [M-H]-, (positive): m/z 609 [M+H]+, 630 [M+Na]+. 
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7.3 Chapter 3 Experimental 
7.3.1 Chapter 3 HPLC-NMR Characterisation (from on-flow and stop-flow 
HPLC-NMR) 
Haemodorone (3.41)  
HPLC-NMR (WET-1D, 500 MHz, 60:40 CH3CN:D2O, on-flow HPLC-NMR, ) 8.31 (1H, d, J = 
7.5 Hz), 8.19 (1H, s), 7.45 (1H, d, J = 7.5 Hz), 7.37 (3H, m), 7.33 (2H, m), 3.16 (3H, s). 
 
Haemoxiphidone (3.42) also known as 5-Hydroxy-2,6-dimethoxy-9-phenyl-phenalen-1-one 
HPLC-NMR (WET-1D, 500 MHz, 60:40 CH3CN:D2O, on-flow HPLC-NMR, ) 8.35 (1H, d, J = 
8.0 Hz), 7.46 (1H, s), 7.45 (1H, d, J = 8.0 Hz), 7.35 (2H, d, J = 7.5, 7.5 Hz), 7.32 (1H, dd, J = 
7.0, 7.0 Hz), 7.26 (2H, d, J = 8.0 Hz), 6.96 (1H, s), 3.91 (3H, s), 3.73 (3H, s). 
 
5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione (3.44) 
HPLC-NMR (WET-1D, 500 MHz, 80:20 CH3CN:D2O, stop-flow HPLC-NMR, ): 8.39 (1H, d, J 
= 7.5 Hz), 8.38 (1H, s), 7.48 (1H, d, J = 7.5 Hz), 7.38 (3H, m), 7.29 (2H, m), 3.95 (3H, s), 
3.27 (3H, s). 
 
Haemodordioxolane (3.45)  
HPLC-NMR (WET-1D, 500 MHz, 80:20 CH3CN:D2O, stop-flow HPLC-NMR, ): 8.43 (1H, d, J 
= 7.5 Hz), 8.17 (1H, s), 7.55 (1H, d, J = 7.5 Hz), 7.43 (5H, s), 6.03 (2H, s). 
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7.3.2 Chapter 3 Off-line Characterisation  
5-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (3.2) 
O
O
OCH3
12c
12a
12
10b
10a
9
6a
5a
5
3a
1
 
 
Isolated as an orange powder; IR (film) max cm
-1: 3423, 2956, 2922, 2851, 1608, 1575, 1558, 
1465, 1407, 1381, 1309; UV (c, 0.038 mg/mL in EtOH) max (nm) 233, 278, 313, 522 ( = 
5021, 1887, 1097, 1761 respectively); 1H NMR (500 MHz, d6-DMSO, ) 8.55 (1H, d, J = 8.0 
Hz, H-12), 8.46 (1H, d, J = 8.0 Hz, H-10), 8.42 (1H, d, J = 8.0 Hz, H-11), 8.22 (1H, s, H-4), 
8.09 (1H, d, J = 10.0 Hz, H-3), 7.67 (1H, ddd, J = 8.0, 7.5, 1.0 Hz, H-8), 7.59 (1H, d, J = 8.5 
Hz, H-7), 7.46 (1H, dd, J = 8.0, 7.5 Hz, H-9), 6.75 (1H, d, J = 10.0 Hz, H-2), 4.10 (3H, s, 5-
OCH3). 
13C (125 MHz, d6-DMSO, ppm) 183.2 (s, C-1), 151.7 (s, C-6a), 142.6 (s, C-5), 141.5 
(s, C-5a), 141.0 (d, C-3), 133.1 (s, C-10b), 132.9 (d, C-8), 131.1 (d, C-12), 127.6 (d, C-2), 
127.5 (s, C-12a), 125.6 (d, C-9), 125.0 (d, C-10), 121.9 (s, C-12b), 120.9 (d, C-4), 120.1 (s, 
C-3a), 119.7 (s, C-12c), 119.2 (s, C-10a), 118.4 (d, C-7), 117.0 (d, C-11), 57.3 (q, 5-OCH3); 
ESI-MS (positive): m/z 301 [M+H]+. 
 
5-hydroxy-2-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (3.4) 
O
O
OH
H3CO
12c
12a
12
10b
10a
9
6a
5a
5
3a
1
 
 
Isolated as a purple powder; IR (film) max cm
-1: 3346, 3219, 2922, 2851, 1731, 1665, 1608, 
1575, 1558, 1454, 1391, 1366, 1219; UV (c, 0.035 mg/mL in EtOH) max (nm) 237, 255 sh, 
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276 sh, 317, 364, 384, 544 ( = 8884, 6472, 4512, 3277, 1679, 1715, 1995 respectively); 1H 
NMR (500 MHz, d6-DMSO, ) 10.24 (1H, bs, 5-OH), 8.54 (1H, d, J = 8.0 Hz, H-12), 8.41 (1H, 
d, J = 7.5 Hz, H-10), 8.34 (1H, d, J = 8.0 Hz, H-11), 7.81 (1H, s, H-4), 7.63 (1H, dd, J = 8.5, 
7.0 Hz, H-8), 7.51 (1H, d, J = 8.5 Hz, H-7), 7.40 (1H, dd, J = 8.0, 7.0 Hz, H-9), 7.40 (1H, s, H-
2), 3.87 (3H, s, 2-OCH3). 
13C (125 MHz, d6-DMSO, ppm) 177.3 (s, C-1), 153.0 (s, C-2), 151.9 
(s, C-6a), 140.5 (s, C-5), 137.6 (s, C-5a), 133.1 (s, C-10b), 132.8 (d, C-8), 130.4 (d, C-12), 
127.4 (s, C-12c), 125.1 (d, C-9), 125.0 (d, C-10), 122.5 (d, C-4), 120.7 (s, C-3a), 120.3 (s, C-
12a), 119.1 (s, C-10a), 118.3 (d, C-7), 117.6 (s, C-12b), 116.7 (d, C-11), 113.2 (d, C-3), 55.9 
(q, 2-OCH3); ESI-MS (positive): m/z 317 [M+H]
+. 
 
Haemodorone (3.41) 
O
O
O
OCH3
OH
1'
9b
9a
8
6a
4'
5
3a
1
 
 
Isolated as a yellow powder; 1H NMR (500 MHz, d6-DMSO, ) 8.53 (1H, d, J = 8.0 Hz, H-9), 
8.45 (1H, s, H-4), 7.66 (1H, d, J = 8.0 Hz, H-8), 7.49 (5H, s, H-2’, H-3’, H-4’, H-5’, H-6’), 3.16 
(3H, s, H-10); ESI-MS (positive): m/z 321 [M+H]+. 
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Haemoxiphidone (3.42) also known as 5-Hydroxy-2,6-dimethoxy-9-phenyl-phenalen-1-one 
OCH3
O
OH
H3CO
1'
9b
9a
8
6a
4'
5
3a
1
 
 
Isolated as a yellow powder; m.p. 282-286°C; 1H NMR (500 MHz) and 13C (125 MHz) in d6-
DMSO as well as the 2D COSY and HMBC correlations are detailed in Table 3.1; 1H NMR 
(500 MHz) in d6-acetone described in Table 3.1; ESI-MS (negative): m/z 331 [M-H]
-. 
 
5,6-dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione (3.44) 
O
O
O
OCH3
H3CO
1'
9b
9a
8
6a
4'
5
3a
1
 
 
Isolated as fine fluorescent yellow crystals; Crystal data, C20 H14 O5.0.5(H2O), M = 343.32T = 
130.0(2) K, = 1.5418, Monoclinic, space group C2/c, a = 18.455(2), b = 8.077(1) c 
=21.455(2), Å,  = 105.72(1)°, V = 3078.7(6) Å3, Z = 8, Dc = 1.481 mg M
-3 (Cu-K) 0.904 
mm-1, F(000) = 1432, crystal size 0.45 x 0.05 x 0.03 mm. 5526 reflections measured, 2765 
independent reflections (Rint = 0.071) the final R was 0.0585 [I > 2(I)] and wR(F
2) was 
0.1488 (all data). Crystallographic data for 3.44 has been deposited at the Cambridge 
Crystallographic Data Centre (CCDC 912701)* 12 Union Road, Cambridge, CB2 1EZ, UK 
(www.ccdc.cam.ac.uk/data_request/cif); m.p. (uncorr.) 256-258C; 1H NMR (500 MHz, 
CDCl3, ) 8.51 (1H, d, J = 7.0 Hz, H-9), 8.42 (1H, s, H-4), 7.55 (1H, d, J = 7.0 Hz, H-8), 7.42 
(3H, m, H-3’, H-4’, H-5’), 7.35 (2H, m, H-2’, H-6’), 4.06 (3H, s, 5-OCH3), 3.38 (s, 6-OCH3). 
13C 
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(125 MHz, CDCl3, ppm) 160.8 (s, C-1), 160.6 (s, C-3), 151.8 (s, C-6), 150.9 (s, C-4), 146.7 
(s, C-7), 142.2 (s, C-1’), 131.3 (d, C-9), 130.7 (d, C-8), 128.2 (d, C-2’, C-6’), 127.9 (s, C-9b), 
127.3 (d, C-3’, C-4’, C-5’), 125.9 (s, C-6a), 123.7 (s, C-3a), 120.6 (d, C-4), 117.9 (s, C-9a), 
60.9 (q, 6-OCH3), 56.9 (q, 5-OCH3); ESI-MS (positive): m/z 335 [M+H]
+. 
 
Haemodordioxolane (3.45) also known as 1-phenyl-5,8,10-trioxa-cyclopenta[a]phenalene-
4,6-dione 
O
O
O
O
O
1'
10
9b
9a
8
6a
4'
5
3a
1
 
 
Isolated as a fluorescent yellow needles; m.p. (uncorr.) 215-218°C; IR (film) max cm
-1: 2956, 
2926, 2854, 1770, 1728, 1679,1463, 1379, 1265; UV (c, 0.033 mg/mL in EtOH) max (nm) 
220 sh, 254, 314 sh, 327, 368, 421 sh ( = 7430, 5083, 1137, 1272, 1081, 242 respectively); 
1H NMR (500 MHz) and 13C (125 MHz) d6-DMSO and CDCl3 details as well as the 2D COSY 
and HMBC correlations are detailed in Table 3.2; ESI-MS (positive): m/z 319 [M+H]+, HR-
ESI-MS displayed an m/z at 319.0603 [M+H]+ (calcd. for C19H11O5: m/z 319.0606). 
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Haemodoroxychysenose (3.46) also known as 11-O-β-D-glucopyranosyloxy-5-methoxy-6-
oxabenzochrysen-1-one 
O
O
OCH3
O
O
HO
OHOH
OH
12c
12a
12
10b
10a
9
6a5a
5
3a
1
1'
6'
3'
 
 
Isolated as a fluorescent pink powder; m.p. (uncorr.) 155-160°C; []
25
D  +16.2° (c, 3.8 mg/mL in 
MeOH); IR (film) max cm
-1: 3383, 2956, 2921, 2851, 1731, 1593, 1564, 1415, 1380, 1358, 
1318; UV (c, 0.033 mg/mL in EtOH) max (nm) 236 sh, 266 sh, 288 sh, 371 sh, 402, 537 (= 
8217, 3900, 3399, 882, 731, 2581 respectively); 1H NMR (500 MHz, d6-DMSO) and 
13C (125 
MHz, d6-DMSO) details as well as the 2D COSY and HMBC correlations are detailed in 
Table 3.3; ESI-MS (positive): m/z 479 [M+H]+, HR-ESI-MS displayed an m/z at 479.1337 
[M+H]+ (calcd. for C19H11O5: 479.1342). 
 
7.4 Chapter 4 Experimental 
7.4.1 Chapter 4 HPLC-NMR Characterisation (from stop-flow HPLC-NMR) 
Droserone (4.7) 
HPLC-NMR (WET-1D, 500 MHz, stop-flow HPLC-NMR, ) 7.48 (dd, J = 8.5, 7.5 Hz, H-7), 
7.34 (d, J = 7.5 Hz, H-8), 6.97 (d, J = 8.5 Hz, H-6), 1.74 (s, H-9) signal partially suppressed in 
CH3CN region. 
 
 
 
 
Marine and Terrestrial Natural Products Discovery 
227 
Hydroxydroserone (4.8) 
HPLC-NMR (WET-1D, 500 MHz, stop-flow HPLC-NMR, ) 7.17 (d, J = 9 Hz, H-6), 7.09 (d, J 
= 9 Hz, H-7), 1.79 (s, H-9) signal partially suppressed in CH3CN region. 
 
Co-eluting droserone-5-O--glycoside (4.9) and Hydroxydroserone-5-O--glycoside (4.10) 
HPLC-NMR (WET-1D, 500 MHz, stop-flow HPLC-NMR, ) 7.65-6.70 (m), 5.04 (m), 5.00 (s), 
4.85 (s), 3.20-3.80 (m), 1.80 (s, H-9) signal partially suppressed in CH3CN region. 
 
7.4.2 Chapter 4 Off-line Characterisation  
Plumbagin (1.267)  
1
5
8 9
3
8a
4a
O
OOH  
 
Isolated as a stable brown oil; 1H NMR (500 MHz, d6-DMSO, ) and 
13C (125 MHz, d6-
DMSO) details in Table 4.2; ESI-MS (negative): m/z 203 [M-H]-. 
 
Droserone (4.7)  
1
5
8 9
3
8a
4a
O
OOH
OH
 
 
Isolated as a stable yellow oil; 1H NMR (500 MHz, d6-DMSO, ) 11.43 (bs, 5-OH), 7.69 (dd, J 
= 7.5, 8.0 Hz, H-7), 7.48 (dd, J = 1.0, 7.5 Hz, H-8), 7.24 (dd, J = 1.0, 8.0 Hz, H-6), 1.91 (s, H-
9). 13C (125 MHz, d6-DMSO, ppm) 184.6 (s, C-1), 183.9 (s, C-4), 160.0 (s, C-5), 155.5 (s, C-
3), 136.8 (d, C-7), 132.4 (s, C-8a), 122.7 (d, C-6), 120.3 (s, C-2), 118.2 (d, C-8), 113.6 (s, C-
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4a), 8.7 (q, C-9), 3-OH not detected; 1H NMR (500 MHz, CDCl3, ) 7.61 (dd, J = 8.0, 8.0 Hz, 
H-7), 7.29 (d, J = 8.0 Hz, H-8), 7.23 (d, J = 8.0 Hz, H-6), 2.08 (s, H-9), 3-OH and 5-OH not 
detected; ESI-MS (negative): m/z 203 [M-H]-. 
 
Hydroxydroserone (4.8)  
1
5
8 9
3
8a
4a
O
OOH
OH
OH
 
 
Isolated as a stable brown oil; 1H NMR (500 MHz, d6-DMSO, ) 12.95 (s, 8-OH), 11.73 (s, 5-
OH), 7.34 (d, J = 9.3 Hz, H-7), 7.27 (d, J = 9.3 Hz, H-6), 1.93 (s, H-9); 13C (125 MHz, d6-
DMSO, ppm) 188.8 (s, C-1), 182.9 (s, C-4), 157.0 (s, C-5), 156.0 (s, C-8), 155.3 (s, C-3), 
129.9 (d, C-7), 127.2 (d, C-6), 120.2 (s, C-2), 110.9* (s, C-4a), 110.8* (s, C-8a), 8.1 (q, C-9), 
3-OH not detected; 1H NMR (500 MHz, CDCl3, ) 12.83 (s, bs, 8-OH), 7.27 (d, J = 9.3 Hz, H-
6), 7.16 (d, J = 9.3 Hz, H-7), 2.10 (s, H-9); 13C (125 MHz, CDCl3, ppm) 188.9 (s, C-1), 182.1 
(s, C-4), 157.5 (s, C-5), 157.0 (s, C-8), 154.0 (s, C-3), 131.3 (d, C-7), 127.4 (d, C-6), 121.6 
(s, C-2), 110.7 (s, C-8a), 110.2 (s, C-4a), 8.3 (q, C-9), 3-OH and 5-OH not detected; ESI-MS 
(negative): m/z 219 [M-H]-. * Chemical shifts interchangeable 
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Droserone-5-O--glycoside (4.9)  
6'
O
OO
OH
O
HO
OH
HO
OH
1
5
8 9
3
8a
4a
4'
1'
 
 
Isolated as a stable yellow/brown oil; 1H NMR (500 MHz, d6-DMSO, ) 10.84 (bs, 3-OH), 7.74 
(dd, J = 8, 8 Hz, H-7), 7.66 (d, J = 8 Hz, H-8), 7.55 (d, J = 8 Hz, H-6), 5.12 (d, J = 8.0 Hz, H-
1’), 3.69 (d, J = 11 Hz, H-6’b), 3.48 (m, H-6’a), 3.41 (m, H-5’), 3.38 (m, H-2’), 3.29 (m, H-3’), 
3.20 (m, H-4’), 1.89 (s, H-9). 13C (125 MHz, d6-DMSO, ppm); 184.3 (s, C-1), 179.0 (s, C-4), 
157.0 (s, C-5), 155.9 (s, C-3), 135.2 (d, C-7), 133.9 (s, C-8a), 120.6 (d, C-6), 119.3 (d, C-8), 
117.9 (s, C-4a), 117.3 (s, C-2), 100.0 (d, C-1’), 76.9 (d, C-5’), 76.3 (d, C-3’), 73.2 (d, C-2’), 
69.2 (d, C-4’), 60.3 (t, C-6’), 8.3 (q, C-6’), 2’-OH, 3’-OH, 4’-OH, 5’-OH and 6’-OH not 
detected; ESI-MS (negative): m/z 203 [M-H]-. 
 
Hydroxydroserone-5-O-β-glycoside (4.10)  
1
5
8 9
3
8a
4a
O
OO
OH
O
HO
OH
HO
OH
OH
6'
4'
1'
 
 
Isolated as a stable brown oil; 1H NMR (500 MHz, d6-DMSO, ) and 
13C (125 MHz, d6-
DMSO) details in Table 4.3; ESI-MS (negative): m/z 203 [M-H]-. 
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7.5 Chapter 5 Experimental 
7.5.1 Chapter 5 HPLC-NMR Characterisation (from stop-flow HPLC-NMR) 
Plocamenone (5.21)  
HPLC-NMR (WET-1D, 500 MHz, 70% CH3CN/D2O, ); 6.26 (s, H-5), 6.18 (s, H-1b), 6.09 (s, 
H-1a), 4.44 (dd, J = 2.5, 9.5 Hz, H-7), 4.18 (dd, J = 2.5, 13 Hz, H-8b), 3.74 (dd, J = 9.5, 13 
Hz, H-8a), 1.82 (s, H-9)*, 1.65 (s, H-10); HPLC-NMR (13C, 125 MHz, obtained from the WET-
2D HSQC NMR experiment, ppm); 134.0 (d, C-5), 133.2 (t, C-1), 63.5 (d, C-7), 48.0 (t, C-8), 
27.9 (q, C-10), all other carbons not observed. *indicates signal was partially suppressed. 
 
Isoplocamenone (5.24)  
HPLC-NMR (WET-1D, 500 MHz, 70% CH3CN/D2O, ): 6.78 (s, H-5), 5.93 (s, H-1b), 5.80 (s, 
H-1a), 4.85 (dd, J = 2.0, 9.5 Hz, H-7), 4.27 (dd, J = 2.0, 12.5 Hz, H-8b), 2.06 (s, H10), 1.92 
(s, H-9)*, H-8a suppressed. *indicates signal was partially suppressed. 
7.5.2 Chapter 5 Off-line Characterisation  
Plocamenone (5.21) also known as (Z)-7-Bromo-4,6,8-trichloro-2,6-dimethylocta-1,4-dien-3-
one 
1
5
8
9
10
O
Cl
Cl
Br
Cl
 
 
Isolated as a stable colorless to light brown oil; [] 21
D
 −21.5° (c, 4.58 mg/mL in CHCl3); IR 
(film) max cm
−1: 2960, 1670, 1450, 1349, 1092, 947; UV (MeOH) max 244 nm (ε = 17000); UV 
profile extracted from HPLC using photodiode array detection (CH3CN/H2O) 236 nm; 
1H NMR 
(500 MHz), 13C (125 MHz), COSY, HSQCAD and HMBC assignments are detailed in Table 
5.2 (CDCl3) and in Table 5.4 (CD3OD); ESI-MS (positive) m/z 335 [M+H]
+, 299 [M−Cl]+, 219 
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[M–Cl−Br]+; GC-MS (EI); m/z 299 [M−Cl]+, 191 [M−C2H3BrCl]
+, 169, 156 [M−C2H3BrCl2]
+, 
127, 91, 77, 69, 51; HR-GC-MS (EI); m/z 298.9050 [M−Cl]+ (calculated for C10H12O
35Cl2
81Br: 
m/z 298.9403), 216.9908 [M–Cl−Br]+, 190.9774 [M−C2H3BrCl]
+, 169.0190, 156.0127 
[M−C2H3BrCl2]
+, 77.0285, 69.0248. 
 
Isoplocamenone (5.24) also known as (E)-7-Bromo-4,6,8-trichloro-2,6-dimethylocta-1,4-dien-
3-one 
Cl
O
Cl
Br
Cl
1 5
8
910
 
 
Isolated as an unstable colorless to light brown oil; UV profile extracted from HPLC using 
photodiode array detection (CH3CN/H2O) 240 nm; 
1H NMR (500 MHz), 13C (125 MHz), 
COSY, HSQCAD and HMBC assignments are detailed in Table 5.3 (CDCl3) and in Table 5.4 
(CD3OD); ESI-MS (positive) m/z 335 [M+H]
+, 299 [M−Cl]+, 219 [M−Cl−Br]+; GC-MS (EI); m/z 
299 [M−Cl]+, 191 [M−C2H3BrCl]
+, 169, 156 [M−C2H3BrCl2]
+, 127, 91, 77, 69, 51; HR-GC-MS 
(EI); m/z 298.9397 [M−Cl]+ (calculated for C10H12O
35Cl2
81Br: m/z 298.9403), 217.0148 [M–
Cl−Br]+, 191.0016 [M−C2H3BrCl]
+, 169.0419, 156.0326 [M−C2H3BrCl2]
+, 77.0365, 69.0311. 
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7.6 Chapter 6 Experimental 
7.6.1 Chapter 6 HPLC-NMR Characterisation (from on-flow HPLC-NMR) 
Compound (6.1)  
21
17
13 9
5
1  
 
HPLC-NMR (WET-1D, 500 MHz, 90:10 CH3CN:D2O, ) 5.77 (1H, tt, J = 8.0, 7.0, 1.5, H-2), 
5.31 (10H, m, H-6, H-7, H-9, H-10, H-12, H-13, H-15, H-16, H-18, H-19), 4.95 (1H, d, J = 
17.5 Hz, H-1a), 4.88 (1H, d, J = 10.0 Hz, H-1b), 1.38 (2H, tt, J = 7.5, 7.0 Hz, H-4), 0.89 (3H, 
t, J = 7.5 Hz, H-21), all other peaks supressed; GC-MS (EI); m/z 284 (6) [M]+ 159 (17), 145 
(34), 131 (52), 119 (54), 105 (100). 
 
Compound (6.2)  
21 17
13 9
5
1  
 
HPLC-NMR (WET-1D, 500 MHz, 90:10 CH3CN:D2O, ) 5.77 (1H, m, H-2), 5.30 (8H, s, H-6, 
H-7, H-9, H-10, H-12, H-13, H-15, H-16), 4.95 (1H, dd, J = 16.5, 1.0 Hz, H-1a), 4.88 (1H, dd, 
J = 11.0, 1.0 Hz, H-1b), 1.38 (2H, tt, J = 7.5, 7.0 Hz, H-4), 2.36 (4H, t, J = 7.5 Hz), 1.48 (2H, 
tt, J = 7.5, 7.0 Hz, H-4), 1.29 (2H, m), 1.23 (6H, m), 0.82 (3H, t, J = 7.0 Hz, H-21), all other 
signals supressed; GC-MS (EI); m/z 286 (2) [M]+, 215 (32), 201 (30), 175 (48), 161 (53), 147 
(100). 
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Compound (6.14)  
1 5 9
13
17
HO
OH
4'
1'
 
 
HPLC-NMR (WET-1D, 500 MHz, 80:20 CH3CN:D2O, ) 6.08 (2H, d, J = 2.0 Hz, H-2’, H-6’), 
6.02 (1H, d, J = 2.0 Hz, H-4’), 5.29 (8H, m, H-5, H-6, H-8, H-9, H-11, H-12, H-14, H-15), 2.76 
(6H, m, H-7, H-10, H-13), 2.37 (2H, t, J = 7.5 Hz, H-1), 1.48 (2H, tt, J = 7.5, 7.5 Hz, H-2), 
1.28 (2H, tt, J = 7.5, 7.5 Hz, H-3), 0.87 (3H, t, J = 7.5 Hz, H-17); ESI-MS (negative): m/z 339 
[M-H]-. 
 
Compound (6.15)  
1 5 9
13 17
4'
1'HO
OH  
 
HPLC-NMR (WET-1D, 500 MHz, 80:20 CH3CN:D2O, ) 6.08 (2H, d, J = 1.5 Hz, H-2’, H-6’), 
6.02 (1H, d, J = 1.0 Hz, H-4’), 5.28 (6H, m, H-5, H-6, H-8, H-9, H-11, H-12), 2.74 (4H, m, H-7, 
H-10), 2.37 (2H, t, J = 7.5 Hz, H-1), 1.48 (2H, tt, J = 7.5, 7.5 Hz, H-2), 1.28 (2H, tt, J = 7.5, 
7.5 Hz, H-3), 0.87 (3H, t, J = 7.0 Hz, H-17); ESI-MS (negative): m/z 341 [M-H]-. 
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Compound (6.16)  
1
5
9
13
4'
1'HO
OH
19
 
 
HPLC-NMR (WET-1D, 500 MHz, 80:20 CH3CN:D2O, ) 6.08 (2H, d, J = 2.0 Hz, H-2’, H-6’), 
6.02 (1H, d, J = 2.0 Hz, H-4’), 5.30 (10H, m, H-4, H-5, H-7, H-8, H-10, H-11, H-13, H-14), 
2.76 (8H, m, H-6, H-9, H-12, H-15), 2.38 (2H, t, J = 8.0 Hz, H-2), 1.53 (2H, t, J = 7.5 Hz, H-
2), 0.87 (3H, t, J = 7.5 Hz, H-19); ESI-MS (negative): m/z 365 [M-H]-. 
 
Compound (6.17)  
1 5
9
13
4'
1'
19
HO
OH  
 
HPLC-NMR (WET-1D, 500 MHz, 80:20 CH3CN:D2O, ) 6.08 (2H, d, J = 1.0 Hz, H-2’, H-6’), 
6.02 (1H, d, J = 1.5 Hz, H-4’), 5.29 (8H, m, H-7, H-8, H-10, H-11, H-13, H-14, H-16, H-17), 
2.74 (6H, m, H-9, H-12, H-15), 2.36 (q, J = 8.0 Hz), 1.53 (t, J = 7.5 Hz), 0.80 (3H, t, J = 7.0 
Hz, H-19); ESI-MS (negative): m/z 367 [M-H]-. 
 
HPLC-NMR assignment of compound (6.18)  
1 5
9
13
4'
1'
17
HO
OH  
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HPLC-NMR (WET-1D, 500 MHz, 80:20 CH3CN:D2O, ) 6.08 (2H, d, J = 2.0 Hz, H-2’, H-6’), 
6.01 (1H, d, J = 2.0 Hz, H-4’), 5.28 (m), 2.70 (t, J = 6.5 Hz), 2.36 (t, J = 8.0 Hz), 0.80 (3H, t, J 
= 7.0 Hz, H-17); ESI-MS (negative): m/z 343 [M-H]-. 
 
7.6.2 Chapter 6 Off-line Characterisation  
Compound (6.12) 
1 5 9 13
4'
1'HO
OH  
 
ESI-MS (negative): m/z 291 [M-H]- 
 
Compound (6.14)  
HO
OH  
 
1H NMR (500 MHz, CDCl3) and 
13C (125 MHz, CDCl3) details as well as the 2D NMR COSY 
and HMBC NMR correlations are detailed in Table 6.2. 
 
Compound (6.19)  
1
5
9 13
4'
1'
17
HO
OH
21
 
 
ESI-MS (negative): m/z 391 [M-H]- 
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